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Ventricular tachycardia (VT) typically occurs several years after a patient survives a 
myocardial infarction (MI). VT may present as a single episode or as a clustering of 
multiple episodes known as electrical storm (ES). ES is a state of electrical instabil-
ity and is characterised by 3 or more episodes of VT or ventricular fibrillation (VF) 
within 24 hours.¹ The implantable cardioverter defibrillator (ICD) can effectively 
terminate ventricular arrhythmia, however it will not eliminate or modify the trigger 
or substrate of ES.2 Mortality in the early and subacute phase of ES is high.³
Treatment of ES can be very complex and entails the administration of anti-arrhyth-
mic drugs (AAD), suppression of sympathetic tone and sometimes urgent catheter 
ablation (CA). Furthermore patients with ES are in need of a tailored approach. A 
select patient group presenting with ES benefits from a CA intervention.⁴ CA has 
shifted from a last resort treatment towards an early treatment strategy.⁵ CA is 
reported to decrease the likelihood of subsequent ICD shocks. It prolongs the time 
to VT recurrence and decreases VT burden.⁶-⁸ 
Catheter ablation
Episodes of monomorphic VT in patients with post MI scar are characterised by 
re-entry. Post MI scar is complex and leads to VTs emanating from re-entry path 
with multiple and interconnected circuits with numerous entrances, exits and 
dead-end tracts.9,10 Therefore besides targeting the critical isthmus of a clinical VT, 
targeting the substrate during CA is also of critical importance.
Optimizing the outcome of VT ablation remains a challenge. Longterm outcome 
is hampered by diagnostic inaccuracy, ablation approach and ablation technique. 
Diagnostic accuracy can be improved by better visualisation of the substrate and 
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identification of critical parts of the scar. A substrate ablation approach leads to an 
improved outcome compared to an approach targeting the critical isthmus of the VT 
only.11 Multiple forms of substrate ablation have been described such as: substrate 
homogenisation, elimination of abnormal potentials and scar de-channeling. All aim-
ing to thoroughly abolish any abnormal electrical activity.12 An incomplete substrate 
approach may subsequently lead to incomplete abolition of VTs. Combined endo 
-epicardial ablation in post MI VT was shown to be beneficial especially in the set-
ting of transmural scars.13 Despite endo -epicardial ablation, ablation lesions do not 
necessary penetrate the complete myocardial wall and midmyocardial VT circuits 
may be left untouched.14 Finally, for optimal outcome in VT ablation improving lesion 
formation is needed. Optimal wall contact during ablation is mandatory. Excursion 
of the ventricle, especially during tachycardia, may lead to an unstable catheter po-
sition. An unstable catheter position results in intermittent impaired energy delivery 
and subsequent inadequate lesion formation.15 Wall contact during myocardial con-
traction can be maintained by remote magnetic navigation (RMN).16 Effective lesion 
formation is enhanced by the knowledge of good contact with the myocardial wall.17 
Optimal contact is equally important in adequate three-dimensional electro- 
anatomic mapping (EAM).18 Ideally, contact force (CF) sensing is integrated in RMN 
as both entities could magnify the benefit of remote magnetic navigation. Contact 
feedback only became available recently with the development of the e-Contact 
Module (ECM).
Visualising the substrate
Performing a cardiac magnetic resonance (CMR) remains a challenge in patients 
implanted with an ICD, however it is not impossible. The ICD artefact most common-
ly affects the basal left anterior free wall.19 Computed tomography (CT) has the ad-
vantage of not being limited by ICD artefacts. Relatively preserved wall thickness on 
CT correlates with ridges within areas of pronounced wall thinning in the scar. These 
areas of preserved wall thickness have been recognized as the arrhythmogenic sub-
strate of scar-related VT.20
In patients with VT after MI both modalities of imaging help to identify, delineate 
and characterize the scar. An electro-anatomical map (EAM) aids to define the scar 
and the border zone of the scar. Yet, scar is 3-dimensional and a voltage map is 
limited in spatial resolution.21 Moreover arrhythmogenic substrate may be found in 
heterogeneous tissue with normal voltages.22 In the era of revascularized MI, limited 
and inhomogeneous substrate is more frequently seen. In addition, inhomogeneous 
substrate is often more difficult to diagnose with bipolar EAM. Borderzone channels 
of inhomogeneous scar may be better depicted by contrast enhanced CMR.23
With pre-procedure imaging, imaging modalities can guide towards the best abla-
tion approach. Integrating imaging in the procedure and visualising myocardial scar 
real time, facilitates VT ablation by focusing on the area of interest and providing 
more accurate substrate characterization. 
A substrate approach
A substrate approach precludes the need for support devices during hemody-
namically intolerant scar related VT ablation. Also ongoing scar related intra-atrial 
re-entry tachycardia during ablation, in patients with corrected congenital heart 
disease, can result in hemodynamic instability. Not only patients with scar related 
VT benefit from a substrate ablation approach, but also patients with scar from 






Aim and outline of thesis
The present thesis aims to contribute to the current attitude and approach to scar 
related arrhythmia. We investigate the role of remote magnetic navigation, contact 
force, a substrate approach and image-integration in patients with scar related 
atrial and ventricular arrhythmias.
In Part 1, the outcome of ventricular tachycardia (VT) ablation is studied, and how  
remote magnetic navigation (RMN) and contact force (CF) can influence the outcome. 
Chapter 2 provides a detailed overview on the role of catheter ablation for ventricular 
tachycardias for the treatment of patients with electrical storm. Chapter 3 highlights 
the triggers and mechanism leading to ES and their consequent treatment options. 
Conservative treatment and early and delayed catheter ablation in the outcome of pa-
tients with electrical storm is compared in Chapter 4. In Chapter 5 and 6, CF is com-
pared to RMN in a population with idiopathic ventricular arrhythmia (VA) and a popula-
tion with all different types of VA respectively. CF is integrated in RMN and the benefit 
of the e-contact module in ischemic VT is discussed in Chapter 7.
Part 2 descripes imaging, endo- epicardial VT ablation and their common denomi-
nator. The role of imaging guided ablation for scar-related VT will be systematically 
discussed and in Chapter 8 imaging guided and non imaging guided VT ablation is 
compared in a meta-analysis. In Chapter 9 a study design is presented, a combined 
endo- epicardial ablation as a first procedure is randomised to a stepwise approach 
in a population with ischemic VT. Chapter 10 shows a case series of potential 
life-threatening complications of epicardial VT ablation.
In Part 3, the focus is on the substrate. Chapter 11 paraphrases the role of de-
layed-enhancement magnetic resonance imaging in atrial fibrillation ablation. 
Substrate ablation as described in Chapter 12, can be used in the treatment of 
intra-atrial re-entrant tachycardia (IART) for patients after congenital heart surgery. 
In Chapter 13 it is shown how IART can deteriorate the hemodynamic status of a pa-
tient with a Fontan circulation, and how a percutaneous left ventricular assist device 
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Outcome of VT 
ablation, and the role 
of magnetic navigation 
and contact force
In the eye of the storm, however, it is 
uttermost serene  
Remember that the storm is a good opportunity for 




The role of catheter 
ablation of ventricular 
tachycardias in the 
treatment of patients 
with electrical storm
Astrid A. Hendriks, Tamás Szili-Török
Department of Clinical Electrophysiology, Erasmus Medical Center 
Journal of Cardiovascular Emergencies 
2015;1(1):8-11.
2 chapter 2










Since electrical storm due to the development of life threatening sustained ventric-
ular tachycardias is a cardiac emergency, acute catheter ablation can be lifesaving. 
Electrical storm (ES) can be characterized as a period of severe cardiac electrical 
instability manifested by recurrent ventricular arrhythmias.1 The development of 
ES has a strong negative impact on the outcome of patients. The highest mortality 
risk is in the first 3 months after the occurrence of the index event as shown by the 
AVID trial.2 Although the presence of implantable cardiac defibrillator decreases 
mortality, it is also not without risks. Indeed, the increased utilization of catheter 
ablation (CA) is partly driven by data suggesting that ICD shocks may be associated 
with increased mortality, partly due to the limited possibilities and adverse events 
of medical therapy. Every defibrillator shock therapy multiplies the mortality risk by 
direct cell injury.3,4,5 Other mechanisms how ES directly affects patient prognosis is 
by progressive deterioration of cardiac function from prolonged low-output states, 
and/or an adverse haemodynamical effect of antiarrhythmic medication6 and thus, 
CA may become a life-saving procedure for these patients.
Mechanism of VT in electrical storm
The term “electrical storm” indicates a state of cardiac electrical instability mani-
fested by several distinct episodes of VTs within a short period of time.1 In patients 
with an ICD, ES is best defined as 3 or more appropriate VT detections in 24 hours, 
treated by antitachycardia pacing, shock or eventually untreated, but sustained in 
a VT monitoring zone. Incessant VT, defined as VT starting shortly (after ≥1 sinus 
cycle and within 5 minutes) after a technically successful therapy, represents a 
serious form of electrical storm. Ventricular monomorphic tachycardia is the most 
common arrhythmia in patients with an electrical storm, and reentry is the most 
common underlying mechanism.7
Scarring—i.e. the development of fibrous tissue is the anatomical and electro-
physiological substrate. It is therefore also the target for CA. Other targets can 
be premature ventricular contractions (PVC), since those can trigger sustained 
arrhythmias.8 The study Hayashi et al. that investigated ES in acute heart failure, 
described PVC arising from the Purkinje fibers that not only triggered VF but also 
for about 30% of the monomorphic VTs.9 Likewise early post-myocardial infarction 
(MI) incessant VT is mostly triggered by PVC.10,11 In these patient categories target-
ing the PVCs resulted in a reasonable ablation success.9,10,11
VT ablation in electrical storm 
In electrical storm catheter ablation has been considered as a realistic and valid 
treatment option.7 Carbuccio et al.12 have shown the superiority of CA to conven-
tional medical therapy (92% and 66%, respectively). CA is lifesaving; it also im-
proves quality of life and reduces the recurrent VA episodes.13 A systematic review 
by Nayar et al. included 39 studies with 471 ventricular arrhythmia (VA) storm 
patients concluded that ventricular arrhythmia storm ablation has high acute suc-
cess rates, with a low rate of recurrent storm.14 They found high acute success rate 
of invasive management of VA storm, with 91% of patients having elimination of 
the clinical VA and 72% of patients having all inducible VA eliminated. Ninety-four 
percent of the patients were free from VA storm on follow-up.
For the better success rates sometimes multiple procedures (1.3 + 0.4 per pa-
tient) are needed.14 In the study of Carbuccichio et al. one to three procedures 
were needed to suppress clinical VTs in 89% of patients.12 Among the patients 
with all clinical VTs abolished during the ablation, no recurrence of electrical storm 
Abstract
Electrical storm due to the development of repetitive sustained ventricular tachy-
cardias (VT) is a potentially life-threatening clinical entity. Acute catheter ablation 
can be lifesaving. Electrical storm (ES) can be characterized as a period of severe 
cardiac electrical instability manifested by recurrent ventricular arrhythmias. ES 
adversely affects short and long term prognosis. The highest mortality risk is in 
the first 3 months after the occurrence of the index event as shown by the AVID 
trial. The appearance of a ventricular tachycardia (VT) storm is associated with a 
rather high mortality despite the presence of an internal cardioverter defibrillator. 
Catheter ablation (CA) in VT storm is evolving as a standard of care therapy. The 
increased utilization of CA is partly driven by data suggesting that ICD shocks may 
be associated with increased mortality, partly due to the limited possibilities and 
adverse events of medical therapy. The aim of this review is to summarize recent 
advances in CA of VTs in emergency setting. 
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occurred during the follow-up period, and the mortality was significantly lower 
compared to those who showed persistent inducibility of ≥1 VT at the end of the 
procedure. Interestingly enough, Kozeluhova et al. found non-inducibility of the VT 
at the end of the study was not predictive of ES or VT recurrences during follow-up 
which might be explained by the inclusion of not only monomorphic VT but also
polymorphic VTs.6 Despite a remarkable initial success rate in VT ablation patients 
in ES, only a moderate long term efficacy at follow-up has been reported.15 Es-
pecially non-ischaemic dilated cardiomyopathy, is reported to be an independent 
predictor of failure of CA procedure in patients with ES.12 Arya et al. reported an ex-
cellent survival rate after successful CA procedures in patients with non-ischemic 
dilatated cardiomyopathy. Probably more aggressive ablation strategies targeting 
all inducible VTs may be appropriate as it improves long term freedom from VTs.16 
The same group evaluated Long term efficiency of CA using remote navigation in 
VT ablation in patients with ischemic heart disease and ES. During a mean followup 
of 7.8 months, 21 patients (70%) had no recurrence of VTs and received no appro-
priate ICD therapy. Multisite stimulation induction method was found very useful 
in assessment of the success of CA procedure.17 The authors concluded that a 
significantly more aggressive ablation strategy, including epicardial mapping and 
ablation of all inducible VTs, may improve the ablation outcome especially among 
those who had an initially failed ablation procedures.17 Di Biase et al. compared en-
docardial surface with limited substrate ablation to endocardial and epicardial scar 
homogenization in patients with an electrical storm and an underlying ischemic 
cardiomyopathy. A significant difference in outcome was observed after 25 months 
(p = 0.006) in favour of the endo/epicardial homogenization group.13 Limited sub-
strate ablation abolishes circuits relevant to the arrhythmia burden at the time of 
the procedure, but more extensive ablation endo- and epicardial substrate homog-
enization may be more successful at long term.12
CA for hemodynamically unstable VTs
Acute cardiac decompensation can be either a cause or a consequence of ES. 
Unstable and decompensated patient is an important sub-entity of ES.18 Urgent 
radiofrequency catheter ablation in the setting of an acute heart failure (AHF) 
decompensation in patients with monomorphic VT was found safe, with the 
exception for a temporary exacerbation of pulmonary congestion in 20% of the 
patients.9 Urgent RFCA for drug-resistant sustained ventricular tachyarrhythmias 
during AHF decompensations is a feasible therapeutic option.8 In this study PVCs 
were found responsible for the ventricular arrhythmias and targeted for ablation. 
In monomorphic VT percutaneous left ventricular assist device-assisted VT 
ablation is a reasonable alternative to substrate mapping for haemodyanamically 
unstable, medically refractory VT in high-risk patients.19 Of all ES studies 23% of 
all patients required major invasive haemodynamic support during the procedure.14 
Hemodynamic support is crucial for this patient population.
It can be achieved in the form of counter pulsation balloon pump, Impella device or 
by LVAD.19,20
Long term prognosis after CA of electrical storm patients
VT free long term survival may be improved by early invasive intervention. Deneke 
et al. performed catheter ablation within 24h after admission of the patient with 
electrical storm and showed a high cumulative mid-term survival (median 15 
months) of 91%.21 CA for VT in the early post infarction period may also be a feasi-
ble treatment.11 In the study of Saggu et al. 5 patients short after myocardial  
infarction underwent catheter ablation within 48 hours for the treatment of VTs.
CA is fairly called a “lifesaving” approach with an acceptable efficacy and safety 
profile and a low complication rate (1%).14 The risk of death has been found the 
greatest at 3 months after ES.2 Severely depressed LVEF, a higher degree of LV 
dilation, renal insufficiency, and ES recurrence after previous CA procedure were 
identified as predictors of adverse outcome within the first 6 months after the 
procedure.6 In AHF decompensated VT patients, AHF after RFCA was ameliorat-
ed in 93% of the patients.9 Nevertheless heart failure is the dominant cause of 
death in the long term in patients having a successful procedure.14 In this subset of 
patients, the magnitude of the cardiac damage is too extensive and chronic heart 
failure far advanced.6 Looking at it this way ES may rather be an epiphenomenon 
of progression of heart failure and even successful CA does not guarantee a good 
prognosis. High arrhythmia rate heralds pre-terminal pump failure, yet failure of the 
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zone. Incessant VT, defined as VT starting shortly (after 
≥1 sinus cycle and within 5 minutes) after a technically 
successful therapy, represents a serious form of electrical 
storm. 
Ventricular monomorphic tachycardia is the most com-
mon arrhythmia in patients with an electrical storm, and 
reentry is the most common underlying mechanism [7]. 
Scarring—i.e. the develop ent of fibrous tissu  is the 
anatomical and electrophys ological substrate. It is there-
fore also the target fo  CA. Oth r targets can be prema-
ture ventricular contractions (PVC), since those can trig-
ger sustained arrhythmias [8]. The study Hayashi et al. 
that investigated ES in acute heart failure, described PVC 
arising from the Purkinje fibers that not only triggered VF 
but also for about 30% of the monomorphic VTs [9]. Like-
wise early post-myocardial infarction (MI) incessant VT is 
mostly triggered by PVC [10,11]. In these patient categories 
targeting the PVCs resulted in a reasonable ablation suc-
cess [9,10,11].
VT ABLATION IN ELECTRICAL STORM
In electrical storm catheter ablation has been considered 
as a realistic and valid treatment option [7]. Carbuccio et 
al. [12] have shown the superiority of CA to conventional 
medical therapy (92% and 66%, respectively). CA is life-
saving; it also improves quality of life and reduces the 
recurrent VA episod s [13]. A systematic review by Nayar 
et al. included 39 s udi s with 471 ventricular arrhythmia 
(VA) storm patients conclud d that ve tricular arrhyth-
mia storm ablation has high acute success rates, with a 
low rate of recurrent storm [14]. They found high acute 
success rate of invasive management of VA storm, with 
91% of patients having elimination of the clinical VA and 
72% of patients having all inducible VA eliminated. Nine-
ty-four percent of the patients were free from VA storm 
on follow-up. 
For the better success rates sometimes multiple proce-
dures (1.3 + 0.4 per patient) are needed [14]. In the study 
FIGURE 1. Three dimensional electro-anatomical map of a LV ventricle in a patient with a large scar (red). LAVAs (local abnormal ventricular 
activities) are tagged with white colors. The patient had multiple morphologies of ventricular tachycardias. Extensive scar ablation (dark red 
dots) in an emergency setting rendered all tachycardias non-inducible.
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CA procedure carries an even higher mortality.14
Conclusion
In conclusion, progressively increasing number of studies support that CA is very 
effective in suppressing ES and it may be a life-saving therapy for a very troubled 
patient population.
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Electrical storm is a state of electrical instability and is characterised by several 
episodes of ventricular tachycardia (VT) or ventricular fibrillation (VF). The implant-
able cardioverter defibrillator (ICD) can effectively terminate ventricular arrhythmia 
(VA); however, it will not eliminate or modify the trigger or substrate of electrical 
storm.1 Electrical storm patients usually present as a severe medical emergen-
cy characterised by multiple ICD shocks and haemodynamic instability. Because 
of the infrequent nature and unpredictability of electrical storm associated with 
a potential lethal outcome many physicians feel uncertain in the acute setting. Mor-
tality in the early and subacute phase is high.2,3 Several factors are associated with 
a negative outcome in electrical storm patients: severely impaired left ventricular 
ejection fraction (LVEF),4 pre-existing advanced New York Heart Association class, 
cardiogenic shock5 and older age.
Electrical storm can be a distressing experience for patients and their families, 
leading to significant psychological consequences. Effective management of elec-
trical storm is crucial, and a collaborative hospital network with a dedicated electri-
cal storm team has been suggested as beneficial.6,7 Treatment of electrical storm 
can be very complex and consists of the administration of antiarrhythmic drugs 
(AADs), suppression of sympathetic tone, device re-programming and sometimes 
urgent catheter ablation (Table 1).
Definition of electrical storm: diversity in the literature
The clinical syndrome of electrical storm has been defined empirically. In the 
past a variety of definitions were used. In those early definitions the VT episodes 
ranged between two and 20 within 24 hours.5,8 At present, in the era of ICDs the 
most commonly accepted definition is three or more separate arrhythmia episodes 
leading to ICD therapy occurring over a single 24-hour time period.9 The episodes 
of VT must be separate, meaning that the persistence of VT following unsuccessful 
ICD therapy is not considered as a second episode.10 Incessant VT is a condition in 
which a sustained VT resumes within 5 minutes after successful ICD therapy and 
continues for over 12 hours. No study to date has determined a certain threshold 
burden of ICD therapy that begins to confer an adverse outcome.
Mechanisms underlying electrical storm
Crucial for the occurrence of electrical storm is an interplay between the autonom-
Chapter 3
Abstract
Electrical storm is characterised by a state of severe electrical instability that oc-
curs in a rare combination of circumstances, and may lead to multiple implantable 
cardioverter defibrillator shocks and haemodynamic instability, and possible death.
The main goal of treating electrical storm is to eliminate the trigger and modify the 
substrate of the arrhythmia. The aim of this educational review is to provide infor-
mation for a better understanding of the underlying mechanisms and therefore help 
to improve the treatment of electrical storm patients.
Table 1 Learning objective
  
1  How the mechanism and trigger of electrical storm can guide 
electrical storm treatment
2  To learn about the importance of the sympathetic nervous system in 
the initiation and maintenance of electrical storm
3  To tailor AAD treatment considering efficacy, drug-related pro-
arrhythmia and other side effects
4  How to programme an ICD to avoid recurrent shocks
5  To learn about the indication and timing of catheter ablation
 






ic nervous system, cellular milieu and a predisposing electrophysiological sub-
strate. Both the trigger and the substrate may change over time influenced by the 
progression of scarring, left ventricular remodelling and the progression of heart 
failure. The critical role of an increased activation of the sympathetic nervous sys-
tem in initiating and maintaining electrical storm is demonstrated in electrical storm 
patients who have exacerbation of heart failure.11
Electrical storm: disease or symptom
Although electrical storm directly affects the patients’ prognosis, by preventing the 
next episode of electrical storm the mortality does not necessarily decrease.12
Electrical storm often represents part of the natural history of advanced cardiac 
disease and may predict a serious deterioration in the underlying processes. It can 
even be debated if electrical storm is a marker for mortality in the near future and 
accordingly functions as a major bystander. This raises the question of whether all 
electrical storm patients would be potential candidates for catheter ablation. It is 
also a valid question as to whether a severe disbalance in the cellular milieu could 
outweigh a modification of the substrate? At the other end of the spectrum is those 
presenting with a first episode of electrical storm, who may benefit much more 
from a catheter ablation intervention and have a possible survival benefit.13 There-
fore, every patient that presents with even a single ICD shock should be considered 
as a possible electrical storm, whereas it may be preceded by multiple episodes of 
VT successfully treated by antitachycardia pacing (ATP).
Treatment of electrical storm: corresponding to the mechanism and trigger
Searching for and correction of reversible factors 
In the majority of cases, no clear cause for electrical storm can be identified. 
Triggers such as electrolyte imbalance, acute ischaemia, exacerbation of heart 
failure, adjustment of or non-compliance to anti-arrhythmic medication1 and recent 
introduction to biventricular pacing have been identified.14 They should be actively 
searched for and promptly corrected in each electrical storm patient. Flow limiting 
coronary artery disease and volume overload should be adequately treated. De-
creased left ventricular wall stress can be achieved with non-invasive and invasive 
haemodynamic support including a left ventricular assist device (LVAD), venoarte-
rial extracorporeal membrane oxygenation (ECMO) and continuous flow percutane-
ous ventricular assist devices. Fever is a more rare trigger of electrical storm, and 
is especially important in patients with Brugada syndrome, in whom unsuppressed 
fever may lead to medically resistant incessant polymorphic and possibly fatal VT.15
Device programming
Shocks delivered for self-limiting haemodynamically tolerable arrhythmias ought 
to be avoided. Detection time can be prolonged and ATP can be given as an initial 
therapy.16 Augmentation of ATP attempts, when feasible, is encouraged especial-
ly when shown previously to be successful.17 During an electrical storm an effort 
should be made to avoid further conscious shocks18,and temporary disabling of 
shock therapy may be considered.
Anti-arrhythmic drugs
Frequently, the first step in the treatment of electrical storm is the administration of 
beta-blockers. Beta-blockers play a fundamental role in the management of electri-
cal storm by blocking the sympathetic system. Adding beta-blockers intravenously 
in electrical storm patients already on oral beta-blocker therapy may help to keep 
an electrical storm episode under control.19 Propranolol, a lipophilic unselective 
beta-blocker that penetrates the central nervous system, has been demonstrated 
to be effective in suppressing VAs as compared to metoprolol and amiodarone.20 In 
the presence of structural heart disease amiodarone is one of the most frequently 
used drugs for the treatment of electrical storm. Procainamide, a class 1C AAD, has 
demonstrated its superiority compared to amiodarone for the treatment of haemody-
namically tolerated monomorphic VT in the PROCAMIO trial.21 However, it has been 
investigated only in patients without manifest heart failure and without severely de-
pressed LVEF, in whom it is considered safe. The incidence of IV-amiodarone-refrac-
tory electrical storm is approximately 30%. IV-amiodarone-refractory VT storms are 
frequently induced by triggering premature ventricular contractions (PVCs) with a 
narrow QRS complex22, and may be successfully suppressed with additional adminis-
tration of mexiletine, a class 1B AAD.23 Reperfusion often leads to the development of 
automaticity or delayed afterdepolarisations originating from the Purkinje network,24 
which in fact is sodium channel mediated.25 Lidocaine, a class 1B AAD is used in the 
setting of acute ischaemia.26
There is no consensus on the optimal drug treatment for refractory malignant VA, and 
AADs may be given in a manner of trial and error. Drug combinations are sometimes 
necessary to alter electrical instability. AADs carry the risk of increasing the cycle 
length of re-entry VAs and make VT more stable, which may precipitate to incessant 
VT. AADs should be given individually, taking into account not only the efficacy but 
also the increased risk of drug-related proarrhythmia and other side effects. 
Overdrive pacing and sedation
Temporary (atrial) overdrive pacing may help to interrupt an incessant or re-occurring 
VA, especially in conditions such as Brugada and early repolarisation syndrome.26 
Overdrive pacing helps by preventing PVCs from occurring and reduces early afterde-
polarisation.27  
As the sympathetic nervous system plays a major role in the initiation but also the 
maintenance of VAs11, sedation and/or intubation may be needed in order to suppress 
the sympathetic tone. A complete sympathetic blockade can be performed by left 
cardiac sympathetic denervation.28
Radiofrequency catheter ablation
In the majority of electrical storm patients the episodes are characterised by a mono-
morphic VT based on re-entry. Therefore catheter ablation, targeting the substrate 
in which re-entry has formed, is an important treatment option for electrical storm. 
In a pooled meta-analysis29 of 471 electrical storm patients who underwent catheter 
ablation, catheter ablation had a high success rate with a low rate of recurrent electri-
cal storm. Acute procedural success was 72% and procedural failure was 9%. During 
a follow-up of 15 months, 60% of patients were free of VA recurrences and 94% were 
free of electrical storm. Since then ablation of VT has evolved, and new approaches 
and technologies, such as the substrate approach30, remote magnetic navigation31, 
and a combined endo-epicardial substrate ablation32, have improved the outcome of 
VT ablation (Table 2).33
There is also a role for catheter ablation in patients who suffer from recurrent VF 
episodes. In 29 patients with ischaemic heart disease, recurrent VF was triggered by 
monomorphic ventricular extrasystole that originated from the fibrous peri-infarction 
zone. In eight patients with drug refractory electrical storm, ablation of the  
ventricular extrasystole was successfully performed, and control of electrical storm 
was achieved.34










Compared to medical therapy catheter ablation reduces the number of subsequent 
VT episodes especially when VT ablation is performed within one month of electrical 
storm.35 VT ablation in patients with a LVEF of 25% or greater is shown most bene-
ficial.12 Freedom from recurrent VT after catheter ablation has been associated with 
an improved survival.13,36 Morawski et al.13 showed that in a first time electrical storm 
population, VT ablation was significantly more effective than any other form of thera-
py in reducing death at any time, even though the recurrence rate was not lower in the 
catheter ablation group. Yet, it is also known that patients with electrical storm have 
an increased risk of non-cardiac death. In other studies a mortality benefit from VT 
ablation in electrical storm patients was not shown.2
This underlines the importance of the selection of patients as potential candidates 
for ablation. The timing of catheter ablation, the approach and support should be 
tailored. Patients with incessant drug refractory VT who fail on haemodynamic sup-
port can benefit from a rescue VT ablation.37 Patients with advanced heart failure 
and unstable VTs are at highest risk of haemodynamic collapse during the ablation 
procedure; they can benefit from mechanical support during catheter ablation.38 
Alternatively, the ablation can be confined to a substrate approach only. Consequent 
fluid overload related to irrigated catheter ablation may precipitate acute decom-
pensation39, and preventive measures such as LVAD or ECMO may still be indicated 
in patients with severely depressed left ventricular function. In a small proportion of 
patients there is such a limited reserve in cardiac output that limited ablation should 
be aimed for, targeting only the critical isthmus of the clinical VT.
Conclusion
Electrical storm is a critical condition and even after successful catheter ablation pa-
tients continue to bear an increased burden of morbidity and mortality. Early recogni-
tion and referral to a tertiary electrophysiology centre is mandatory. Electrical storm 
should be treated by a team that offers a structured and tailored approach.
Key points
1.  Early recognition of electrical storm and referral to a tertiary electrophysiology 
centre is mandatory. 
2.  Electrical storm should be treated by an experienced team that offers a structured 
and tailored approach.
3.  An increased activation of the sympathetic nervous system is critical in the 
initiation and maintenance of electrical storm.
4.  Electrical storm often represents part of the natural history of advanced cardiac 
disease and may be a predictor of serious deterioration of the underlying disease.
5.  By treating electrical storm we attempt to eliminate the trigger and modify the 
substrate of the ventricular arrhythmia.
6.  Treatment of electrical storm is complex and consists of the administration of anti-
arrhythmic drugs, suppression of sympathetic tone, device re-programming and 
catheter ablation.
7.  Anti-arrhythmic drugs should be given individually, taking into account not only the 
efficacy but also an increased risk of drug-related pro-arrhythmia and other side 
effects.
8.  Electrical storm is a critical condition and even after successful catheter ablation 
patients continue to bear an increased risk of morbidity and mortality.
Chapter 3
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ICM:  ischaemic cardiomyopathy; MT: medical therapy; NA: not applicable; 
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Background - Current guidelines on electrical storm (ES) recommend urgent cath-
eter ablation (CA) in patients with structural heart disease. However, studies on ES 
may include a highly selected group characterised by a referral bias for ablation 
and therefore limited outcome data is available to show superiority and support 
immediate CA. The aim of the present study is to show real world data on the out-
come of ES and the influence of timing of CA. 
Methods - ES patients were selected from a prospective implantable cardioverter 
defibrillator (ICD) database. ES was defined as > 3 appropriate ICD therapy within 
24h. VT recurrences were compared between patients who underwent early CA, 
late CA and patients who had conservative treatment (CNT). Early CA occurred 
within 90 days of the first ES.  
Results - In 2544 ICD patients, 129 were identified that fulfilled the definition of 
ES. Patients had a median follow-up of 6.4 years [IQR 3.9 - 9.2]. Sixteen patients 
had CA for ES, in 6 early and in 10 late. CA for ES led to a 6-fold ICD therapy reduc-
tion as compared to an increase of 1.5 in CNT. Patients with early CA had a lower 
number of ICD therapy on follow-up: 1 [0-20] versus 63 [12-135] in patients with 
late CA (p = < 0.05). 
Conclusions - CA for ES in the absence of reversible triggers in a highly selected 
patient group may reduce the burden of ICD - therapy on follow-up as compared to 
CNT if undertaken within 90 days.
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Introduction
Electrical storm (ES), a state of electrical instability manifested by several ep-
isodes of ventricular tachycardia (VT) in a short period of time, leads to high 
morbidity and mortality.1,2 ES often occurs in the setting of a critically ill patient.3,4 
An implantable cardioverter defibrillator (ICD) can terminate VT, however it will 
eliminate neither the trigger nor the substrate of the arrhythmic storm3 and ICDs 
do not provide definite protection against sudden cardiac death (SCD).⁵ Current 
guidelines recommend urgent catheter ablation (CA) in patients with scar re-
lated heart disease.⁶ Urgent CA however, often carries a logistic challenge. Yet, 
the guidelines that advocate early intervention is based on a single publication.⁷ 
In this article on patients with ES who underwent CA there was no analysis per-
formed in order to provide data on timing of ablation, apart from a group who 
underwent CA < 24h for drug refractory VT in refractory cariogenic shock. Few 
comparative studies between conservative treatment (CNT) and ablation for ES 
have been performed.8,9 Studies on ES may represent a highly selected group 
characterized by a referral bias for ablation. Consequently there is limited out-
come data available to show superiority and support for immediate catheter 
ablation. More importantly, clear recommendations have been provided for the 
optimal timing of intervention for ES despite the current lack of available data 
on proper timing of ES ablation. There is an urgent need for more data to justify, 
replace or support current guidelines. 
The aim of the present study is to show real world data from an ICD database on 
the outcome of ES and the influence of timing of ablation.
Methods
Study Cohort
The study population was included from the ICD registry of the cardiology de-
partment of Erasmus MC. All ICD carrying patients in Erasmus MC are prospec-
tively followed and all of those patient who had ES between January 2005 until 
March 2017 were included in the present study. In total 2544 ICD patients were 
screened. ES patients were selected from the ICD database taking all events into 
consideration. ES was defined as > 3 ICD -therapies within 24h with the episodes 
of VT separated by more than 5 minutes.²,¹⁰ If patients had more than one ES, the 
first ES after ICD implantation was seen as the index ES. Type and timing of inter-
vention after ES was studied.
Ethical approval
This was a retrospective cohort analysis of patients with a clinical indication for 
ICD - therapy. The need for written informed consent was waived.
Intervention
Medical therapy and/or ablation and timing of the ablation was decided at the 
discretion of the treating physician, influenced by current guidelines and insight.
Ablation Protocol
VT ablation was performed for patients not responding to AAD or as a first-choice 
for recurrent or incessant arrhythmia. All CA procedures were performed in ac-
cordance with institutionally approved local medical treatment protocols of the 
Erasmus Medical Center. 
Ablation was performed targeting VTs induced by programmed electrical stimula-
tion (PES) and modifying the electrical substrate. CA was performed either manu-
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ally or using remote magnetic navigation (Stereotaxis, Inc., St. Louis, MO, USA.) 
when available.
The left ventricle was accessed through a transaortic or transseptal approach. 
Electroanatomic maps were obtained while patients were in sinus rhythm (CARTO 
3, Biosense Webster Inc, Diamond Bar, CA; or EnSite, St. Jude Medical, Minneap-
olis, MN). Bipolar voltage criteria were used to identify scar (< 0.5 mV), scar-bor-
der zone (0.51–1.49 mV) and healthy tissue (> 1.5 mV).
If not incessant, VT was induced by PES and activation or entrainment mapping 
was performed to locate exit sites and critical isthmuses. Pace-mapping was used 
for hemodynamically unstable VTs. Substrate modification was based on the elim-
ination of local abnormal potentials. PES was used at the end of the procedure to 
assess ablation success. Successful ablation was defined as no inducible VT.
Follow-up
Follow-up started at the time of the occurrence of the index ES. In-clinic device in-
terrogation was performed on regular visits scheduled every 3–6 months and after 
symptomatic events. The ICD settings were left at the discretion of the physician 
and were influenced by the most recent guidelines at the time of presentation. In 
addition to in-clinic interrogation, some patients used remote monitoring of their 
implanted ICD system. All ICD - therapies were analyzed for appropriateness. Pa-
tients were monitored for recurrent ES. Early CA was defined as ablation that took 
place within 90 days of the first ES.
Endpoints
We analyzed the following parameters: mortality, heart transplantation, recurrenc-
es, number of recurrences and ES during follow-up. VT and ES recurrences were 
compared between patients who underwent CA and those with CNT. If patients had 
more than one ES, time to ablation was calculated for the index ES. The outcome of 
CA related to timing was analyzed.
Statistical analysis
After checking for normality, mean values and standard deviations were calculat-
ed for normally distributed continuous variables. Median and interquartile ranges 
(IQR) were computed for continuous variables with non-normal distribution. De-
scriptive statistics for categorical data were expressed in absolute numbers and 
percentages. Comparison of continuous variables between groups was made by 
unpaired Student’s t -tests. In the case of non-normal distribution of data, the 
Mann–Whitney U-test and for related samples the Wilcoxon test was used. When 
comparing frequencies, the chi-square test, ANOVA and Kruskal Wallis test were 
used, as appropriate. Event-free survival rates were determined using the 
Kaplan Meier method and differences were evaluated by the log-rank test. A 2-sid-
ed P-value of < 0.05 (2-tailed) was considered significant. Data were analyzed 
using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). 
Results
Among 2544 ICD patients, 129 patient who had ES were included in the registry 
and had a follow-up duration of 6.4 years.
Study population
In this ES cohort of 129 patients, ischemic, dilated and hypertrophic cardiomyop-
athy were present in respectively 54, 25 and 6% (Table 1). Other underlying etiol-
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ogies were arrhythmic right ventricular cardiomyopathy (n = 1), corrected congen-
ital heart disease (n = 7) and channelopathies (n =7). In 48% of the patients ICDs 
were implanted for primary prevention. ES occurred a median of 438 days after ICD 
implantation [IQRS 55-1331] (Table 2). ES was the first occurrence of arrhythmia in 
36% of the patients. On average, 3 ICD - therapies occurred during ES with a maxi-
mum of 49 ICD - therapies. The median CL of the first ES episodes was 315ms (319 
ms in CNT and 366ms in the ablation group) (p = 0.02). Of all 129 first ES episodes, 
11 (7%) were VF. There were not significantly more VF episodes in the CNT group: 
8.9% versus 6.3% in the ablation group. (p = NS), However slow VT occurred more 
often in the ablation group (11 versus 45% in the ablation group, p < 0.01).
Age, ejection fraction (EF), New York Heart Association functional classification 
(NYHA) class, number of patients with ischemic heart disease, use of class III an-
ti-arrhythmic drugs (AAD) and co-morbidities were not significantly different be-
tween the conservative, early and late ablation treatment group. ES was stabilised 
with medical therapy in 41 patients (3 in the ablation group), in 80% the prescribed 
AAD was Amiodarone. During follow-up an anti-arrhythmic drug was used in 78% of 
all the ES patients, and in 79% of the patients treated with CA.
Course of electrical storm
During a follow-up of 6.4 years [IQR 3.9 - 9.2], 74% of the patients had recurrent 
ICD - therapies after ES with a median number of 4 ICD - therapies (Table 3). ES 
re-occurred in 46% of the patients. Patients who had ICD - therapy before the first 
ES had a median of 11 [1-40] VA recurrences versus 1 [0-6] VA recurrences without 
ICD - therapy before the first ES (p = < 0.05). Patients who had an ICD for primary 
prevention had a median of 3 [IQRS 0- 11] VA recurrences after ES versus a median 
of 10 [IQRS 1-37] VA recurrences in patients with an ICD for secondary prevention (p 
< 0.05). Thirty-eight percent of the patient in this cohort died during follow-up and 
6% received a heart transplant. 
ES trigger and cause of death
The trigger for ES was known in 29% of the cases. In 18 patients the trigger for ES 
was either acute decompensation of chronic heart failure, terminal heart failure, low-
ering or cessation of anti-arrhythmic drugs, or electrolyte imbalances. In few cases 
the initiation of biventricular pacing with left ventricular stimulation, sepsis or heart 
surgery was thought to be the triggering factor. 
Forty-nine patients (38%) died during a median of 6.4 ± 3.1 years of follow-up. Two 
patients died at the same day as the ES and 4 patient died within 30 days of ES. In 
only 2 cases death was directly attributed to ES. One patient had refractory ventric-
ular fibrillation during follow-up. Terminal heart failure was the cause of death in 10 
patients. Four patients died of multi organ failure due to sepsis. Other causes were 
cancer (1 patient), trauma (1 patient) and rejection to heart transplant (1 patient). In 
the remaining cases the cause of death was unknown.
Catheter ablation for ES
Sixteen patients had an ablation for ES, with an average interval of 373 days after 
the first ES. Nine patients had an earlier episode of VT before the occurrence of ES. 
Patients who underwent late CA (Table 2) had more total number of ICD - therapies 
(p = 0.04), a higher number of previous ICD - therapies (p < 0.01), but not more ICD 
- therapies during ES. Eight patients had substrate modification. In 2 cases the PVC 
that triggered VF or polymorphic VT was the target of ablation, 1 in the early ablation 










phic VT. In 6 out of 16 cases ablation was performed with remote magnetic navi-
gation. On ablation was performed with the aid of a hemodynamic support device 
(Impella). Acute procedural success was 94%. Ablation was unsuccessful in 1 case 
and in 2 cases only partly successful. In 3 patients a repeat VT ablation was re-
quired, in 1 of the 3 cases the focus was not reached from the endocardium at the 
initial unsuccessful baseline procedure and during repeat ablation 2 weeks later 
was successfully targeted epicardially.
Ablation versus conservative treatment
Patients treated by CA for ES had 12.3 ICD - therapy/year before the CA procedure 
(Figure 1). After CA the year-burden of ICD - therapy decreased to 2.4 ICD - ther-
apies/year (P < 0.05). Patients who had CNT for ES had 1.2 ICD - therapies/year 
before ES and after ES it increased to 3.0 ICD - therapy/year after (P = NS).
Timing of intervention by ablation
In 6 and 10 patients ablation took place within 90 days (early ablation) and after  
90 days (late ablation) of the index ES, respectively. If patients had an early abla-
tion for ES (Table 3) 60% of the patients had a recurrence and 0% of the patients 
had a repeat ES on follow-up versus 90% and 40% respectively in the late ablation 
group (p = NS). Patient with an early ablation had a significant lower median num-
ber of ICD - therapies of 1 [0-20] versus 63 [12-135] in patients with a late ablation  
(p < 0.05). Figure 2 demonstrates the Kaplan Meier survival curves for mortality, 
recurrence and ES recurrence. Recurrence free survival is significantly different  
(p = 0.05) within the 3 groups in favour of early ablation.















age 59 SD ± 15 58 ± 7 63 ± 8 59 ± 16 0.77
iCMP 69 (54) 3/6 (50) 6 (60) 60 (53) 0.90
LVEF 30 [25-35] 27 [22-30] 30 [28-40] 30 [25-36] 0.46




138 [99-167] 125 [108-
153]
0.71
median nyha class 2 [1-3] 2 [1.8-2.3] 2 [2-2] 2 [1-3] 0.94
ICD for primary 
prevention
62 (48) 2 (33) 2 (20) 58 (51) 0.13
atrial fibrillation 38 (30) 2 (33) 1 (10) 25 (22) 0.52
CKI* 20 (16) 0 (0) 3 (30) 17 (15) 0.26
DM 16 (12) 0 (0) 4 (40) 34 (30) 0.22
amiodarone at baseline 26 (20) 3 (50) 2 (20) 21 (19) 0.18
CKI: chronic kidney injury; DM: diabetes mellitus; CMP: ischemic cardiomyopathy; LVEF: left ventricular 
ejection fraction; NYHA: New York Heart Association functional classification
*CKI chronic kidney injury : defined as creatinine > 120
Baseline characteristics in all ES patients, in the different subgroups and a p- value was calculated 
within the 3 subgroups






























358 [39-990] 489 [66-
1332]
0,62
median number of ICD-
therapy before ES
1 [IQR 0-4] 3.5 [0-26] 22 [IQR 0-88] 1 [0-4] < 0.01
number of patients 
with first shock = 
shock during ES (%)
47 (36) 2 (33) 2 (20) 43 (38) 0.5
median number of ICD-
therapy during ES
3 [3-8] 4 [3-8] 4 [IQR 3-14.5] 4 [3-7] 0.87












number of patients 
with VF during first first 
episode of ES (%)
11 (9) 1 (17) 0 (0) 10 (89) 0.48
number of patients 
with slow VT during 
first episode of ES (%)
19 (15) 3 (50) 4 (40) 12 (11) < 0.01
median total number of 
ICD-therapy
18 [IQR 8 - 
39]
10 [8-30] 72 [IQR 39-
142]
16 [8-35] 0.04
Table 2  ICD data at baseline and during follow-up















- mean FU duration 
(yr) - SD
6.4 ± 3.1 6.1 ± 3.3 6.2 ± 4.1 6.4 ± 3.1 0.96
ICD-therapy
patients with 
recurrence of ICD 
-therapy
95 (74) 4 (60) 9 (90) 82 (73) 0.45
patients with 
recurrence ES
52 (40) 0 (0) 4 (40) 48 (43) 0.12
median number of ICD-
therapy after index ES
4 [0-21] 1 [0-20] 63 [12-135] 4 [0-19] < 0.05
other
mortality 49 (38) 1 (17) 4 (40) 44 (39) 0.55
heart transplantation 8 (6) 0 (0) 1 (10) 6 (5) 0.72
Table 3 Follow-up after electrical storm
CNT: Conservative treatment; ES: electrical storm; ICD: implantable cardioverter defibrillator; SD 
standard deviation; yr year
Follow-up data in all ES patients, in the different subgroups and a p- value was calculated within the  
3 subgroups










Figure 2 Kaplan Meier  
A. Kaplan Meier Recurrence 





















Kaplan Meier Recurrence 
conservative treatment
ablation < 90 days
ablation > 90 days
p = 0.05
Page 1
Figure 1 shock reduction early versus late ablation
before and after ES treatment
before and after ablation for ES
p= NS
p< 0.05
shock reduction per patient-year























































C. Kaplan Meier Survival 






















ablation < 90 days
ablation > 90 days
p = 0.71
Page 1
B. Kaplan Meier Electrical Storm 

















Kaplan Meier Electrical Storm
conservative treatment
ablation < 90 days
ablation > 90 days
p = 0.37
Page 1
B. Kaplan Meier recurrence of Electrical Storm 
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 6
  113





























C. Kaplan Meier Survival 
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Discussion
The present study a real life outcome data study demonstrating the natural evolve-
ment of ES. CA for ES leads to a 6-fold shock reduction as compared to an increase 
of 1.5 fold in case of CNT for ES. If ablation for ES takes place within 90 days of the 
first ES, invasive treatment may lead to a lower ICD - therapy burden.
Main findings compared to previous results
The incidence of ES in this study, a mixed population of primary and secondary 
prevention, was 5.1% during a median follow-up of 6.4 years.In comparison to pre-
vious studies the incidence was low, also set against the observed patient popula-
tion. In the VANISH trial an incidence of ES in 25-33% was seen during a follow-up 
period of 28 months. Patients after MI were included when they had experienced 
an ICD shock, 3 or more ATP or ES in the previous 6 months. In the MADIT-II21, a 
study on ICD for primary prevention, 4% of patients developed ES during an aver-
age follow-up of 20.6 months. After 2014 there has been a considerable change 
in ICD programming after the MADIT-RIT study22 impacting primary prevention 
patients. Also heart failure therapy has intensified in the previous decade, including 
the use of resynchronisation devices.
In our cohort ES adversely affects outcome. Mortality amongst this population is 
high, 38% in 6.4 years. In the MADIT-2 sub-study 2-year mortality was as high as 
54%, in a population with cardiomyopathy of ischemic origin and severely impaired 
EF. Factors such as impaired left ventricular EF13, pre-existing NYHA class, cardio-
genic shock14, age and other co-morbidities influence the outcome of patients with 
ES. We found that if patients had their ICD for secondary prevention or had ICD 
- therapy before the first ES, a significant higher percentage of the patients had 
recurrences on follow-up. In the AVID trial15, the development of ES was a relatively 
late phenomenon, with the initial episode occurring 9.2±11.5 months after ICD im-
plantation. In the current study it was even longer: 16 months (2-44). This probably 
indicates earlier referral for primary implantation for an ICD.
 
Ablation treatment for ES
VT ablation compared to CNT did not reduce the number of patients with recur-
rence, neither did VT ablation effect mortality. Nonetheless shock burden was 
significantly reduced after ablation. Late ablation for ES had a comparable outcome 
as CNT. This latter observation probably derives from a selection of patients with 
highest ventricular arrhythmia (VA) burden in the late ablation group. Patients with 
single ICD - therapy events before ES and ICD implanted for secondary prevention 
had significantly higher number of ICD - therapies during follow-up. In previous 
studies besides ICD implanted for secondary prophylaxis, lower left ventricular EF, 
serum creatinine were independent predictors for ES recurrence.¹³
Rationale for early VT ablation for electrical storm
CA for ES in the absence of reversible triggers reduces the burden of ICD - ther-
apy if performed within 90 days. Search for contingent conditions that may have 
precipitated ES is crucial. In the current study potential triggers were found in a 
minority. 
Our results are in line with previous trials that show a longer VT free survival16 
when ES patients have CA within 30 days compared to a delayed ablation. Evidence 
for prophylactic ablation for unclustered arrhythmic events to reduce the burden of 
shock¹⁷, ¹⁸ and maintaining longer VT free survival¹⁹ has previously been published.
Yet, there is limited evidence for superiority of a rescue ablation (< 24h)7 compared 
to conventional stabilization in the majority of ES patients. Further research to con-
firm our results is warranted.
Electrical storm prognostic value or symptom
It remains a question whether ES contributes to higher mortality in a direct manner 
or rather is an epiphenomenon of advanced heart disease or systemic illness. Most 
of the deaths on follow-up were non-SCD, which points in the direction of ES being 
a marker of progression of underlying disease. 
Patients with early VT recurrence had higher mortality than those without VT re-
currence during follow-up.²⁰ Previous studies found that successful VT ablation in 
patients after ES improves survival.² However, survival of patients with ES even in 
the absence of VT recurrences during follow-up were lower compared to patients 
without either ES and VT recurrences after a single arrhythmic event, suggesting 
that non-arrhythmic factors still act on these patients and might lead to death.
Limitations of the Study
There are several limitations to note. The current study is limited by historical 
evolving treatment of ES, more evolving ablation techniques and ICD programming 
that constitutes with the current standard of care. Including only patients who had 
> 3 ICD therapy < 24hours, patients with ES and VT under the therapy zone of the 
ICD may have been missed. We cannot exclude a bias in selection for the relative 
small number of subjects that had CA. The relatively low incidence of ICD therapies 
before ES may have influenced decision to follow CNT. Therefore the limited num-
ber of patients that underwent CA may hamper generalizability.
Currently, substrate homogenisation has become an established therapy for VT 
ablation.21 In recent years ICD programming has evolved to prevent shocks, by 
delayed ICD - therapy and ATP first.12,22 The study ensures detection of all recurrent 
treated VTs, but not the monitored or unmonitored VTs. Lastly the studied popu-
lation was heterogeneous therefore our conclusions cannot be directly extrapo-
lated to the individual patient. Large differences in the burden of ICD interventions 
amongst the different study groups could also be addressed to different type of 
patients in term of electrical instability and those selected for late CA could be 
patients who were beholding the highest electrical instability. The observed differ-
ence in outcome in different timing for CA in patients with ES, should be verified in 
a randomised controlled fashion with a larger number of patients. Yet, at present 
this is the largest real outcome study that compares ablation to CNT for ES.
Conclusion
Ablation for ES in the absence of reversible triggers may reduce the burden of ICD 
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Currently, comparative data on procedural and long-term clinical outcome of out-
flow tract (OT) idiopathic ventricular arrhythmia (IVA) ablation with manual (MAN), 
contact force (CF), and magnetic navigation system (MNS) ablation are lacking. 
The aim of this study was to compare the procedural and long-term clinical out-
come of MAN, CF, and MNS ablation of OT IVAs.
Methods and results
Seventy-three patients (31 MAN, 17 CF, and 25 MNS patients; consecutive per 
group) with OT IVA, who underwent catheter ablation in our centre were analysed. 
Procedural success rates (success at the end of the procedure), procedural data 
and long-term follow-up data were compared. Baseline patient demographics were
comparable. Procedural success rates were similar (MAN 81%, 71% CF, and MNS 
92%; P = 0.20). Median fluoroscopy time was shorter in the MNS group: MAN 29 
(16–38), CF 37 (21–46), and MNS 13 (10–20) min (P = 0.002 for MNS vs. CF and 
MAN). The overall complication rate was: MAN 10%, CF 0%, and MNS 0% (P = 
0.12). Median follow-up was: MAN 2184 (1672–2802), CF 1721 (1404–1913), and 
MNS 3031 (2524–3286) days (P <0.001). Recurrences occurred in MAN 46%, CF 
50%, and MNS 46% (P = 0.97). Repeat procedures were performed in MAN 20%, 
CF 40%, and MNS 33% (P = 0.32).
Conclusion 
Procedural and long-term clinical outcome of OT IVA ablation are equal for MAN, 
CF, and MNS. MNS has a favourable procedural safety profile due to the shorter 
fluoroscopy time compared with MAN and CF.
Introduction
Idiopathic ventricular tachycardias (VTs) account for approximately 10% of all VTs.1 
Additionally, depending on the measurement duration and the method of detec-
tion, premature ventricular contractions (PVCs) in patients without structural heart 
disease can be found in about 4–50% of the population.2,3 They are commonly 
located in one of the cardiac outflow tracts (OT).1 Idiopathic ventricular arrhythmias 
(IVAs) generally have a benign course.1 However, they can be highly symptomatic 
and frequent arrhythmias can result in the development of tachycardiomyopathy.1 
Therefore, it is important to consider that treatment with catheter ablation leads to 
a better quality of life and reversal of tachycardiomyopathy.4,5 Catheter ablation
of VTs is an important and increasingly performed treatment and has a high pro-
cedural success rate for both VTs and PVCs.1,6 Recent technological advances 
have been made to increase the safety and efficacy of this treatment. The use of a 
magnetic navigation system (MNS) has been shown to result in higher procedural 
success rates and a better safety profile compared with manual (MAN) ablation
due to the flexible nature of the MNS catheters.7,8 Additionally, contact force (CF) 
sensing ablation catheters have been developed to reduce cardiac perforations 
and have been shown to enhance lesion formation in ablation of atrial fibrillation.9 
Data on IVA ablation with CF are sparse and there are very few comparative stud-
ies on longterm clinical outcome of these techniques. The aim of this study is to 




This prospective registry included 73 patients, consecutive per group, who un-
derwent catheter ablation for OT IVAs either with MAN, CF, or MNS ablation before 
2014. A total of 31 patients were included in the MAN group, 17 in the CF group, 
and 25 in the MNS group. There are two separate electrophysiology laboratories at 
our centre: one equipped with the MNS system and one without. For all patients the 
index procedure was a first procedure. Paediatric patients were defined younger 
than the age of 18 years. A medical ethical committee, the METC, approved data 
collection as prospective registry. 
Electrophysiology studies — ablation strategy
The procedures were performed by the same group of senior electrophysiologists 
and with the assistance of two fellows over the entire study duration. In our centre, 
all operators are equally trained in both manual and remote MNS ablation. All ablation 
procedures were performed in accordance with institutionally approved local med-
ical treatment protocols from the Erasmus MC, Thoraxcenter, Rotterdam. Informed 
consent was obtained from all patients before the ablation procedure. Within 48 h 
post-procedure, a resting 12-lead electrocardiogram, laboratory tests, a chest X-ray, 
and two-dimensional echocardiography were obtained from all patients. Standard 
periprocedural medication protocols were followed in all patients. Patients were 
instructed to discontinue antiarrhythmic drugs (except amiodarone) for a period of at 
least four half-lives prior to the planned ablation procedures. After a successful pro-
cedure the use of antiarrhythmic drugs was halted. The procedures were performed 
during a fasting state, with use of local or general anaesthesia.
As clinically indicated at the discretion of the operator, market-approved diagnos-
tic, and ablation catheters were used. Left-sided access was achieved via retro-
















•  This is the first study directly comparing the procedural and 
long-term clinical outcome of catheter ablation of exclusively 
outflow tract idiopathic ventricular arrhythmias between manual 
(MAN), contact force (CF), and magnetic navigation system (MNS) 
catheter ablation.
•  The major findings of this study are that there are no significant 
differences in procedural or long-term success rates 
between these three groups and that fluoroscopy time is 
shorter for MNS compared with MAN and CF.
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and the exact location of the arrhythmia. All procedures were performed using a 
three-dimensional mapping system. Standard ablation andmapping techniques 
were applied based on hospital protocol at the operators’ discretion. For induction, 
programmed stimulation was performed using up to triple extra-stimuli pacing from 
the right ventricular apex, right ventricular outflow tract (RVOT), or left ventricle.
Isoproterenol was administered in a dosage ranging between 1.3 mg/min and 2.7 
mg/min. As a first step usually an activation map was created (preferably with a lo-
cal activation timing pre-QRS of -30ms). This was then followed by pace mapping 
(the site with a paced 12-lead QRS morphology identical (12/12) to an inducible 
monomorphic VT or PVC was assumed to be the exit site of that particular VA) for 
verification.
Additionally, early presystolic discrete potentials were targeted when present. 
There were no differences between ablation strategies in the MAN, CF, or MNS ab-
lation groups. Crossovers were excluded from the study. The following definitions 
of endpoints of procedural success were applied: if the VT was inducible, non-in-
ducibility was the endpoint; if only PVCs were present, then the complete termina-
tion of clinical PVCs or presence of <5 PVCs per hour from different locations was 
required. The presence of a pacemaker (PM) or implantable cardioverter-defibril-
lator (ICD) was not considered a contraindication for MNS guided ablation proce-
dures, which is consistent with the product labelling for the MNS.8 
Magnetic navigation system-guided ablations 
The procedures in the MNS group were performed with the NiobeVR II Magnetic 
Navigation System (Stereotaxis, Inc., Saint Louis, MO, USA) in an EP lab equipped 
with a Siemens Axiom Artis (Siemens, Erlangen, Germany) fluoroscopy system. All 
patients were treated with a NaviStar RMT ThermoCool catheter (Biosense Web-
ster, Inc., Diamond Bar, CA, USA). Electroanatomical mapping was performed using 
the CARTO RMT (BiosenseWebster, Inc., Diamond Bar, CA, USA) system.8 
Manual- and contact force-guided ablations 
The manual catheter ablation procedures took place in an EP lab equipped with 
a Philips Allura Xper (Philips, Eindhoven, the Netherlands) fluoroscopy system. 
Electroanatomical mapping was performed either with the EnSite NavX system (St. 
Jude Medical, Inc.) or CARTO (Biosense Webster Inc.). The ablation catheters that 
were used included the following: Biosense Webster Navistar Thermocool D and 
F curve and St. Jude Cool Path Duo.8 Contact force ablation was performed in the 
same lab using the same equipment as mentioned for MAN ablation. Ablation cath-
eters that were used included the following: Thermocool Smarttouch CF (Biosense 
Webster Inc., Diamond Bar, California, USA) and TactiCath (Endosense/ St Jude 
Medical, St Paul, Minnesota, USA). A target contact force of between 10 and 20 g 
was pursued for all ablations. 
Data collection and analysis
The parameters that were analysed for all groups include the following: procedural 
success rate, fluoroscopy time, procedure time, total radiofrequency (RF) appli-
cation time, RF application number, and major and minor procedure related com-
plications. The procedural success rate was assessed based on the conclusions 
in the procedural reports. At follow-up, recurrences and repeat procedures were 
assessed. Fluoroscopy time was recorded from the fluoroscopy system in both 
rooms. 
Procedure
Time was specified as the interval between subcutaneous injection of lidocaine
to the groin and removal of catheters from the patients’ body, including a 30-min 
waiting period for every case. Any adverse event registered by the operator during 
the procedure, by the attending cardiologist prior to hospital discharge or by the 
general physician during follow-up was examined by a trained electrophysiologist 
and was considered as a complication if the event could be ascribed to the proce-
dure. Major complications were defined as pericardial effusion and/or tamponade, 
permanent AV block, PM/ICD damage requiring device or electrode replacement, 
stroke, major bleeding, or death. Minor complications were defined as minor 
bleeding, transient ischaemic attack, new permanent bundle branch block, tran-
sient ST-elevation, pericardial effusion without the need for intervention, an audible 
steam pop without consequences and temporary AV block.8
Follow-up
Routine follow-up visits were scheduled at the outpatient clinic of our department 
for all patients 3 months after the procedure and subsequently every 6 months. 
24-h Holter recordings were employed during these visits for documentation of 
recurrent arrhythmias. For long-term follow-up, patient records were analysed and 
all patients were contacted by phone and interviewed concerning recurrences and/
or repeat ablation procedures (performed in other institutions).
Statistics
The normality of distribution was assessed using the Shapiro–Wilk test. Descriptive 
statistics are presented as mean ± standard deviation for continuous variables if 
normally distributed, or otherwise as median with 25th and 75th percentiles, where 
appropriate. Data were compared by one-way ANOVA, Kruskal–Wallis test, or 
Mann–Whitney test, as appropriate.
Categorical data were expressed as percentages and compared with Fisher’s exact 
test. Statistical analysis was performed using SPSS version 21 (IBM Corp., Somers, 
NY, USA). Statistical significance was defined as P-value of <0.05 (two-tailed).
Results
Demographics and procedural results
Baseline characteristics including age, gender distribution, number of paediatric 
patients, medication use, and left or right OT VA did not significantly differ be-
tween the three groups, except for beta-blocker use, which was higher in the CF 
group compared with the MNS group (P = 0.007) (Table 1). There was no significant 
difference in procedural success rates between the groups (Table 2). Fluorosco-
py time was significantly shorter in the MNS group compared with the MAN and 
CF group (P= 0.002 for MNS vs. MAN and CF). Procedure time, application time, 
number of applications, and hospital stay were equal in all three groups (Table 2). 
The application time was not significantly different between MAN and CF [499 
(128–870) vs. 200 (120–270) s; P= 0.57] or MAN and MNS [499 (128–870) vs. 291 
(183–431) s; P = 0.15].
Complications
The complication rates are reported in Table 2. There were no significant differenc-
es in overall, minor, or major complication rates. In total, one major complication 
(tamponade after perforation, with full recovery after pericardiocentesis) occurred, 
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both from the MAN group (Table 2). In both instances an audible steam pop oc-
curred without consequences and a normal CT afterwards.
Long-term follow-up
Median follow-up was 2184 (1672–2802) days for the MAN group, 1721 (1404–1913) 
days for the CF group, and 3031 (2524–3286) days for the MNS group (P <0.001). In 
total, five patients were lost to follow-up. In the MAN group, one patient was unable 
to answer our telephone inquiry due to Alzheimer’s disease. In the CF group, two 
patients were lost to follow-up; both patients did not respond to our efforts to con-
tact them. In the MNS group, two patient were lost to follow-up; one patient due to 
loss of contact after emigration and one patient deceased because of acute myeloid 
leukaemia. The number of recurrences and repeat procedures were equal in the three 
groups (Table 2, Figures 1 and 2). Six patients had an early recurrence during the ad-
mission period after a reported successful procedure.
Of those, three patients were in the MAN group, one was in the CF group and two 
were in the MNS group. Repeat procedures were successful in 67% (4 out of 6) pa-
tients in the MAN group, 83% (5 out of 6) patients in the CF group, and 100% (8 out of 
8) patients in the MNS group. The ablation technique used for the repeat procedures 
was MAN in 28% (5/18), CF in 39% (7/18), MNS in 28% (5/18), and cryoablation in 6% 
(1/18). Of two repeat procedures the ablation technique was not reported. Repeat 
procedures with MAN were successful in 80% (4/5) of procedures, with CF in 86% 
(6/7), with MNS in 100% (5/5), and with cryoablation also in 100% (1/1) of procedures. 
Overall, there were no major complications during repeat procedures. During repeat 
procedures one minor complication (post-ablation pericarditis) occurred after a CF 
procedure. In two repeat procedures occurrence of complications was not reported.
MAN CF MNS p-value
Patient total (n) 31 17 25 25
Patient age (years) 48 ± 16 45 ± 18 49 ± 13 0.72
Sex (male) 18 (58%) 8 (47%) 10 (40%) 0.40
Paediatric 2 (7%)  2 (12%) 0 (0%)  0.25
ASA  4 (13%) 3 (18%)  3 (12%) 0.86
Acenocoumarol  2 (7%) 0 (0%) 0 (0%) 0.25
AADs
Class III 5 (16%)  0 (0%) 1 (4%) 0.10
Beta blocker 15 (48%) 12 (71%)  7 (28%) 0.024*
VA region 0.51
RVOT 23 (74%) 15 (88%) 20 (80%)
LVOT  8 (26%) 2 (12%) 5 (20%)
Patient characteristics and comparison of ablation results between the MAN and MNS groups. 
Descriptive statistics are presented as mean ± SD for continuous variables.
*P < 0.05 for MNS vs. CF. 
AADs: antiarrhythmic drugs; ASA: acetylsalicylic acid; CF: contact force; LVOT: left ventricular outflow 
tract; MAN: manual; MNS: magnetic navigation system; RVOT: right ventricular outflow tract;  
SD: standard deviation; VA: ventricular arrhythmia.










Table 2  Procedural data
MAN (n= 31) CF (n= 17) MNS (n= 25) P-value
Procedural success 25 (81%) 12 (71%) 23 (92%) 0.20
Ablation data
Approach (% of group total) 0.55
Antegrade  22 (71%) 15 (88%) 20 (80%)
Transseptal  1 (3%) 1 (6%) 0 (0%)
Retrograde  7 (23%) 1 (6%) 5 (20%)
Epicardial 1 (3%) 0 (0%)  0 (0%)







Application number 11 (4–21) 7 (3–17) 7 (4–9) 0.35
Application time (s) 499 (128–870) 200 (120–270) 291 (183–431) 0.46
Fluoroscopy time (min) 29 (16–38) 37 (21–46) 13 (10–20) 0.001*
Procedure time (min) 175 (123–221) 165 (146–180) 150 (120–173) 0.31
Hospital stay (days) 3 (2–5) 3 (2–4) 2 (2–3) 0.51
Complications
Overall 3 (10)% 0 (0%) 0 (0%) 0.12
Minor 2 (7%) 0 (0%) 0 (0%) 0.25
Major 1 (3%) 0 (0%)  0 (0%) 0.50
Long-term follow-up







Recurrences 12 (46%) 5 (50%) 10 (46%) 0.97
Repeat procedures 6 (20%) 6 (40%) 8 (33%) 0.32
Comparison of ablation results between the MAN, CF, and MNS groups. Descriptive statistics are 
presented median with (25th and 75th percentile). *P < 0.05 for MNS vs. MAN and CF.
CF: contact force; LVOT: left ventricular outflow tract; MAN: manual; MNS: magnetic navigation system
Figure 1 Repeat procedure-free rate and time 
to repeat procedure. CF: contact force; MAN: 
manual; MNS: magnetic navigation system
Figure 2 The recurrence-free rate and time to 
recurrence. CF: contact force; MAN: manual; 
MNS: magnetic navigation system
Discussion
This is the first study directly comparing the long-term clinical outcome of exclusive-
ly OT IVA ablation between MAN, CF, and MNS catheter ablation. The major findings 
of this study are that there are no significant differences in procedural or long-term 
success rates between these three groups and that fluoroscopy time is shorter for 
MNS compared with MAN and CF.
Manual catheter ablation success rates and complications
In literature, conflicting success rates are reported for manual catheter ablation 
of IVAs. Procedural success rates between 54% and 100% have been reported.10,11 
Reported mid-term success rates also vary, ranging between 55% and 100%.12,13 In 
our present study, the procedural success rate of manual catheter ablation was 81%. 
These varying success rates may reflect differences in follow-up methods, defini-
tions of success, and inclusion bias. Additionally, it may also demonstrate the het-
erogeneity in IVA presentation, from easily accessible and frequently seen locations 
such as the RVOT to more complex regions like the aortic cusps.
Minor complications during manual catheter ablation are reported in literature to be 
between 0% and 20%,13,14 while major complications occur in 0–6%.11,15 In our study, 
minor complications occurred in 7% of the MAN group and major complications in 3%.
Contact force ablation
A recent innovation regarding manual catheter ablation is the use of contact force 
sensing catheters. These catheters were designed to improve catheter—tissue 
contact by providing direct and quantified feedback to the operators of the applied 
pressure on the endo- or epicardium in order to enhance lesion formation and to 
simultaneously improve safety by guarding against excessive applied force.
The advantage of CF ablation is the additional force information that is obtained 
during the ablation. A disadvantage, however, is the increased stiffness of CF cathe-
ters. A recent meta-analysis comparing 19 studies showed that for ablation of atrial 
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fibrillation, the use of CF catheters vs. non-CF MAN catheters resulted in a signifi-
cantly lower occurrence of acute pulmonary vein reconnections and recurrences 
as well as a reduced major complication rate and improved procedure parameters 
during 1 year follow-up.9 However, very few data exist on CF ablation of VAs. One 
study from our centre demonstrated that CF ablation of idiopathic VAs in general 
showed no improvement on complication rate, acute success rate or recurrence rate 
during long-term follow-up compared with MAN or MNS ablation.16
In the current study, we found no improvement of procedural success or recurrences 
and repeat procedures when we compared CF with MAN or MNS ablation.  
Additionally, the CF group complication rate was equal compared with MAN ablation.
Magnetic navigation system ablation
One of the main advantages of MNS over MAN ablation reported in literature is 
safety. Upon publication, not a single myocardial perforation during ablation with 
theMNS has been reported, which is due to the soft and flexible quality of the 
catheter. Furthermore, after completion of an initial learning curve, the use of MNS 
most likely shortens procedure time, which in turn may prevent operator fatigue, 
shortens fluoroscopy time (as supported by the data in this report) and helps to 
reach less easily accessible areas in the heart during mapping.7,17 Another advan-
tage during mapping is the fact that the flexible catheter rarely induces mechanical 
PVCs, which makes identifying focal localizations of ventricular arrhythmias less 
challenging.18 
A report on endocardial voltage maps for the diagnosis of arrhythmogenic right 
ventricular dysplasia comparing MAN and MNS acquired maps, showed MNS maps 
were more accurate because of better defined low voltage regions and higher 
surface areas and volumes of the RV.19 Emphasis on procedural safety is important 
in general, but even more so in the treatment of usually non-lethal conditions such 
as IVAs. The ratio of treatment benefit vs. treatment risk in these cases needs to be 
weighed extra carefully. This makes a system like the MNS particularly useful for 
treating IVAs.
Additionally, as noted in the literature and again demonstrated in this study, most 
IVAs are ablated in the RVOT, which is a vulnerable area due to a relatively thin 
wall and neighbouring structures such as the bundle of his, the left main coronary 
artery, the left anterior descending artery, and the right and left coronary ostia.1,20 
Precision steering and reproducibility of mapping sites by using stored vectors 
helps to avoid these structures and to navigate back to previously determined safe 
and effective ablation targets.17
Clinical outcome
Our data did not show a significant difference in procedural success rates between 
the three groups. As mentioned earlier, apart from a study which showed no sig-
nificant differences between MAN and CF regarding acute and long-term success 
of idiopathic VA ablation in general,16 very few data exist on CF ablation of VAs. A 
recent randomized controlled study comparing MAN and MNS ablation of RVOT 
arrhythmia in 30 patients similarly showed no significant difference in procedural 
success.14 One report comparing MAN and MNS ablation for all VT entities, which 
included a subgroup of IVA, did show a significant difference in procedural success 
(MAN 62% vs. MNS 84%), although the IVA subgroups were unevenly distributed 
in number (21 vs. 49) and included a variety of both OT and non-OT VT locations.8 
Our report did not show any significant differences in long-term clinical outcome; 
recurrences and repeat procedures were similar in all three groups.
Limitations of the study
This study is not a randomized trial and contains a relatively small patient cohort. 
Nonetheless, it should be taken into account that for the studied population of id-
iopathic VA patients this sample size is very reasonable. Additionally, follow-up was 
long and consecutive patients were included in both groups in compensation of the 
nonrandomized nature of this study.
Conclusion
Procedural and long-term clinical outcome of IVA ablation are equal for MAN, MNS, 
and CF. MNS has a favourable procedural safety profile due to the shorter fluoros-
copy time compared with MAN and CF. To confirm our conclusions, more prospec-
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Poor catheter-to-myocardial contact can lead to ineffective ablation lesions and sub-
optimal outcome. Contact force (CF) sensing catheters in ventricular tachyarrhythmia 
(VT) ablations have not been studied for their long-term efficacy. 
Purpose 
The aim of this study was to compare CF ablation to manual ablation (MAN) and re-
mote magnetic navigation (RMN) ablation for safety and efficacy in acute and long-
term outcome. 
Methods 
A total of 239 consecutive patients who underwent VT ablation with the use of MAN, 
CF, or RMN catheters were included in this single-center cohort study from January 
2007 until March 2014. The primary endpoints were procedural success, acute major 
complications, and VT recurrences at follow-up. The median follow-up period was 25 
months.
Results 
Acute successwas achieved in 182 out of 239 procedures (76%). Acute success in-
manual ablation, CF ablation and RMN ablation was 71%, 71%, and 86%, respectively (P 
= 0.03). Major complications occurred in 3.3% and there were less major complications 
(P = 0.04) in the RMN group. After an initial successful procedure, 66 of 182 patients 
(36%) had a recurrence during follow-up. This was not significantly different between 
groups. Using an intention-to-treat analysis, 124 patients (52%) had a recurrence. The 
recurrence rate was lowest in the RMN group.
Conclusion 
The use of CF sensing catheters did not improve procedural outcome or safety profile 
in comparison to non-CF sensing ablation in this observational study of ventricular 
arrhythmia ablations. 
Introduction
Catheter ablation of ventricular tachycardia (VT) has become standard therapy.1-3 
Meanwhile, there is a persistent demand for novel technologies to reduce complica-
tions and to improve success rates. Poor catheter-to-myocardial contact can
lead to ineffective lesions and suboptimal outcomes. Information on contact force 
(CF) has shown to be an important determinant for the success of radiofrequency 
(RF) catheter ablation of atrial fibrillation.4,5 It has been suggested that CF sensing also 
improves the acute outcome of VT ablation in small cohorts and improves safety.6-8 
However, there is a lack of data on the long-term clinical outcomes of with VA ablation 
using CF sensing catheters.
Remote magnetic navigation (RMN) in VT ablation has shown to be superior to manual 
catheter ablation, especially in nonstructural heart disease.9,10 However, there has not 
been a direct comparison of visual and tactile feedback for VT ablation. The aim of this 
study is to compare CF ablation, manual (MAN) ablation, and RMN ablation for safety 
and efficiency in acute and long-term outcomes. Our primary hypothesis was that the 
use of CF catheters improves safety and efficacy compared to manual ablation.
Methods
Study Population and Data Collection
All patients who underwent ablation for ventricular arrhythmias (including patients with 
VT and ventricular extrasystoles [VES]) between January 2007 until March 2014 were 
included in this study. All data were collected prospectively with the exception of the 
CF data, which was collectedlater. The local ethics committee approved the study.
Preprocedural Protocol
All catheter ablation procedures were performed in accordance with institutionally 
approved local medical treatment protocols of the Erasmus Medical Center. Written in-
formed consent for the procedure was obtained from all patients. Thrombus in the left 
ventricle was excluded by the use of a 2-dimensional transthoracic echocardiography. 
Antiarrhythmic drugs were discontinued for at least 4 half-lives prior to the procedure 
with the exception of amiodarone. In the case of an emergency VT procedure antiar-
rhythmic drugs were not ceased.
Procedural Protocol
The procedures were performed under local or general anesthesia. The choice of ac-
cess (retrograde transaortic or transseptal) to the left ventricle was left up to the
preference of the operator. Transseptal punctures were always guided by intracardiac 
echocardiography (ICE). Programmed electrical stimulation (2 drive trains at 400 and 
600 milliseconds, up to 3 extrastimuli) was performed before and after the ablation to 
induce VT and to determine success, respectively. The procedures were
performed using EnSite NavX 3D (St. Jude Medical Inc., St. Paul, MN, USA) mapping or 
the CARTO system (Biosense Webster, Inc., Diamond Bar, CA, USA). The following CF 
ablation catheters were used: Thermocool Smart Touch catheter (Biosense Webster) 
and EndosenseTacticath SA (St. Jude Medical Inc.). Contact between the catheter and 
the myocardium for each mapping point was measured in average and the maximum 
force and expressed in grams (g). The area under the real time force is measured as 
force time integral expressed in gram seconds (gs).
In patients with a focal origin of the VES or VT, ablation targets were the site of the 
earliest activation and/or the site of identical pace mapping. In patients with fascicular 
VT, ablation targets are the diastolic potential in the descending limb of the fascic-
ular circuit or the presystolic fused Purkinje potential at the VT exit. In patients with 
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scar-related VT, ablation target include presystolic electrical activity within the infarct 
zone that demonstrates concealed entrainment (critical isthmus) or the exit sites. For 
substrate VT ablation, a combination of voltage mapping, pace mapping, and elec-
trogram mapping is used. Scar homogenization was usually performed to abolish 
late-activated channels within scar and VT exit sites. Established peak-to-peak bipolar 
voltage criteria were used for identifying scar (0.5 mV), scar-border zone (0.51–1.49 
mV) and healthy tissue ( 1.5 mV). For irrigated catheters, the electrode-tip tempera-
ture limit is usually set at 42 °C, with a power of 30–45 W, and irrigation flow of 30 mL/
min. The ablation time is usually 60 seconds or shorter, depending on the location and 
effect. The catheter selection was dependent on logistics and the clinical judgment of 
the operator. Crossover to another ablation technique was allowed at the discretion 
of the operator. Crossover from manual catheter navigation to RMN ablation was not 
possible due to logistical reasons.
Postprocedural Protocol
Within 48 hours of the procedure a resting 12 lead electrocardiogram, laboratory tests, 
and chest radiograph were performed. All patients were seen for regular follow-up at 
3 months after the ablation. For idiopathic VT or VES, a 24-hour Holter recording was 
scheduled for the 3-month follow-up visit and thereafter when symptomatic.
Complications
Acute complications were defined as complications occurring before the end of the 
procedure. All complications up to 30 days after the index procedure were identified. 
Complications were subdivided in minor and major complications. Minor complications 
included groin hematomas, AV fistula, pericardial effusion not requiring intervention, 
transient ischemic attack, and temporary AV block. The following complications were 
considered major complications: pericardial effusion requiring intervention, persistent 
AV-block, stroke, arterial venous fistula requiring surgery, and major bleeding. We also 
specifically studied ablation-related complications that excluded complications related 
to the vascular access.
Recurrence Rates
Recurrence was defined as any VT documented during follow-up. If antiarrhythmic 
drugs were necessary to remain free of VT it was considered a recurrence. When 
available, the morphology and the cycle length of the VT were studied. Medical charts 
from emergency room visits, discharge letters, ICD interrogation, electrocardiograms 
and, Holter recordings were studied. Time to recurrence from the index procedure and 
number of ICD therapy (shock and/or antitachycardia pacing ATP]) were analyzed. In 
case of an ablation of ventricular extrasystole (VES), recurrence was defined as VES on 
Holter recording < 95% reduction compared to preablation beats per 24 hours, with a 
morphology identical to the ablated VES.
Statistical Analysis
Data was analyzed using SPSS 15.0 (SPSS Inc., Chicago,IL, USA). We analyzed the fol-
lowing parameters: acute procedural success, complications, and recurrences during 
follow-up. Acute procedural success was defined as noninducibility of the clinical ven-
tricular arrhythmia. After checking for normality, mean values and standard deviations 
were calculated for normally distributed continuous variables. Median and interquartile 
ranges (IQR) were computed for continuous variables with non-normal distribution. 
Comparison of continuous variables between groups was made by unpaired Student’s 
t-tests. In the case of nonnormal distribution of data, the Mann–Whitney U-test was 
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used. Descriptive statistics for categorical data were expressed in absolute numbers 
and percentages. When comparing frequencies, the chi-square test or ANOVA test 
was used, as appropriate. Event-free survival rates were determined using the Kaplan–
Meier method for both intentionto-treat analysis and for patients after an acute suc-
cessful procedure. A 2-sided P-value of <0.05 (2-tailed) was considered significant.
Results
Baseline and Procedural Characteristics
A total of 239 consecutive patients were included in this study. The baseline charac-
teristics of the study population are depicted in Table 1. There were 41 patients in the 
CF group, 112 patients in the MAN group, and 86 patients in the RMN group. Patients 
in the CF group more often had VES ablation, outflow tract ablation, and a transaortic 
route in comparison to the other groups. Patients in the MAN group less often had a 
redo ablations and outflow tract ablations in comparison to the other groups. Patients 
in the RMN group more often had a structural normal heart in comparison to the other 
groups. The median number of RF applications was lowest in the RMN group (Table 2). 
Procedural time was similar for all groups.
Procedural Outcome
Acute success was obtained in 76% of all procedures (Table 3). The highest acute pro-
cedural success was achieved in the RMN group. When stratified by the presence or 
absence structural heart disease, it is clear that RMN had a better outcome in patients 
with a structural normal heart (Figure 1, Table 1).
Crossover
In 1 patient of the RMN group and 4 patients of the CF group there was a crossover to a 
non-CF catheter. The reason for switching in the RMN group was the need for cryoab-
lation. Reasons for switching from CF sensing catheters to a non-CF sensing catheter 
were the use of cryoablation (n = 2); ineffective ablation (n = 1); and damage to the 
catheter (n = 1). Cryoablation was used in 3 patients due to the location of the VA (cor-
onary sinus and posterior fascicle) and due to intolerability of RF in 1 patient.
Complications
Major complications occurred in 3.3% of all procedures, and 0.4% of the major com-
plications were acute (Table 3). There were significantly more major complications in 
the CF group (P = 0.04). Four out of 8 complications (50%) were due to the vascular 
access site and were not related to the CF catheter itself. One patient in the CF group 
died within 48 hours after a failed VT ablation due to refractory heart failure. In this 
patient the procedure was done under left ventricular assist device (LVAD), which had 
been indicated for cardiogenic shock. 
Recurrence Rate
The median follow-up duration was 25 months [IQR 14- 35]. By using an intention 
to treat analysis, 124 patients (52%) had a recurrence (Table 3). The Kaplan–Meier 
analysis demonstrated that the RMN group had the lowest recurrence rate (Figure 2, 
log-rank P = 0.016). When looking at the outcome of 182 patients who had an initial 
successful procedure, 66 patients (36%) experienced a recurrence. There was no 
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ALL CF MAN RMN P-value
Acute success  182 (76%) 29 (71%) 79 (71%) 74 (86%) 0.03
-Structural heart 
disease   
87 (77%) 16 (73%) 50 (78%) 21 (81%) 0.80
-Nonstructural heart 
disease  
95 (75%) 13 (68%) 29 (62%) 53 (88%) 0.005
Complications   26 (11%) 8 (19%) 13 (12%) 5 (5.8%) 0.06
-Major   8 (3.3%) 4 (10%) 3 (2.7%) 1 (1.2%) 0.04
-Major acute  1 (0.4%) 1 (2.4%) 0 (0%) 0 (0%) 0.57
-Major catheter 
ablation related  
4 (1.7%) 1 (2.4%) 2 (1.8%)  1 (1.2%) 0.31
-Major vascular access 
related   
4 (1.7%) 2 (4.9%) 1 (0.9%) 1 (1.2%) 0.38
- Minor   18 (7.5%) 4 (9.6%) 10 (8.9%) 4 (4.7%) 0.44
FU time, months 25 [14–35] 18 [12–27] 25 [17–37] 29 [15–39] 0.001
Recurrences 
(intention-to-treat)   
124 (52%) 24 (59%) 64 (57%) 36 (42%) 0.07
- Structural heart 
disease   
69 (61%) 15 (68%) 38 (59%) 16 (62%) 0.72
- Nonstructural heart 
disease  
55 (44%) 9 (29%) 26 (47%) 20 (33%) 0.07
Time to recurrence 
(months) [IQR] 
0.5 [0–3] 1 [0–3] 0 [0–3] 3 [0–10] 0.09
Recurrence after acute 
successful procedure  

































Table 3  Acute Success, Complications and Recurrences, CF, MAN, and RMN
Table 2  Procedural Characteristics
CF: contact force; MAN: manual; RMN: remote magnetic navigation; IQR: interquartile range
ALL CF MAN RMN P-value
Total 239 41 112 86
Male 174 (73%)  25 (61%) 88 (79%) 61 (71%) 0.09
Age (SD) 52.3 ± 16.7 55.5 ±16.2 53.2 ± 17.7 52.4 ± 15.8 0.70
Pediatric 12 (5%) 2 (5%) 7 (6%) 3 (4%)  0.68
VES 88 (35%) 21 (51%) 33 (30%)  31 (36%)  0.04
Redo 48 (20%) 10 (24%) 11 (10%)  27 (31%)  0.001
OT  84 (35%) 27 (58%) 25 (22%) 36 (41%) 0.001
Fascicular  24 (10%) 1 (2%)  12 (11%) 11 (13%) 0.18
Left sided  128 (54%) 17 (42%) 68 (61%) 43 (50%) 0.14
- Transaortic route  113 (88%) 2 (12%) 59 (87%) 39 (91%) 0.03
- Transseptal puncture  13 (10%) 15 (88%) 9 (13%) 2 (5%) 0.03
Ischemic 82 (34%) 15 (37%) 48 (43%) 19 (22%) 0.009
Non-SHD  126 (53%) 19 (46%) 47 (42%) 60 (70%)  < 0.001
SHD, nonischemic  31 (13%) 7 (17%) 16 (15%) 7 (8%) 0.24
ICD  103 (43%) 15 (37%) 62 (55%) 26 (30%) 0.001
OAC 22% 17% 26% 12% 0.05
B-blockers 54% 63% 56% 46% 0.15
Class I AAD 19% 24% 23% 13% 0.23
Class III AAD 38% 37% 48% 23% 0.01
Table 1  Baseline Characteristics
AAD: antiarrhythmic drugs; OAC: oral anticoagulation; OT: outflow tract; VES: ventricular extrasystole; 
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Discussion
This is the first study that investigates the long-term clinical outcome in VT abla-
tion using CF catheters. In this ventricular arrhythmia cohort, CF did not improve 
results in terms of complications, acute success, or recurrence during follow-up. 
RMN was superior with regard to acute success, reduction of major complications, 
and recurrence rate using an intention-to-treat analysis.
Main Findings
A wide range of acute success of VT ablation has been reported, varying from 41 
to 99%.11-15 One of the first prospective multicenter studies was reported in 2000.14 
Over time there has been a remarkable evolution of mapping and ablation tech-
niques, and also the indication for VT ablation has become wider. These are fac-
tors that possibly affect procedural success. In the present study, patients were 
included as early as 2007 up to 2014 and there was an acute success rate of 76%. 
Other studies over the last years have reported a long-term efficacy of VT ablation 
ranging from 27 to 49% during a follow-up of 8 to 48 months, which is comparable 
to the 36% recurrence rate in our cohort. Our group has previously shown a posi-
tive effect of RMN on the outcome of VT ablation in patients with structural heart 
disease.9 With the current data, CF was not superior to RMN or MAN ablation.
Rationale for CF in VT Ablation
The TOCCATA study was one of the first catheter ablation studies in atrial fibril-
lation patients that showed a clinical benefit of CF on clinical outcome.4 Recent-
ly, 2 clinical studies from Mizuno and Titz et al.7,8 studied CF in VT ablation and 
Figure 1 Acute procedural success in the 3 
groups stratified by the presence of structural 
heart disease. *P = not significant. CF: contact 
force; MAN: manual; non-SHD: nonstructural 
heart disease; RMN: remote magnetic 
navigation; SHD: structural heart disease. 
Figure 2 Recurrence-free survival stratified by 
the 3 groups (intentionto-treat analysis).  
CF: contact force; MAN: manual; RMN: remote 
magnetic navigation. 

























MAN 112      55   41      30               15
RMN  86    57   41      36               22
CF  41      15    10       5       1
Numbers at risk
found that continuous information on contact force resulted in less inefficient or 
excessive lesion formation. The 2 studies, however, were limited in their num-
ber of cases (17 and 10, respectively) and lacked proof of clinical outcome. Our 
observations did not confirm the extrapolated theoretical improvement of lesion 
formation into an improved long-term outcome or a better safety profile. In gen-
eral, catheter force related complications in VT ablation such as perforation and 
tamponade are rare.13,16 
Secondly, the lack of an integrated feedback loop in CF ablation may be critical 
in the current results. An optimal endocardial lesion in the ventricles in an animal 
model needed a total force of 30–40 g,6 substantially higher than the averageand 
even maximum force in the present study. Despite being informed, the operator 
might not know how to interpret and integrate the given information. In the ani-
mal study of Sacher et al. a dramatic decrease was observed in the number of RF 
applications that do not result in adequate lesion formation with the addition of 
CF information.6 An in vivo study of Mizino et al. calculated the best cut-off value 
for CF in ventricular ablation is at least 8 g when compared to other parameters of 
lesion formation.7 Although CF sensing may be useful to prevent exertion of excess 
force on the myocardium, there is no consensus regarding how CF sensing may be 
useful to guide the formation of effective lesions in VT ablation. 
Remote Magnetic Navigation Versus Contact Force 
The average contact force in the current study is relatively low. However, we also 
know that RMN does not provide high contact force.17 Therefore, it is unlikely to be 
the reason for the relatively low success. Of note, CF has primarily been used as a 
safety tool, not an efficacy tool. A possible explanation for the higher acute suc-
cess in RMN-guided VT ablation is enhanced maneuverability.18,19 It has the ability 
to reach anatomical structures which are otherwise difficult to access. Also, im-
proved catheter stability in RMN is an important advantage.20 The better long-term 
outcome of RMN in the intention-to-treat analysis can probably be explained by the 
higher acute procedural success rate.
Force Behavior During Ventricular Tachycardia 
Low CF during ablation in atrial fibrillation has proven to be associated with a high-
er recurrence rate.4,21 In contrast to the ablation of atrial arrhythmias the excursion 
of the ventricle during a VT ablation especially during tachycardia itself might lead 
to a less stable catheter position. An unstable catheter position results in intermit-
tent impaired energy delivery and subsequent inappropriate lesion formation. This 
might explain why the use of CF in atrial arrhythmia is well established, while the 
benefit is not so clear for VT ablations. Ideally, CF sensing in the future can be inte-
grated in robotic navigation as both entities could magnify the benefit of CF.22 
Limitations of the Study 
Although this study was able to provide data on followup from a substantial number 
of patients who underwent VT ablation, it was not randomized. The study cohort 
was heterogeneous; the indication for ablation varied from VES, idiopathic VT to 
scar relatedVT. Baseline characteristics significantly differed between groups. 
Another limitation of the study was that ICD recordings were only available for a 
minority of patients for follow-up. In the other patients, Holter and clinical events 
were used. Considering the inherent limitations of an observational study, all con-
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Remote Magnetic Navigation (RMN)-guided catheter ablation (CA) is a feasible 
treatment option for patients presenting with ischemic ventricular tachycardia (VT). 
Catheter-tissue contact feedback, enhances lesion formation and may conse-
quently improve CA outcomes. Until recently, contact feedback was unavailable for 
RMN-guided CA. The novel e-Contact Module (ECM) was developed to continu-
ously monitor and ensure catheter-tissue contact during RMN-guided CA.
Objective: The present study aims to evaluate the effect of ECM implementation on 
acute and long-term outcomes in RMN-guided ischemic VT ablation. 
Method
This retrospective, two-center study included consecutive ischemic VT patients 
undergoing RMN-guided CA from 2010–2017. Baseline clinical data, procedural 
data, including radiation times, and acute success rates were compared between 
CA procedures performed with ECM (ECM+) and without ECM (ECM–). One-year 
VT-free survival was analyzed using Cox-proportional hazards models, adjusting 
for potential confounders: age, left ventricular function, VT inducibility at baseline 
and substrate based ablation strategy.
Results
The current study included 145 patients (ECM+ N=25, ECM– N=120). Significantly 
lower fluoroscopy times were observed in the ECM+ group (9.5 (IQR 5.3–13.5) ver-
sus 12.5 minutes (IQR 8.0–18.0), P=0.025). Non-inducibility of the clinical VT at the 
end of procedure was observed in 92% ECM+ versus 72% ECM– patients (P=0.19). 
ECM guidance was associated with significantly lower VT-recurrence rates during 
1-year follow-up (16% ECM+ versus 40% ECM–; multivariable HR 0.29, 95%–CI 
0.10–0.69, P=0.021, reference group: ECM–). 
Conclusion 
Contact feedback by the ECM further decreases fluoroscopy exposure and im-
proves VT-free survival in RMN-guided ischemic VT ablation.
Introduction
Catheter ablation (CA) is an important treatment option for patients with ischemic 
heart disease presenting with ventricular tachycardia (VT).1, 2 CA is reported to 
decrease the likelihood of subsequent ICD shocks, prolongs the time to VT recur-
rence and decreases VT burden in patients diagnosed with ischemic VT.3-5 
Several CA techniques are currently available for ischemic VT ablation. Some stud-
ies reported superiority of remote magnetic navigation (RMN) over manual guided 
VT ablation, exhibiting lower procedure and fluoroscopy times, higher acute suc-
cess rates, lower VT recurrence rates and less adverse events.6-8
CA techniques are rapidly evolving and there is a continuous search for novel 
technologies to improve long-term success and reduce complication rates.2 As the 
quality of contact between the catheter tip and the myocardial tissue is believed to 
be of vital importance for lesion formation9, there has been a focus on the devel-
opment of technologies providing contact feedback. Contact force (CF) sensing 
catheters appeared to be beneficial in manual guided atrial fibrillation ablation.10 
However, in an observational study of VT ablations, the use of CF sensing catheters 
was still inferior to RMN-guided CA with respect to procedural outcome, long-term 
outcomes and safety.7 A possible explanation for the lack of benefit of CF sensing 
catheters in manual VT ablation is the loss of tissue contact during ventricular con-
traction which can be maintained with RMN. In RMN-guided CA, contact feedback 
only recently became available with the development of the e-Contact Module 
(ECM). The present study aims to evaluate the effect of the ECM on RMN-guided 
ischemic VT ablation outcomes. Our primary hypothesis is that use of the ECM 
benefits lesion formation, resulting in lower VT recurrence.
Methods
Study design
This study is a retrospective, two-center study investigating ischemic VT abla-
tion procedures performed with RMN. Index procedures performed with the ECM 
(ECM+) were compared with index procedures performed without ECM (ECM–). 
Primary endpoint was the freedom of VT recurrence during 12-months of follow-up 
(FU). We also analyzed the following secondary endpoints: procedural parameters 
(including radiation times), acute procedure success, complication rates, the redo 
procedure rates and all-cause mortality at 12-months of follow-up (FU). Addition-
ally, the ICD therapy burden during the 12 months anticipating and the 12 months 
following the index procedure were evaluated, as well as the proportion of ECM 
guided applications applied in optimal or suboptimal contact. The local ethical 
committees approved data collection (MEC-2018-1114 and WO 15.142). The study 
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
Procedural informed consent was obtained from all the patients prior to the elec-
trophysiological study (EPS).
Study population
All consecutive patients undergoing the first RMN-guided CA procedure for VT 
with an ischemic substrate in one of the two participating centers between January 
2010 until December 2017 were included in this study. Patients with VTs caused by 
a non-ischemic cardiomyopathy were not eligible for inclusion. Participating cen-
ters were the Onze Lieve Vrouwe Gasthuis (OLVG, Amsterdam, the Netherlands) 
and the Erasmus Medical Center (Erasmus MC, Rotterdam, the Netherlands). Pa-
tients were eligible for VT ablation based on the most recent guidelines and recom-
mendations at the time of procedure.1, 2
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Definitions
Index procedures were defined as the first RMN-guided VT ablation procedure 
performed in a patient in one of the participating centers within the mentioned 
time frame. All repeat VT ablation procedures following the index procedure were 
considered redo procedures. Acute procedure success was defined as non-induc-
ibility of the clinical VT at the end of procedure. Recurrence of VT was regarded 
when a patient had a recurrence of a sustained VT, or VT treated with implantable 
cardioverter defibrillator (ICD) therapy (either anti-tachy pacing (ATP) or shock). 
Total procedure time was defined as the time from first puncture until the removal 
of catheters. Mapping time was defined as the time from start mapping (first point 
taken) until completion (last point taken), whereas ablation time was defined as 
time from first application until last application. Minor complications were peri-
cardial effusion not requiring intervention and access site complications. Major 
complications were cardiac tamponade, hemorrhagic shock, stroke and proce-
dure-related death. Chronic kidney disease was considered when a patient had an 
estimated Glomerular Filtration Rate (eGFR) using the CKD-EPI formula of  
59 ml/min/1.73m2 or lower (i.e. chronic kidney disease (CKD) stage IIIa or higher).
Data collection
Baseline demographic and clinical characteristics were collected from the institu-
tional electronic patient dossiers (HiX version 6.1 (ChipSoft BV, Amsterdam, NL) 
or Epic Hyperspace 2017 (Epic Systems Corporation, Verona, WI, USA)). Proce-
dural data was derived both from the electronical medical files, as well as from the 
procedural log files recorded with the EP-workmate (St. Jude Medical Inc., St. Paul, 
MN, USA), the Niobe II or Niobe ES Magnetic Navigation System (Stereotaxis Inc., 
St. Louis, MO, US) and the Odyssey Cinema system (Stereotaxis Inc., St. Louis, MO, 
USA). All patient information was de-identified. 
Procedural protocol
All CA procedures were performed in accordance with institutionally approved local 
medical treatment protocols of the OLVG and EMC. Ablation was performed target-
ing VTs induced by programmed electrical stimulation (PES) and/or modifying the 
electrical substrate. The left ventricle (LV) was accessed through a transaortic or 
transseptal approach based on the operator’s preference. In all patients, electro-
anatomic maps were obtained while patients were in sinus rhythm with the Carto 
3D mapping system as standard of care (CARTO 3 (Biosense Webster Inc., Dia-
mond Bar, CA, USA). Bipolar voltage criteria were used to identify scar (<0.5 mV), 
scar-border zone (0.51–1.49 mV) and healthy tissue (>1.5 mV). If not incessant, 
VT was induced by PES and activation or entrainment mapping was performed if 
VT was hemodynamically tolerable, to locate critical isthmuses and exit sites. The 
main target of scar-related VT ablation was the critical isthmus of hemodynamically 
stable sustained VT identified using conventional diagnostic criteria (i.e. middi-
astolic potentials). Another target was the exit of the VT circuit identified during 
activation mapping or pace mapping. In the case of hemodynamically unstable or 
noninducible sustained VT, substrate ablation was performed focused on areas 
within the scar demonstrating fractionation or late potentials during sinus rhythm. 
It was up to the operator’s preference to perform substrate ablation in hemody-
namically stable VT as well in addition to targeting critical isthmus and exit sites. 
Ablation was performed using the following radiofrequency settings: right ventricle 
(RV): 40-45W, 20ml/min, max 43°C; LV: 50-55W, 30ml/min, max 43°C. PES was 
performed at the end of the procedure to evaluate the effect of the applied thera-
py. RMN (Stereotaxis, Inc., St. Louis, MO, USA.) was used in all cases.
Follow-up
Following the index procedure, all patients were checked at the out-patient clinic at 
regular intervals. Standard follow-up visits were: 6 months and 12 months after the 
procedure, including ICD check-up. Voluntary follow-up patients were: 3 months 
and 9 months after procedure. Some patients were seen even more frequently 
when they experienced VT recurrences. Some patients had their FU at referral hos-
pitals. This data was also collected and included in the present study.
e-Contact Module
The ECM, a recently developed hardware and software module compatible with the 
Niobe ES RMN system, incorporates 16 types of data of three categories to deter-
mine whether the catheter is in contact with cardiac tissue or not. The following 
types of data are used to determine whether the catheter is in (optimal) contact 
with cardiac tissue: 1) electrical impedance measurements; 2) cardiac induced 
motion of the catheter tip; and 3) the torque being applied by the magnetic field. 
To confirm the different threshold levels of contact, qualitative assessments based 
on observations during pre-clinical studies were made while visually observing 
contact using intra-cardiac ultrasound. The contact assessment is visualized to the 
user as a starburst near the catheter tip and as a blue line on the contact tracing 
(Figure 1). When there is minimal contact, the starburst is small, whereas in optimal 
contact the starburst is bolder. Without any contact, there is no starburst. The ECM 
was installed in the EMC in April 2016 and in the OLVG in July 2017. 
Figure 1  The e-Contact Module
The figure shows the three types of output of the e-Contact Module. 
Left:  When the catheter is not in contact with myocardial tissue, the ablation catheter is displayed 
without starburst. 
Middle:  When the catheter is placed in contact with myocardial tissue, a starburst appears at the tip 
of the ablation catheter.
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Quality of Contact
As contact is established by the ECM by a mathematical algorithm, calculated from 16 
variables, as described above, this algorithm could be used to evaluate the quality of 
contact of all RF applications applied in patients included in the study. For every single 
RF application, its time being applied in either optimal, suboptimal or without contact 
with myocardial tissue was derived from the procedural log files recorded by the ECM 
and the Stereotaxis systems. 
Statistical analysis
Normality was assessed by the Kolmogorov-Smirnov test, or when appropriate, Sha-
piro-Wilk test. Mean and standard deviation (SD) were calculated for normally distrib-
uted continuous variables. Median and interquartile range (IQR) were computed for 
continuous variables with non-normal distribution. Descriptive statistics for categori-
cal data were expressed in absolute numbers and percentages. Continuous variables 
were compared between groups by the unpaired Student’s T-tests. For variables 
with non-normal distributions, the Mann-Whitney U-test was used. For comparing 
frequencies, the Chi-square test was used, or, when appropriate, Fisher’s exact test. 
Univariable and Multivariable Cox proportional hazards models were used to examine 
the relationship between treatment group and long-term outcomes, adjusting for po-
tential confounders. In all ECM+ patients, Cox proportional hazards models were also 
used to evaluate the relationship between the quality of contact as measured by the 
ECM and the long-term outcomes. A 2-sided P-value of <0.05 was considered signifi-
cant. Data were analyzed using SPSS 24.0 (SPSS Inc., Chicago, IL, USA).
Results
This study included 187 RMN-guided VT ablation procedures, of which 145 were 
index procedures and 42 were redo procedures (Figure 2). Of the 145 index pro-
cedures, 120 were performed without ECM (ECM–) and 25 with ECM (ECM+) 
guidance. In total, the OLVG included 91 patients (63%) and the Erasmus MC 54 
patients (37%). In the OLVG, 5 patients (6%) were treated with ECM guidance, 
whereas in the Erasmus MC it was used in 20 patients (80%). In the OLVG, proce-
dures were performed by 2 operators in total. The first operator from this center 
performed 95% of procedures, which was comparable between study groups. In 
the second center, 5 operators in total performed the procedures over time. First 
operator performed the majority of procedures (57%), the second operator per-
formed 4%, the third 4%, the fourth 20% and the fifth 15% of procedures, which 
were also comparable between groups. 
Demographic and baseline clinical data
Demographic and baseline clinical data are presented in Table 1. The mean age was 
67.9 ± 9.6 years. The majority of patients had a poor LVEF <30% (N=82 (57%)). At 
baseline, 83 (58%) patients were on amiodarone therapy. In total, 136 (94%) patients 
had an ICD. Baseline demographic and clinical data were not significantly different 
between groups, except for PCI being more frequently performed in the ECM+ group 
(ECM– 55% versus ECM+ 80%, P=0.019).
Descriptive procedural parameters are presented in Table 2. Epicardial ablation was 
performed in 3 patients (3%). The ECM was not applied to the epicardium in this 
study. In all ECM+ patients (N=25, 100%) an ablation strategy including substrate ab-
lation was applied versus in 83% of the ECM– patients (P=0.024). In the 21 patients 
(14%) were no substrate ablation was performed, the ablation strategy focused on 
elimination of critical isthmuses and/or exit sites only.
Figure 2. Study population 
The study population is presented in figure 2. We included 145 index procedures in our study, 
of which 120 were performed without ECM and 25 with ECM guidance. In total 42 redo 
procedures were performed, which were all RMN guided CA procedures, some performed 
with and others without ECM guidance. 




Mean total procedure time was 200 ± SD 76 minutes and was comparable between 
groups (P=0.12), as is shown in Table 3. The mean application duration was 1943 ± SD 
1064 seconds. There was no significant difference between groups (ECM– 1823 ± SD 
1117 seconds versus ECM+ 2119 ± SD 979 seconds, P=0.29). Fluoroscopy time was 
significantly lower in ECM+ patients (9.5 (IQR 5.3 – 13.5) minutes versus 12.5 (IQR 8.0 
– 18.0) minutes, P=0.025). Moreover, the ablation time was significantly lower in ECM+ 
group (83 ± SD 49 versus 112 ± 60 minutes, P = 0.028), whereas the mapping times 
were comparable between groups. Non-inducibility of the clinical VT at the end of the 
procedure was observed in 115 patients (79%), whereas non-inducibility of all VT was 
observed in 84 patients (56%). The non-inducibility rates were comparable between 
groups (P=0.19 and P=0.27, respectively).
Long-term outcome
At 12-months FU, VT recurrence was observed in 48 (40%) ECM– patients, com-
pared to 4 (16%) ECM+ patients (P=0.023), as illustrated in Table 3. Moreover, 
ECM– patients were more frequently admitted to the hospital because of VT recur-
rence (39 (33%) ECM– versus 3 (12%) ECM+, P=0.040). We observed a tendency 
towards more redo procedures performed in ECM– patients when compared to 
ECM+, although this was statistically not significant (30 (25%) versus 2 (8%) re-
spectively, P=0.06). Anti-arrhythmic drugs were stopped during FU in 22 patients 
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rable between groups. Twelve month FU data was incomplete in 22 patients (15%), 
which was comparable between groups (ECM– 18 patients (15%) versus ECM+ 4 
patients (15%), P = 0.90).
CA procedures performed with ECM guidance (ECM+) were associated with 
improved VT-free survival during the 12 months of follow-up, when compared to 
ECM– (multivariable HR 0.29, 95%-CI 0.10–0.69, P=0.021, with ECM– as the refer-
ence group) (Table 4a and Figure 3). Age, gender, LVEF, VT inducibility at baseline 
EPS and an ablation strategy using substrate ablation, did not show a significant 
relation with the outcome. As a sensitivity analysis, center of procedure, medical 
history of PCI, non-inducibility of clinical VT at end of procedure and non-induc-
ibility of all VT at end of procedure, were consecutively also added to the univar-
iate and multivariate models, and did not show any significant associations with 
the primary outcome either (data not shown). There was no significant difference 
between groups in all-cause mortality (multivariable HR 1.47, 95%-CI 0.37–5.88, 
P=0.59, with ECM– as the reference group) (Table 4b), or in the redo procedure 
rates (multivariable HR 0.51, 95%-CI 0.11–2.33, P=0.39, with ECM– as the reference 
group) (Table 4c). Age, gender, LVEF and an ablation strategy using substrate abla-
tion, procedurecenter and medical history of PCI, did not show a significant rela-
tion with all-cause mortality and redo procedure rate. However, VT inducibility at 
baseline EPS was significantly related to a lower redo procedure rate (multivariable 
HR 0.43, 95%-CI 0.12–0.97, P=0.044, with VT non-inducibility at baseline EPS as 
the reference group). 
ICD therapy burden
In 120 patients who had an ICD implanted, the ICD therapy burden in the 12 months 
anticipating and 12 months following the index procedure was evaluated. In 16 
patients, no pre-operative ICD data was available, as the ICD was implanted during 
the same hospital admission as the VT ablation procedure. Additionally, 9 patients 
did not have an ICD at all. Post-procedurally, a significant lower proportion of ECM+ 
patients experienced ICD shocks, as compared to ECM– patients (4% versus 24%, 
P = 0.048). A median reduction of 2.0 (IQR 0.0 – 10.0) ATP episodes and a median 
reduction of 1.0 (IQR 0.0 – 3.0) shock were observed after the VT ablation proce-
dure (Table 5), which were comparable between groups. 
Quality of contact
The quality of catheter-tissue contact during all ECM+ procedures was calculated 
and analyzed. The majority of the total application duration was applied in optimal 
contact (71% (IQR 42 – 83)). A small part of the total application duration was ap-
plied without contact (6% (IQR 1 – 17)), whereas 21% (IQR 7 – 29) of the total appli-
cation duration was applied in suboptimal contact. There was no significant relation 
between the type of contact and the 12-months VT recurrence rates (applications 
applied without any contact: univariate HR 1.02, 95% CI 0.98 – 1.06, P = 0.407; 
applications applied in suboptimal contact: univariate HR 0.94, 95% CI 0.86 – 1.04, 
P = 0.227; applications applied in optimal contact: univariate HR 1.00, 95% CI 0.96 
– 1.04, P = 0.958). There were no significant associations between LV approach 
(transaortic or transseptal) and the measured quality of contact.
Safety data
Major and minor complication rates were not significantly different between groups 
(major: 3% versus 0%, P=0.42; minor: 8% versus 12%, P=0.56). Major complica-
Table 1 Demographic and baseline clinical data
ECM– N=120 ECM+ N=25 Total N=145 P-value
Age (years) * 67.5 ± 9.9 69.8 ± 7.7 67.9 ± 9.6 0.27
Female 24 (20%) 3 (12%) 27 (19%) 0.35
BMI (m/kg2) † 26.9 (24.2 – 
30.8)
26.0 (23.5 – 
29.3)
26.4 (24.2 – 
30.5)
0.44
Hypertension 46 (38%) 9 (36%) 55 (38%) 0.83
Diabetes 20 (17%) 6 (24%) 26 (18%) 0.39
Atrial Fibrillation 40 (33%) 11 (44%) 51 (35%) 0.31
COPD 23 (19%) 5 (21%) 28 (19%) 0.85
Chronic Kidney disease 
  (stage ≥ IIIa)
56 (48%) 15 (60%) 71 (50%) 0.27
eGFR (ml/min/1.73m2) 61 ± 19 60 ± 26 61 ± 20 0.85
Hemodialysis 2 (2%) 0 (0%) 2 (1%) 0.51
NYHA class I 30 (42%) 9 (45%) 39 (42%) 0.79
NYHA class II 18 (25%) 7 (35%) 25 (27%) 0.37
NYHA class III 24 (33%) 4 (20%) 28 (30%) 0.25
NYHA class IV 0 (0%) 0 (0%) 0 (0%) 1.00
Ischemic CMP 120 (100%) 25 (100%) 124 (100%) 1.00
Thrombolysis 12 (10%) 3 (12%) 15 (10%) 0.78
PCI 65 (55%) 20 (80%) 85 (59%) 0.019
CABG 37 (31%) 11 (44%) 48 (33%) 0.20
ICD 111 (93%) 25 (100%) 136 (94%) 0.16
VT storm 29 (24%) 4 (16%) 33 (23%) 0.38
tions were CVA (1 patient, who had post-procedural hemianopia and dysartria 
which improved significantly 5 days after the procedure), a complete AV block  
(1 patient, who already had an DDD-ICD implanted) and RV tab during attempting 
pericardial access. The RV tab was initially dry and therefore the procedure was 
continued, however a few hours after completion of the procedure the patient de-
veloped cardiac tamponade for which pericardiocentesis was performed  
(1 patient, who recovered without sequelae). The majority of minor adverse events 










* Mean ± SD † Median (IQR)
BMI: body mass index; CABG: coronary artery bypass grafting; CKD-EPI: chronic kidney disease 
epidemiology collaboration; CMP: cardiomyopathy; COPD: chronic obstructive pulmonary disease; 
(D)OAC: (direct) oral anticoagulant; ECM: e-Contact Module; eGFR: estimated Glomerular Filtration 
Rate (using the CKD-EPI formula); ICD: implantable cardioverter defibrillator; LVEF: left ventricular 
ejection fraction; PCI: percutaneous intervention
* Median (IQR)
ECM: e-Contact Module; LV: left ventricle; RV: right ventricle; VT = ventricular tachycardia 
* Mean ± SD † Median (IQR)
ECM: e-Contact Module; VT: ventricular tachycardia
Table 2 Baseline procedural data
Table 3 Acute and long-term outcomes
ECM– N=120 ECM+ N=25 Total N=145 P-value
Approach
  Right sided - Transvenous 3 (3%) 0 (0%) 3 (2%) 0.42
  Left sided - Transseptal 8 (7%) 3 (12%) 11 (8%) 0.36
  Left sided - Transaortic 105 (88%) 22 (88%) 127 (86%) 0.95
  Both Right and Left 
(transaortic)
4 (3%) 0 (0%) 4 (3%) 0.36
VT inducibility at baseline EPS 106 (88%) 18 (75%) 124 (86%) 0.18
Mapping during VT 76 (63%) 15 (60%) 91 (63%) 0.75
Number of VT morphologies* 2.0 (1.0 – 3.0) 1.0 (1.0 – 3.0) 2.0 (1.0 – 3.0) 0.10
VT cycle length (msec)* 391 ± 101 398 ± 70 392 ± 97 0.81
Location of ablation
  RV 7 (6%) 0 (0%) 7 (5%) 0.22
  LV 117 (98%) 25 (100%) 142 (98%) 0.42
  Epicardial 3 (3%) 0 (0%) 3 (2%) 0.42
Substrate modification 99 (83%) 25 (100%) 124 (86%) 0.024
ECM– N=120 ECM+ N=25 Total N=145 P-value
Acute outcomes
Total procedure time (min)* 206 ± 79 175 ± 56 200 ± 76 0.12
Total ablation time (sec) 1823 ± 1117 2119 ± 979 1943 ± 1064 0.29
Total fluoroscopy time (min)† 12.5 (8.0 – 
18.0)
9.5 (5.3 – 13.5) 11.0 (7.2 – 
17.3)
0.025
Non-inducibility clinical VT 92 (77%) 23 (92%) 115 (79%) 0.19
Non-inducibility all VT 66 (55%) 19 (76%) 85 (59%) 0.15
12 month outcomes
VT recurrence 48 (40%) 4 (16%) 52 (36%) 0.023
Hospital admission for VT 
recurrence
39 (33%) 3 (12%) 42 (29%) 0.040
Redo procedure 30 (25%) 2 (8%) 32 (22%) 0.06
All-cause mortality 9 (8%) 3 (12%) 12 (8%) 0.46
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LVEF 
  Normal (≥55%) 5 (4%) 0 (0%) 5 (3%) 0.30
  Mildly Reduced (45-54%) 22 (18%) 3 (12%) 25 (17%) 0.45
  Reduced (30-44%) 27 (23%) 6 (24%) 33 (23%) 0.87
  Poor (<30%) 66 (55%) 16 (64%) 82 (57%) 0.41
(D)OAC 79 (66%) 18 (72%) 97 (67%) 0.55
Beta-blocker 98 (82%) 20 (80%) 118 (81%) 0.85
Ca-antagonist 5 (4%) 1 (4%) 6 (4%) 0.97
Amiodarone 66 (56%) 17 (68%) 83 (58%) 0.27
Sotalol 10 (8%) 3 (12%) 13 (9%) 0.56
Class 1a 4 (3%) 1 (4%) 5 (4%) 0.89
Class 1b 2 (2%) 2 (8%) 4 (3%) 0.08










Table 4a Cox Proportional Hazard models for VT recurrence
Table 4c Cox proportional Hazard models for Redo procedure
Table 5 ICD therapy burden
Table 4b Cox Proportional Hazard models for All-cause mortality
VT-recurrence Univariable model Multivariable model
Hazard 
ratio*
95% CI P-value Hazard 
ratio*
95% CI P-value
ECM guidance 0.34 0.12 – 0.95 0.040 0.29 0.10 – 0.69 0.021
Age 1.01 0.99 – 1.04 0.35 1.01 0.98 – 1.04 0.48
LVEF <45% 1.66 0.75 – 3.70 0.21 1.85 0.83 – 4.17 0.14
VT inducibility at 
baseline EPS
0.62 0.30 – 1.27 0.19 0.53 0.25 – 1.14 0.10
Substrate 
modification
0.80 0.39 – 1.64 0.55 1.02 0.49 – 2.17 0.95
Redo procedure Univariable model Multivariable model
Hazard 
ratio*
95% CI P-value Hazard 
ratio*
95% CI P-value
ECM guidance 0.48 0.11 – 2.04 0.32 0.51 0.11 – 2.33 0.39
Age 0.99 0.95 – 1.03 0.60 0.98 0.94 – 1.02 0.30
LVEF <45% 1.09 0.37 – 3.23 0.88 1.12 0.38 – 3.33 0.83
VT inducibility at 
baseline EPS
0.47 0.17 – 1.27 0.14 0.34 0.12 – 0.97 0.044
Substrate 
modification
2.27 0.88 – 5.88
0.17 – 1.13
0.09 0.41 0.15 – 1.12 0.08
All-cause 
mortality
Univariable model Multivariable model
Hazard 
ratio*
95% CI P-value Hazard 
ratio*
95% CI P-value
ECM guidance 1.56 0.42 – 5.88 0.50 1.47 0.37 – 5.88 0.59
Age 1.03 0.97 – 1.10 0.40 1.03 0.96 – 1.09 0.42
LVEF <45% 0.37 0.05 – 2.86 0.34 2.50 0.32 – 
20.00
0.38
VT inducibility at 
baseline EPS
0.81 0.18 – 3.70 0.78 0.97 0.20 – 4.55 0.97
Substrate 
modification
0.94 0.20 – 4.35 0.94 0.92 0.19 – 4.55 0.92
* Hazard ratios were calculated using the following reference groups: no ECM guidance (ECM–), normal 
LVEF, VT non-inducibility at baseline EPS, no substrate modification performed. 
ECM: e-Contact Module; EPS: electrophysiology study; LVEF: left ventricular ejection fraction; 
VT: ventricular tachycardia
* Median (IQR)
ECM: e-Contact Module; VT: ventricular tachycardia; ICD: implantable cardioverter defibrillator; 
ATP: anti-tachy pacing; CA: catheter ablation
ECM– N=120 ECM+ N=25 Total N=145 P-value
12 months pre-procedure
Documented VT 95 (100%) 25 (100%) 120 (100%) 1.00
  If yes, number of VT 
episodes*
5.0 (2.0 – 15.0) 6.0 (4.0 – 18.0) 5.0 (3.0 – 14.8) 0.52
ATP performed 69 (73%) 19 (76%) 88 (73%) 0.29
  If yes, number of ATP 
episodes
5.0 (3.0 – 14.0) 6.0 (5.0 – 39.0) 5.0 (3.0 – 17.0) 0.10
shock performed 66 (70%) 13 (52%) 79 (66%) 0.10
 If yes, number of shocks 2.0 (1.0 – 4.0)  2.0 (1.0 – 8.0) 2.0 (1.0 – 5.0) 0.19
12 months post-procedure
Documented VT 48 (50%) 4 (16%) 52 (43%) 0.023
  If yes, number of VT 
episodes
3.0 (1.0 – 10.5) 21.0 (5.0 – 99.3) 3.0 (1.0 – 12.5) 0.05
ATP performed 31 (33%) 4 (16%) 35 (29%) 0.22
  If yes, number of ATP 
episodes
3.0 (1.5 – 8.0) 21.0 (4.3 – 99.3) 3.0 (2.0 – 10.0) 0.39
shock performed 23 (24%) 1 (4%) 24 (20%) 0.048
  If yes, number of shocks 2.0 (1.0 – 5.0) 1.0 (1.0 – 1.0) 2.0 (1.0 – 4.5) 0.09
Reduction
VT episode reduction 3.0 (1.0 – 10.3) 5.0 (1.5 – 18.0) 4.0 (1.0 –11.0) 0.23
ATP episode reduction 2.0 (0.0 – 7.5) 5.0 (0.8 – 39.0) 2.0 (0.0 – 10.0) 0.09
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This figure is a case example of one of the patients from our cohort treated with ECM guidance. At the 
left end, CARTO electroanatomic maps of the left ventricle are displayed. The electroanatomic maps 
are displayed more transparent, whereas previous ablation points are displayed in less-transparent 
yellow and orange (i.e. the ‘Ablation History” feature of the Stereotaxis system). On the right, ablation 
parameters of the currently performed application are displayed, including temperature, power and 
impedance (recorded by the Claris system). Panel A displays an application applied in suboptimal 
contact. The suboptimal catheter-tissue contact is shown to the user by the ECM as a small starburst 
at the catheter tip. One can appreciate that during this specific application the impedance was stable. 
On the contrary, Panel B shows an application applied in optimal catheter-tissue contact (visualized by 
a dense starburst at the catheter tip), where we observed a gradual impedance drop during ablation, 
which is related to improved lesion quality.
Figure 4 Case example
Figure 3A  shows the survival curves of VT-recurrence and all-cause mortality, which were 
evaluated by Cox proportional hazards models. Figure 3A displays the VT-free survival 
during 12 months of follow-up. A significant higher VT-free survival was observed in 
patients treated with ECM guidance (ECM+) (multivariable HR 0.29, 95% CI 0.10 – 0.69, 
P=0.021, for VT recurrence with ECM– as the reference group). 
Figure 3A  shows the all-cause mortality during 12 months of follow-up, as evaluated by Cox 
proportional hazards models. The all-cause mortality was not significantly different 
between patients treated with the ECM connected (ECM+) and those treated without 
ECM (ECM–) (multivariable HR 1.47, 95% CI 0.37 – 5.88, P=0.586, for all-cause mortality 
with ECM– as the reference group). 
ECM: e-Contact Module; HR: hazard ratio; LVEF: left ventricular ejection fraction;  VT: ventricular 
tachycardia
Figure 3A Cumulative VT free survival of patients treated with e-Contact Feed-
back (ECM+) versus patients treated without e-Contact Feedback (ECM-)
Figure 3B Cumulative survival of patients treated with e-Contact Feedback 
(ECM+) versus patients treated without e-Contact Feedback (ECM-)
Feedback (ECM-)
Figure 3A. Cumulative VT free survival of patients treated with e-Contact Feedback 
(ECM+) versus patients treated without e-Contact Feedback (ECM-) 
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Figure 3B. Cumulative survival of patients treated with e-Contact Feedback (ECM+) 
versus patients treated without e-Contact Feedback (ECM-) 
Figure 3 shows the survival curves of VT-recurrence and all-cause mortality, which were 
evaluated by Cox proportional hazards models. Figure 3A displays the VT-free survival 
during 12 months of follow-up. A significant higher VT-free survival was observed in patients 
treated with ECM guidance (ECM+) (multivariable HR 0.29, 95% CI 0.10 – 0.69, P=0.021, 
for VT recurrence with ECM– as the reference group).  
Figure 3b shows the all-cause mortality during 12 months of follow-up, as evaluated by Cox 
proportional hazards models. The all-cause mortality was not significantly different between 
patients treated with the ECM connected (ECM+) and those treated without ECM (ECM–) 
29
igure 4. Case example 
 
Figure 4 is a c se example of one f the patients from our c hort treated with ECM guidance. 
At the left en , CARTO electroanatomic maps of the left ventricle are displayed. The 
electroanatomic maps are displayed more transparent, whereas previous ablation points are 
displayed in less-transparent yellow and orange (i.e. the ‘Ablation History” feature of the 
Stereotaxis system). On the right, ablation parameters of the currently performed application 
are displayed, including temperature, power and impedance (recorded by the Claris system). 
Panel A displays an application applied in suboptimal contact. The suboptimal catheter-tissue 
contact is shown to the user by the ECM as a small starburst at the catheter tip. One can 
appreciate that during this specific application the impedance was stable. On the contrary, 
Panel B shows an application applied in optimal catheter-tissue contact (visualized by a dense 
starburst at the catheter tip), where we observed a gradual impedance drop during ablation, 










94 95Chapter 7Chapter 7
Discussion
This is the first study to assess the clinical outcome of contact feedback in 
RMN-guided CA. Our results suggest that contact feedback by the ECM im-
proves VT free survival in RMN-guided ischemic VT ablation. 
The importance of catheter-tissue contact
Effective lesion formation is a major determinant of outcome in VT ablation. 
In addition to traditional indices of power and RF duration, lesion continuity, 
catheter stability and contact have emerged as key elements influencing effec-
tive lesion formation.11 Different contact matters are of importance, including 
contact homogeneity across a line of ablation, spatiotemporal dynamics of 
contact governed by cardiac and respiratory motion and contact directionality.11 
Moreover, contact is of critical importance in adequate three-dimensional elec-
tro-anatomic mapping, another determinant of substrate ablation outcome.12 
This is illustrated by when a normal region is mislabeled as low-voltage scar due 
to poor tissue contact. Improved contact permits to define the areas of reduced 
potentials12 and increases the sensitivity of late potential detection.13 The pres-
ent study observed that implementation of a novel contact assessing technolo-
gy during RMN-guided ischemic VT ablation, resulted in higher VT-free survival. 
Consistently, less ICD shocks and less hospital admissions for VT recurrence 
were observed. Real-time contact feedback potentially improves the efficacy of 
VT ablation by virtue of more accurate maps12 and optimizing lesion formation.11 
First of all, by optimizing mapping, as points were predominantly taken when 
the ECM showed that there was optimal catheter-tissue contact. Secondly, by 
enhancing RF ablation, as the RF application was only started when the ECM 
showed there was optimal contact and catheter position was continuously op-
timized during ablation. It would be interesting to further investigate the ECM’s 
determination of size, definition and resolution of low-voltage areas in future 
studies involving scar related VT. 
Remote Magnetic Navigation versus Manual guided VT ablation
Where manual ablation catheters are still confined to uni- or bidirectional 
movement using pull wires8, magnetic navigation ensures enhanced maneu-
verability of the ablation catheter that makes reach of difficult anatomical 
structures possible.14,15 Magnetic guided ablation by itself aids to achieve more 
adequate lesion formation by enhanced catheter stability and consequently 
improved contact with the myocardial wall.16, 17 This is of critical importance in 
cardiac regions with greater wall motion excursion such as the ventricle. RMN 
facilitates titration of CF between the catheter and the myocardial tissue. Most 
studies comparing manual with RMN-guided VT ablation, reported superiority 
of RMN, with respect to procedure and fluoroscopy times, acute success rates 
and adverse events.7, 8 Moreover, in VT ablation of patients with non-structur-
al heart disease, RMN reported significantly lower VT recurrence rates during 
long-term FU.6 The present study reported lower procedure, fluoroscopy and 
mapping times, when compared to prior studies evaluating RMN guided ablation 
of scar related VT in general.18 Moreover, we observed even significant further 
reduction of VT recurrence, ablation time and fluoroscopy exposure after imple-
mentation of the ECM. In our opinion this illustrates the technological advances 
made in RMN guided ablation over time and highlights that the ECM was rapidly 
embedded in daily practice by the operating electrophysiologists.
The e-Contact Module
CF in manual guided CA is determined electromechanically based on the amount 
of mechanical deformation or diffraction of light experienced by the catheter tip.19 
In contrast to CF sensing catheters in manual guided CA, the ECM does not inform 
on the quantity of force applied. In RMN’s ECM, contact in fact is calculated by a 
combination of factors including the vector of the ablation catheter, wall motion 
and impedance. The ECM in RMN-guided ablation takes into account the angle be-
tween the tip of the catheter and myocardial surface that affects the pattern of the 
systodiastolic contact. In larger scars contact measurements may be less reliable, 
there wall motion may be distorted due to akinesia or dyskinesia and impedance 
is altered due to changes in conduction properties. Yet, the ECM incorporates 16 
variables to gauge contact that aids to high accuracy. The results of the present 
study, are in our opinion a confirmation of the accuracy of this novel feature, assist-
ing to the composition of accurate maps and advancing effective lesion formation. 
The quality of contact
This study also evaluated the measured quality of contact of every single RF ap-
plication. According to the ECM, we observed that 92% of the total RF application 
time was applied in contact with myocardial tissue, of which >70% was applied in 
optimal contact. Six percent of the total RF application time was applied without 
any contact with the myocardium. Interestingly, even though not all applications 
were applied in optimal contact, we observed improved outcomes. Real-time con-
tact feedback of the ECM, allows operators to constantly optimize catheter position 
while ablating reducing cumulative application time in suboptimal catheter position. 
Whether this explains the improved 12-month outcome in this study, should be ver-
ified in future studies where the operator is blinded versus unblinded to the ECM. 
Moreover, it would be interesting to investigate the effect of other parameters, 
such as LV approach, on the measured quality of contact.
Limitations
The present study’s retrospective nature and the lack of blinded adjudication might 
have introduced bias, although this was mitigated by the use of objective mea-
sures. The present study included all procedures performed since the implementa-
tion of ECM. As the operators had to learn how to incorporate the ECM’s feedback 
in their procedural approach, this learning curve might have negatively affected 
our results. Nevertheless, we observed a significantly better long-term outcome in 
procedures performed with ECM. Nowadays substrate ablation is being performed 
as per standard of care in all patients, whereas in the earlier days sometimes the 
procedure focused on elimination of critical isthmus and exit sites only. Moreover, 
insights on substrate ablation methodology changed over time. Possibly, it led to 
an improved abolition of channels20, 21 and this could have biased our results. How-
ever, substrate ablation as potential confounder was added to the Cox proportional 
hazard models and did not show a significant relation with the outcomes.
Conclusion
Contact feedback by the ECM appears to improve 1-year outcome in RMN-guided 
ischemic VT ablation, resulting in a higher 1-year VT free survival. Moreover, im-
plementation of the ECM significantly reduces fluoroscopy exposure and ablation 
times. These observations are most likely the result of improved accuracy of map-
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Albert Einstein
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Magnetic resonance imaging (MRI) and computed tomography (CT) in patients with 
ventricular tachycardia (VT) after myocardial infarction (MI) helps to delineate scar 
from healthy tissue. Imaging- guided VT ablation has not yet been studied on a 
large scale. 
Objective
The aim of the meta-analysis was to compare the long-term outcome of image-
guided VT ablation to a conventional approach for VT after MI.  
Methods
Eight electronic bibliographic databases were searched to identify all relevant 
studies from 2012 until 2018. The search for scientific literature was performed 
for studies that described the outcome of VT ablation in patients with an ischemic 
substrate. The outcome of  image guided ablation was compared to the outcome of 
conventional ablations. 
Results
Of the 2990 citations reviewed for eligibility, 38 articles enrolling a total of 7748 
patients - were included into the meta-analysis. Five articles included patients with 
image-guided ablation. VT-free survival was 82% [74-90] in the image-guided VT 
ablation group versus 59% [54-64] in the conventional ablation group (p < 0.001) 
during a mean follow-up of 35 months. Overall survival was 94% [90-98] in the 
image guided versus 82% [76-88] in the conventional VT ablation (p < 0.001).
Conclusions
Image-guided VT ablation in ischemic VT was associated with a significant benefit 
in VT free and overall survival as compared to conventional VT ablation. Visualizing 
myocardial scar facilitates substrate guided ablation procedures, pre-procedurally 







Magnetic resonance imaging (MRI) and computed tomography (CT) advancing 
ventricular tachycardia (VT) ablation have an important role in diagnosing structur-
al heart disease. In patients with VT after myocardial infarction (MI) these modal-
ities of imaging help to identify, delineate and characterise the scar. Electro-an-
atomical map can be used to define the scar and border zone. However, scar is 
3dimensional and a voltage map is limited in spatial resolution.1 Moreover arrhyth-
mogenic substrate may be found in heterogeneous tissue with normal voltages.2 
Channels that correlate with critical VT isthmuses can be identified by searching 
the scar for abnormal potentials. This may be time consuming and often incom-
plete. High-resolution MRI has been demonstrated to be able to delineate areas of 
surviving myocardial tissue within the scar that correlate with VT channels.3 MRI 
preceding VT ablation can accurately predict recurrences in the presence of scar4 
and is a promising tool to identify ablation strategy in case of transmural scar.5
Currently randomised and large scale trials lack on the long term outcome of image 
guided VT ablation. The aim of the current meta-analysis is to perform a large 
scale analysis, comparing the long term outcome of image-guided VT ablation to a 
conventional VT ablation approach.
Methods
Data sources and search strategy 
This review was conducted in accordance with the PRISMA and MOOSE guidelines 
(Appendix 1, 2). The purpose of our study was to identify all studies that use 
imaging modalities to focus on scar that is performed prior to ablation for ischemic 
VT. We searched Embase.com, Medline via Ovid, Web-of-science Core collection, 
the Cochrane Central registry of trials, Scopus, CINAHL via EBSCOhost and Google 
Scholar from January 2012 until January 2018. The search strategy was created 
with the assistance of a medical librarian (WB). The search strategy combined 
terms for ventricular tachycardia and catheter ablation, and terms for myocardial 
scar due to previous ischemic injury. The search results were limited to English 
language articles. The detailed search methodology for all databases is provided in 
Appendix 3.
Study selection and data extraction criteria
Studies were included if they: (i) were observational studies or randomized 
controlled trials (ii) reported on long-term follow-up of patients that had undergone 
percutaneous CA for ischemic VT, (iii) provided data on recurrences with a follow-
up duration of > 1 year. Articles that focused on patients with structural heart 
disease other than ischemic scar were excluded. Also if the studied population was 
heterogeneous and we were not able to extract the outcome of the patients with 
an ischemic VT, the study was excluded. Individual case reports, editorials, review 
articles and conference meeting abstracts were not included. We compared image-
guided VT ablation to non image-guided VT ablation. If imaging was performed 
preceding VT ablation but did not influenced the ablation procedure it was seen as 
non image-guided VT ablation.
Two reviewers (AAH, ZK) independently evaluated the titles and abstracts 
according to the inclusion and exclusion criteria. For each potentially eligible 
study, two reviewers assessed the full-text. In cases of disagreement, a decision 
was made by consensus or, if necessary, a third reviewer (TSZT). was consulted. 
A predesigned data extraction form was used to collect relevant information on 
baseline characteristics, ablation method, imaging, procedural data and follow-up.
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Risk of bias assessments for the included clinical studies 
The risk of bias within each individual study was evaluated by two reviewers (AAH, 
ZK) based on the nine-star Newcastle–Ottawa Scale (NOS) using three pre-defined 
domains namely: selection of participants, comparability and ascertainment of 
outcomes of interest. The NOS attributes a maximum of four points for selection, 
two points for comparability, and three points for outcome. Studies that received a 
score of nine points were judged to be at low risk of bias; studies that scored seven 
or eight stars were considered at medium risk; those that scored six or less were 
considered at high risk of bias (appendix 4).
Data Synthesis and Analysis
The unpaired Student’s t -tests was used for demographic comparison of 
continuous variables between groups. We used metaprop command to pool 
proportions and we presented a weighted sub-group and overall pooled 
estimates with inverse-variance weights obtained from a random-effects model. 
Heterogeneity was quantified using the I2 statistic, classified as low (I2 ≤25%), 
moderate (I2 >25% and <75%), or high (I2 ≥75%). Additionally, Q-statistic was 
used to assess the presence of heterogeneity. PQ statistic ≥0.05 was considered 
to indicate no significant heterogeneity among the included studies. Study 
characteristics including the location of the study, duration of the study, age, 
male sex, left ventricular function, the presence of VT storm at baseline and the 
percentage of patients using amiodarone were pre-specified as characteristics 
for assessment of heterogeneity and were evaluated using stratified analyses and 
random-effects meta-regression if 10 or more studies were included in the meta-
analysis. Publication bias was evaluated through a funnel plot and asymmetry was 
assessed using the Egger’s test. All tests were two-tailed and p-values of 0.05 or 
less were considered statistically significant. STATA release 14 (Stata Corp, College 
Station, Texas) was used for all statistical analyses.
Results
Identification of relevant studies
The search strategy identified 2454 (1307 citations after excluding articles from 
before 2012), out of which 63 articles were found relevant following initial screen-
ing based on titles and abstracts. After full-texts reading, 25 articles were further 
excluded based on extraction of ischemic VT data and the follow-up criteria. A total 
of 382, 4-40 articles were included that describe the outcome of VT ablation.  
Five4-8 of the 38 articles were image-guided. Figure 1 shows the selection process. 
General characteristics of the included studies
Table 1 shows the key characteristics of the included studies.
Baseline characteristics
A total number of 7748 patients with VT from ischemic scar were included in this 
meta-analysis (Table 2). Image-guided VT ablation had taken place in 224 patients. 
The majority of the non-image guided articles were authors from the USA whereas 
the majority of the image-guided articles were authors from Europe. The average 
age was 65 years and 89% was male. The average ejection fraction was 33%. 
Electrical storm was the reason for VT ablation in 16-100% of the population in the 
23 studies that reported on it.
Substrate ablation was applied in 50% of the included articles. Eighty percent 
of the image-guided VT ablation articles primarily used a substrate approach. In 
7 articles a targeted ablation was applied and in one article9 there was a direct 
comparison between targeted and a substrate approach. Three articles - all 
non-image guided - in the non-imaging guided ablation used remote magnetic 
navigation (49-100% of the patients). Seven articles - all non-image guided 
- commented on using assist devices in patients with non-hemodynamically 
tolerable VTs. Fifty-five and 94% of the patients in the image guided ablation group 
and the conventional VT ablation group respectively were ICD carriers (p = 0.02) at 
baseline. Fifty-eight percent had reported amiodarone use at the time of ablation.
No studies were judged at low bias of risk. Among the observational studies, 
studies were judged to be at median or high risk of bias. Among the randomised 
controlled trials, studies were all judged at median bias of risk.
Techniques used in image guided VT ablation
Different type of image guided ablation was reported. One article5 reported to use 
imaging to plan the ablation strategy, 2 articles7,8 used imaging to integrate in the 
ablation procedure and 2 articles4,6 reported on doing both. One of the articles that 
integrated imaging in the procedure used Automatic Detection of Arrhythmic Sub-
strate (ADAS).8
Procedural difference in characteristics between image-guided and non image-
guided VT ablation
Characteristics between the image-guided and non image-guided VT ablations 
were similar except for a significant difference in percentage of patients who had 
epicardial access, 37 in the image-guided VT ablation versus 6 in the non image-
guided VT ablation group (p < 0.01) (Table 2).
Procedural data
Procedural duration was on average 4.5 hours in the image guided ablation 
versus 3.7 hours in the conventional ablation (p = 0.09). There was no significant 
difference between radiofrequency time and fluoroscopy time in image guided VT 
ablation versus conventional ablation (Table 2). 
Longterm outcome in VT ablation
Sixty-one percent [IQR 54 - 67] of the patients were free of VT recurrences 
during a mean follow-up duration of 35 months with an overall survival of 84% 
[IQR 80-88].
Outcome of image-guided VT ablation
The image-guided VT ablation reported a higher VT free survival of (82% [IQR 
76-88]) compared to the non image-guided VT ablations (59% [IQR 54-64] ) (p 
< 0.001) (Figure 2). Overall survival was 94% [IQR 90-98] in the image guided 
versus 82% [IQR 77-87] in the conventional VT ablation (p < 0.001) (Figure 3). 
High between-study heterogeneity (random- effects model i2 93.56%, p < 0.001) 
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Table 1 Characteristics of included studies
A. Image-guided
B. non image-guided






author year country image- guided  - months
Neijm4 2015 USA OS, Co, SC 8 17
Acosta5 2016 Spain OS, Co, SC 58 23
Yamashita6 2016 France OS, Co, SC 67 17
Yamashita7 2016 France OS, Co, SC 54 28
Andreu⁸ 2017 Spain Os, Co, SC 37 20






author year country Non image- 
guided
 - months
Di Biase9 2012 Hungary, Italy, USA OS, Co, MC 92 25
Dinov10 2012 Germany OS, Co, SC 102 14
Arenal10 2013 Spain OS, Co, SC 59 38
Ghanem12 2013 Egypt OS, Co, SC 22 12
Tung13 2013 USA OS, Co, SC 69 12
Aryana15 2014 USA OS, Co, MC 36 19
Goya16 2014 Japan OS, Co, SC 51 41
Mork17 2014 Denmark OS, Co, SC 90 39
Saggu18 2014 India OS, Co, SC 5 46
Silberbauer20 2014 Italy OS, Co, SC 160 47
Tilz21 2014 Germany OS, Co, SC 12 40
Avila2 2015 Spain OS, Co, SC 46 32
Clemens22 2015 Check Republic OS, Co, SC 31 46
de Riva23 2015 the Netherlands OS, Co, SC 91 23
Di Biase23 2015 China, Europa, USA RCT, MC 118 12
Izguierdo24 2015 Spain OS, Co, SC 50 13
Luther25 2015 UK OS, Co, SC 24 24
Pioretti26 2015 USA OS, Co, SC 87 54
Siontis27 2015 Europa, USA OS, Co, MC 1412 56






author year country Non image- 
guided
 - months
Tsiarchis40 2015 Italy OS, Co, SC 100 52
Tung29 2015 USA OS, Co, MC 1095 12
Yokokowa14 2015 USA OS, Co, SC 906 35
Acosta30 2016 Spain OS, Co, SC 44 46
Dinov31 2016 Germany OS, Co, SC 50 12
Frankel32 2016 Italy, Japan, USA OS, Co, MC 1095 12
Fukunaga33 2016 Japan OS, Co, SC 51 40
Ozcan34 2016 North America OS, Co, SC 44 28
Sapp35 2016 Europe, USA RCT, MC 132 28
Skoda36 2016 Chech Republic, 
Germany, USA
OS, Co, MC 53 12
Jin37 2017 China, Denmark OS, Co, MC 54 17
Kuck38 2017 Germany RCT, MC 60 28
Kuroki39 2017 Japan OS, Co, MC 109 24
Tzou40 2017 USA, Japan OS, co, MC 1174 12
CO: cohort; MC: multi-center; ND: no data; OS: observational study; SC: single-center;
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amiodarone 
therapy
34 68 54 0.41
Prior VT 
ablation
23 32 15 0.14
epicardial 
access
34 37 6 < 0.01
ICD carrier 31 55 94 0.02
- min - min
procedural 
duration





13 34 [ 32 - ] 38 [ 24 -67 ] 0.93
radiation 
exposure
24 54 [ 34 - ] 28 [ 15 -38 ] 0.18
Figure 1 Flowchart of studies for outcome ventricular tachycardia ablation
Full-text articles excluded, 
(n = 25)
Reasons: 
→  not able to extract ischemic origin VT : 16
→ only in-hospital FU: 1
→ FU < 1 year: 2
→  analysis from study from before 2012 :1
→ not english: 1
→ abstract only: 4
Records identified through 
database searching 
(n=1307)
Records excluded during 
first screen (based on title/
abstract) 
( n=1244)
Full-text articles assessed for 
eligibility
(n=63)
Studies included in qualitative 
synthesis
(n =38)





age 38 64 66 0.07
EF 38 34 32 0.09
- % - %
male 36 94 90 0.40
infarct location anterior 21 43 40 0.80
inferoposterior 20 52 46 0.66
nyha class III 
+ IV
18 11 34 0.07
electric storm 23 49 36 0.45
diabetes 
mellitus
22 19 30 0.13
hypertension 27 70 60 0.11















Figure 2 Forrest plot of VT free survival image-guided versus non image-guided Figure 3 Forest plot survival – image-guided versus non-image-guided
Chapter 8
CI: confidence interval, ES: effect size, VT: ventricular tachycardia
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Discussion
The current meta-analysis shows an improved VT free and overall survival in 
patients with ischemic VT by using image-guided VT ablation compared to 
conventional VT ablation. This is the first study that demonstrates true large scale 
benefit. Visualising myocardial scar and integrating imaging in the procedure 
facilitates VT ablation by focussing on the area of interest and providing more 
accurate substrate characterization.
Imaging derived scar versus electro-anatomical map
Generally, there is a good correlation between bipolar voltage mapping and CT and 
MRI derived scar.6,41 Increased transmurality of the scar on MRI correlated well with 
reduced bipolar low voltage on the endocardium42, suggesting the presence of low 
voltage in the epicardium.
However, voltage mapping may fail to accurately delineate the extent of diseased 
myocardium because of limitations such as catheter contact issues, reduced sensi-
tivity to far-field signal of the mid-myocardium43, and the interposition of epicardial 
fat.44 Epicardial fat may lead to false-negative low voltage on epicardial voltage 
mapping, CT accurately visualises epicardial fat and differentiates it from scar.44 
Scar is a 3-dimensional structure and consequently a voltage map has a limited 
spatial resolution. Moreover, bipolar voltage map may show absence of low voltage 
in the presence of an intramural scar and therefore may be missed. It is potential-
ly unmasked with unipolar recordings, but may be best visualised with MRI. In the 
presence of an intramural scar VT recurrences occur more frequently.4 Recognizing 
the presence of intramural scar, high output endocardial ablation, bipolar ablation 
or a radiofrequency needle ablation catheter may reach the mid-myocardium and 
successfully ablate the VT circuit.45
Limitations of MRI
There are certain limitations on the use of cardiac MRI in VT ablation. Currently 
there is no consensus on nor standardisation of image postprocessing.46 Anoth-
er limitation is the presence of artefacts that derive from ICDs, most commonly 
affecting the basal left anterior free wall. The presence of devices not only limits 
the interpretations of scar tissue on MRI but also affect the reliability of contrast 
enhanced imaging due to provoked hyper-intense off-resonance artefacts mim-
icking scar tissue.47 The wideband inversion recovery late gadolinium enhance-
ment (LGE) MRI technique can potentially overcome this type of artefact.48 
Furthermore errors can arise with image integration as well. Geometry can 
change due to respiratory and cardiac motion, and conformational changes can 
occur between the time of MRI and the ablation procedure due to for example dif-
ferences in volume or rhythm.47 Partial-volume effects on the standard thickness 
short-axis slices for example can lead to overestimation of borderzone areas.49 
In EP procedures this is a known phenomenon. During electro-anatomical map-
ping (EAM) the mean maximum amplitude of cardiac and respiratory motion was 
10.2 ± 2.7 mm and 8.8 ± 2.3 mm respectively.50 This may be especially critical in 
the identification of conduction channels.
Using real time MRI minimalizes conformational changes. Non-contrast-en-
hanced T1 weighted imaging with long TI decay times is promising as it was 
shown to be an effective method for visualizing necrosis within radiofrequency 
ablation lesions. Enhancement is more specific and stationary than that from 
contrast LGE MRI. Scar tissue appears dark in the non-contrast-enhanced im-
ages, allowing to differentiate between acute RF ablations and chronic scar.51 
Cardiac motion correction by cardiac triggering improves precision in myocardial 
T1 mapping.52
Imaging guided ablation strategy
Epicardial ablation in ischemic VT is usually restricted to patients with previous 
failed endocardial ablation attempts. Yet, there is a relation between complete 
VT substrate elimination and better ablation outcomes.11 The importance of com-
plete substrate ablation is in the assumption that substrate not related to clinical 
or inducible VT can activate and become a VT isthmus during follow-up. Epicar-
dial borderzone channels in post MI transmural scar are seen in 63%.3 However, 
if epicardial ablation is used as a first-line ablation, a significant proportion of 
patients undergoing epicardial mapping do not exhibit an epicardial arrhythmo-
genic substrate.9 And therefore tools are needed to avoid unnecessary pericardial 
explorations. Acosta et al.5 showed that if patients with a transmural scar on MRI 
had endocardial ablation, a significant lower recurrence free survival compared to 
complete substrate ablation resulted.
Characterize the scar
A large area of scar heterogeneity predicts recurrence of VT after VT ablation.4 
Also successful ablation appears to be in localised areas of heterogeneity, and 
incomplete ablation in these areas predicts VT recurrence in animal models.53 The 
delayed components of the conducting channel electrograms reflect the pres-
ence and activation of viable fibers embedded in fibrosis.54 Borderzone channels 
display a 3D structure within the myocardial wall that can be depicted by contrast 
enhanced MRI.3 Critical sites of ischemic VT are confined to areas of high signal 
intensity. Channels on MRI correlate with areas of survival myocardial tissue which 
help to better locate the target ablation sites and find critical channels in the areas 
of normal voltage.8, 55 Identification of conductive channels channels on EAM aided 
by pixel intensity maps improved when based on 3D imaging with 1.4 x 1.4 x 1.4-
mm resolution compared to conventional 2-dimensional clinical imaging with 5-mm 
slice thickness.3 Identification of conduction channels in the electro-anatomical 
map can be improved when using a cutoff value of 60% of the maximum pixel sig-
nal intensity, both for core and borderzone. Using CT, thicker ridges within areas of 
pronounced wall thinning in the scar, seen as relatively preserved wall thickness, 
are recognized as the arrhythmogenic substrate of scar-related VT.56
Critical VT isthmus sites in patient with prior MI are located in close proximity to the 
area on MRI where transition between >75% transmural scar and the core-border-
zone occurs.57 Critical isthmus sites around the core-borderzone transition suggest 
that the signal intensity threshold of a maximal 50% may indicate a critical mix 
between fibrosis and viable myocytes that allow for slow conduction and there-
by, re- entrant VT. Currently however, 3D imaging and postprocessing methods 
may still be limited at detecting fractionated and late potential regions within EAM 
dense scar.3
Image-integration
Real time integration of VT substrate helps focusing on diseased vs healthy areas 
of the myocardium. Yamashita et al.6 showed that despite a similar number of map-
ping points a higher number of local abnormal ventricular activities (LAVA) sites 
could be identified in patients who had ablation guided by imaging data. Mapping 
more efficiently focuses towards the critical areas when guided by imaging data 
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Clinical implications
Guidance of imaging for VT ablation is not mentioned in the current ventricular 
arrhythmia guidelines.58 The current meta-analysis suggests benefit in VT free and 
overall survival by the use image guidance in VT ablation for patients with ischemic 
heart disease. Larger scale randomized studies are needed to confirm our results, 
in addition we are in need of studies that teach us about cost-effectiveness of im-
age-guided VT ablation.
Limitations
Despite the fact the this is the largest image-guided VT ablation cohort so far 
there are several limitations to note, some inherent to performing a meta-analysis. 
First, some data on patient level was unavailable in the included studies, which 
precluded a detailed evaluation to identify the impact of particular baseline demo-
graphic characteristics (i.e., number of ICD shocks before the ablation), type of 
imaging used (CT or CE-CMR) and procedural factors (use of magnetic navigation 
or contact force) on the outcome of freedom of VT. Additionally we were not able 
to extract data on the correlation between ablation strategy (substrate versus a 
targeted arrhythmia approach) and longterm outcomes in all of the eligible studies. 
There were significantly less patients with an ICD at the time of inclusion in the im-
age-guided group even though ejection fraction was similar. A possible explanation 
for the low % of patients who had an ICD implanted at baseline is a selection bias, 
patients without an implanted ICD during their presentation with VT were possible 
more prone to ondergo MRI before ablation. ICD patients benefit from a continu-
ous monitoring system, it could influence the detection of VT during follow-up. We 
cannot exclude that ICD was implanted during follow-up. Higher VT free and overall 
survival has been seen in patients treated with a substrate approach including 
epicardial ablation compared with a limited ablation.9 Patients with image guided 
VT ablation more often had a substrate approach and had a higher percentage 
of epicardial access, which itself could be an explanation for the lower number of 
recurrences in this group. Yet, determining ablation strategy is one of the poten-
tial benefits from image guided VT ablations.5 There was minimal publication bias 
as indicated by conventional funnel plots and Egger test (Supplement 2), how-
ever these approaches are limited by their qualitative nature. The majority of the 
included studies were observational in nature, with higher risk of selection bias. 
Randomised controlled trials are needed to convince the effectiveness of imaging 
data for VT ablation procedures. Limited scanning capacity and additional costs 
could hinder implementation. Currently, we cannot be confident that our results are 
merely a reflection of the contribution of image guided ablation.
Conclusion
Image-guided VT ablation was found to be associated with a significant benefit in 
VT free and overall survival as compared to conventional VT ablation. Visualizing 
myocardial scar may facilitate substrate guided ablation procedures, pre-
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Appendix 2 MOOSE checklist 
Criteria Brief description of how the criteria were handled in 
the meta-analysis
Reporting of background should include
√ Problem definition Magnetic resonance imaging (MRI) and computed tomography 
in patients with ventricular tachycardia (VT) after myocardial 
infarction helps to delineate scar from healthy tissue. MRI 
preceding VT ablation can prognosticate an increased 
recurrence rate in the presence of intramural scar and is a 
promising tool to identify an epicardial ablation strategy in 
case of transmural scar. No meta-analysis that compares the 
long-term outcome of imaging guided ventricular tachycardia 
ablation to conventional ventricular tachycardia ablation, has 
been published.
√ Hypothesis statement The usage of imaging guided ventricular tachycardia ablation 
improves long-term freedom from ventricular tachycardia 
recurrence as compared to conventional ventricular 
tachycardia ablation. 
√ Description of study 
outcomes
We included studies that estimated the outcome of ventricular 
tachycardia ablation in patient with an ischaemic substrate
√ Type of exposure or 
intervention used
VT ablation with and without the guidance of imaging
√ Type of study designs 
used
Eligible study designs included randomized controlled trials 
(RCTs), cohort, case-control studies.
√ Study population Only studies carried out in adults (>18 years old) were 
included.
Reporting of search strategy should include
√ Qualifications of 
searchers
The credentials of the investigators are indicated in the 
authors list.
√ Search strategy, 
including time 
period included in 
the synthesis and 
keywords
Search strategy and time periods are detailed in page 7 of 
the manuscript and in Figure 1 and the full search strategy is 
available in Appendix 3.
√ Databases and 
registries searched
Medline, Embase, Google Scholar, Scopus, CINAHL 
EBSCOhost, Web-of-Science, Cochrane Central
√ Search software used, 
name and version, 
including special 
features
We did not employ a search software. Endnote was used. to 
merge retrieved citations and eliminate duplications.
√ Use of hand searching We hand-searched bibliographies of retrieved systematic 
reviews and meta-analysis for additional references.
√ List of citations located 
and those excluded, 
including justifications
Details of the literature search process are outlined in the flow 
chart. Citations for the included studies are included in the text 
and table 1. The citation list for excluded studies is available 
upon request.
√ Method of addressing 
articles published in 
languages other than 
English
We placed restrictions to English language.
√ Method of handling 
abstracts and 
unpublished studies
Systematic reviews were used to identify further references. 
√ Description of any 
contact with authors
Authors of included studies were contacted to retrieve missing 
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Criteria Brief description of how the criteria were handled in 
the meta-analysis
Reporting of search strategy should include




for assessing the 
hypothesis to be 
tested
Detailed inclusion and exclusion criteria were described in the 
methods section. 
√ Rationale for the 
selection and coding 
of data
A predesigned data collection form was prepared to extract 
the relevant information from the included full texts, including 
study design, imaging technique, ablation strategy and 
whether endo/epicardial ablation was performed in a first set-
up.
√ Assessment of 
confounding
We performed qualitative analyses to evaluate differences 
between studies
√ Assessment of 
study quality, 
including blinding of 
quality assessors; 
stratification or 
regression on possible 
predictors of study 
results
We used the Newcastle- Ottawa Scale (NOS) to evaluate the 
quality of cross-sectional, case-control and cohort studies 
included in this review.
√ Assessment of 
heterogeneity
We were able to pool the data statistically.
√ Description of 
statistical methods in 
sufficient detail to be 
replicated
Under Data Synthesis and Analysis there is a detailed 
description of the statistical analyses. 
√ Provision of 
appropriate tables and 
graphics
We included 2 main tables, 3 graphs, 4 appendices, and  
2 supplements 
Reporting of results should include
√ Graph summarizing 
individual study 
estimates and overall 
estimate
Figure 2 and 3
√ Table giving 
descriptive information 
for each study included
Tables 1 and 2
√ Results of sensitivity 
testing
Suppl. 1
√ Indication of statistical 
uncertainty of findings
95% confidence intervals or SD’s were presented if available




√ Justification for 
exclusion
We excluded studies that had no or an unclear definition of 
outcome, or data extraction was not feasible.
√ Assessment of quality 
of included studies
We used the Newcastle- Ottawa Scale (NOS) to evaluate the 
quality of cross-sectional, case-control and cohort studies 
included in this review.
Criteria Brief description of how the criteria were handled in 
the meta-analysis





Due to the lack of standardisation of follow-up, it is difficult 
to provide unifying statements within a larger number of 
manuscripts hampered by large levels of heterogeneity.
√ Generalization of the 
conclusions
The generalizability of our findings has been enhanced by 
the involvement of data, including USA and Europe. However, 
there is a clear lack of evidence from the African and most of 
theWest Pacific Region.
√ Guidelines for future 
research
Further work is necessary to standardize the follow-up of 
patients who underwent image guided ventricular tachycardia 
ablation





('heart ventricle arrhythmia'/exp OR (((ventric* OR idioventric* OR rvot OR lv OR rv 
OR lvot) NEAR/3 (tachycard* OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR 
vt):ab,ti) AND ('ablation therapy'/exp OR 'ablation catheter'/de OR 'catheter ab-
lation'/de OR 'radiofrequency ablation'/de OR 'radiofrequency ablation device'/de 
OR 'cryoablation'/de OR (ablati* OR cryoablati* OR rfa):ab,ti) AND ('ischemia'/de 
OR 'ischemic heart disease'/exp OR infarction/exp OR 'heart muscle ischemia'/exp 
OR scar/de OR (ischemi* OR ischaemi* OR infarct* OR postinfarct* OR scar ):ab,ti) 
NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Let-
ter]/lim OR [Note]/lim OR [Editorial]/lim) AND [english]/lim  
Medline Ovid  
(("Arrhythmias, Cardiac "/ AND "Heart Ventricles"/) OR "Ventricular Fibrillation"/ 
OR "Tachycardia, Ventricular"/ OR (((ventric* OR idioventric* OR rvot OR lv OR 
rv OR lvot) ADJ3 (tachycard* OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR 
vt).ab,ti,kf.) AND ("Ablation Techniques"/ OR "Catheter Ablation"/ OR (ablati* OR 
cryoablati* OR rfa).ab,ti,kf.) AND ("ischemia"/ OR "Myocardial Ischemia"/ OR "Myo-
cardial Infarction"/  OR Cicatrix/ OR (ischemi* OR ischaemi* OR infarct* OR postin-
farct* OR scar ).ab,ti,kf.) NOT (exp animals/ NOT humans/) NOT (letter OR news OR 
comment OR editorial OR congresses OR abstracts).pt. AND english.la.  
Cochrane CENTRAL 
((((ventric* OR idioventric* OR rvot OR lv OR rv OR lvot) NEAR/3 (tachycard* OR 
tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt):ab,ti) AND ((ablati* OR cryoab-
lati* OR rfa):ab,ti) AND ((ischemi* OR ischaemi* OR infarct* OR postinfarct* OR 
scar ):ab,ti) 
Web of Science  
TS=(((((ventric* OR idioventric* OR rvot OR lv OR rv OR lvot) NEAR/2 (tachycard* 
OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt)) AND ((ablati* OR cryoab-
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AND DT=(article) AND LA=(english)
Google scholar 




('heart ventricle arrhythmia'/exp OR (((ventric* OR idioventric* OR rvot OR lv OR 
rv OR lvot) NEAR/3 (tachycard* OR tachyarrhythm* OR fibrillat* OR arrhythm*)) 
OR vt):ab,ti) AND ('ablation therapy'/exp OR 'ablation catheter'/de OR 'catheter 
ablation'/de OR 'radiofrequency ablation'/de OR 'radiofrequency ablation device'/
de OR 'cryoablation'/de OR (ablati* OR cryoablati* OR rfa):ab,ti) AND ('imaging'/de 
OR 'cardiac imaging'/de OR 'diagnostic imaging'/de OR 'nuclear magnetic reso-
nance imaging'/exp OR 'nuclear magnetic resonance'/de OR 'computer assisted 
tomography'/exp OR 'positron emission tomography'/de OR (imaging OR image* 
OR (magnet* NEAR/3 resonan*) OR ceMRI OR ceMR OR mri OR nmr OR mr OR 
(comput* NEAR/3 tomograph*) OR ct OR ((cat OR pet) NEAR/3 scan*) OR cmr OR 
cmri OR ((positron* OR  emissi*) NEAR/3 tomogra*)):ab,ti) NOT ([animals]/lim NOT 
[humans]/lim)
Medline Ovid 
("Tachycardia, Ventricular"/ OR (((ventric* OR idioventric* OR rvot OR lv OR rv OR 
lvot) ADJ3 (tachycard* OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt).
ab,ti.) AND ("Ablation Techniques"/ OR "Catheter Ablation"/ OR (ablati* OR cryoab-
lati* OR rfa).ab,ti.) AND ("Cardiac Imaging Techniques"/ OR "Diagnostic Imaging"/ 
OR exp "Magnetic Resonance Imaging"/  OR exp "Tomography, X-Ray Computed"/ 
OR exp "Tomography, Emission-Computed"/ OR (imaging OR image* OR (magnet* 
ADJ3 resonan*) OR ceMRI OR ceMR OR mri OR nmr OR mr OR (comput* ADJ3 to-
mograph*) OR ct OR ((cat OR pet) ADJ3 scan*) OR cmr OR cmri OR ((positron* OR  
emissi*) ADJ3 tomogra*)).ab,ti.) NOT (exp animals/ NOT humans/)
Cochrane 
((((ventric* OR idioventric* OR rvot OR lv OR rv OR lvot) NEAR/3 (tachycard* OR 
tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt):ab,ti) AND ((ablati* OR cryoab-
lati* OR rfa):ab,ti) AND ((imaging OR image* OR (magnet* NEAR/3 resonan*) OR 
ceMRI OR ceMR OR mri OR nmr OR mr OR (comput* NEAR/3 tomograph*) OR ct OR 
((cat OR pet) NEAR/3 scan*) OR cmr OR cmri OR ((positron* OR  emissi*) NEAR/3 
tomogra*)):ab,ti) 
Web of science   
TS=(((((ventric* OR idioventric* OR rvot OR lv OR rv OR lvot) NEAR/2 (tachycard* 
OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt)) AND ((ablati* OR cryoab-
lati* OR rfa)) AND ((imaging OR image* OR (magnet* NEAR/2 resonan*) OR ceMRI 
OR ceMR OR mri OR nmr OR mr OR (comput* NEAR/2 tomograph*) OR ct OR ((cat 
OR pet) NEAR/2 scan*) OR cmr OR cmri OR ((positron* OR  emissi*) NEAR/2 to-
mogra*))) )
Scopus    
TITLE-ABS-KEY(((((ventric* OR idioventric* OR rvot OR lv OR rv OR lvot) W/2 
(tachycard* OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt)) AND ((ablati* 
OR cryoablati* OR rfa)) AND ((imaging OR image* OR (magnet* W/2 resonan*) OR 
ceMRI OR ceMR OR mri OR nmr OR mr OR (comput* W/2 tomograph*) OR ct OR 
((cat OR pet) W/2 scan*) OR cmr OR cmri OR ((positron* OR  emissi*) W/2 to-
mogra*))) )
CINAHL EBSCOhost  
(MH "Tachycardia, Ventricular" OR TI (((ventric* OR idioventric* OR rvot OR lv OR 
rv OR lvot) N2 (tachycard* OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR 
vt) OR AB (((ventric* OR idioventric* OR rvot OR lv OR rv OR lvot) N2 (tachycard* 
OR tachyarrhythm* OR fibrillat* OR arrhythm*)) OR vt)) AND (MH "Ablation Tech-
niques" OR MH "Catheter Ablation" OR TI (ablati* OR cryoablati* OR rfa) OR AB 
(ablati* OR cryoablati* OR rfa)) AND (MH "Cardiac-Gated Imaging Techniques" OR 
MH "Diagnostic Imaging" OR MH "Magnetic Resonance Imaging+"  OR MH "To-
mography, X-Ray Computed+" OR MH "Tomography, Emission-Computed+" OR 
TI (imaging OR image* OR (magnet* N2 resonan*) OR ceMRI OR ceMR OR mri OR 
nmr OR mr OR (comput* N2 tomograph*) OR ct OR ((cat OR pet) N2 scan*) OR cmr 
OR cmri OR ((positron* OR  emissi*) N2 tomogra*)) OR AB (imaging OR image* OR 
(magnet* N2 resonan*) OR ceMRI OR ceMR OR mri OR nmr OR mr OR (comput* N2 
tomograph*) OR ct OR ((cat OR pet) N2 scan*) OR cmr OR cmri OR ((positron* OR  
emissi*) N2 tomogra*))) NOT (MH animals+ NOT MH humans+)
Google scholar 
"ventricle|ventricular|rvot|lv|rv|lvot  tachycardia|tachyarrhythmia|arrhythmia" ab-
lation|cryoablation|rfa imaging|image|"magnetic resonance"|mri|nmr|"computed|-
computer tomography"|"positron emission tomography"
Appendix 4 Newcastle- Ottawa Quality Assessment Scale
Note: A study can be awarded a maximum of one star for each numbered item with-
in the Selection and Exposure categories. A maximum of two stars can be given for 
Comparability.
Selection 
1) Is definition of NCDs adequate?
a) Yes, according to a clear and widely used definition *
b) Yes, eg record linkage or based on self-reports
c) No description
2) Representativeness of the cases
a) Consecutive or obviously representative series of cases *
b) Excluded cases are random *
c)  No description of the excluded cases or potential for selection biases or  
not stated
3) Comparison with a reference group
a) The results are compared with a reference from community or with the status of 
the cases prior to the disease *
b) The results are compared with the results from other patients
c) No description/no comparison available
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a)  Individuals with no NCD or sample from general population or the same  
individuals before NCD suffering*
b) Non community comparator is described
c) No description of source
Comparability 
1) Comparability of the results on the basis of the design or analysis
a) The results are described in age and sex sub groups (sex is not applicable for 
female diseases) *
b) The results are additionally adjusted for/described in different socioeconomic 
factors or disease related confounders*
Exposure (costs, productivity, households)
1) Ascertainment of exposure
a)  Secure record (e.g. surgical records, hospital records, and administrative  
records, national…) *
b) Structured interview were blind to case/control status *
c) Interview not blinded to case/control status
d) Written self-report or medical record only
e) No description
2) Same method of ascertainment for NCDs and comparators
a) Yes *
b) No
c) No comparator group exist
3) Non-Response rate
a) All participants included or same rate for both groups or respondents and 
non-respondents have the same characteristics*
b) Non respondents described
c) Rate different and no designation
d) Response rate not described
Supplement 1  Sensitivity analysis of studies included in meta-analysis





















































































































































Supplement 2. funnel plot

A. overall survival 




B. VT free survival
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The role of epicardial substrate ablation of ventricular tachycardia (VT) as a first-
line approach in patients with ischemic heart disease is not clearly defined. Epicar-
dial ablation as a first-line option is standard for patients with nonischemic dilated 
cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Several 
nonrandomized studies, including studies on patients with ischemic heart disease, 
have shown that epicardial VT ablation improves outcome but this approach was 
often used after a failed endocardial approach. The aim of this study is to deter-
mine whether a combined endo-epicardial scar homogenization as a first-line 
approach will improve the outcome of VT ablation.
Methods/Design
The EPILOGUE study is a multicenter, two-armed, nonblinded, randomized con-
trolled trial. Patients with ischemic heart disease who are referred for VT ablation 
will be randomly assigned to combined endo-epicardial scar homogenization or 
endocardial scar homogenization only (control group). The primary outcome is 
recurrence of sustained VT during a 2-year follow-up. Secondary outcomes include 
procedural success and safety.
Discussion
This study is the first randomized trial that evaluates the role of a combined en-
do-epicardial scar homogenization versus endocardial scar homogenization for the 
treatment of ischemic scar-related VT.
Trial registration: NL4816807814v02
Background
Ventricular tachycardia (VT) is an important clinical sequela after a myocardial in-
farction and may be associated with sudden cardiac death.1 The introduction of the 
implantable cardioverter defibrillator has provided an important tool in the prevention 
of sudden cardiac death. However, a significant proportion of patients experience 
multiple appropriate implantable cardioverter defibrillator shocks due to sustained 
VT. Catheter ablation of VT is useful to reduce the burden of VT. The threshold for 
VT ablation has lowered in recent years, mainly as a result of technological ad-
vancements and increased experience.2–4 The endocardial approach has been the 
preferred first-line approach for VT ablation in patients with ischemic heart disease. 
Recent studies suggest that 12–17% of all VTs in a mixed population of ischemic and 
nonischemic cardiomyopathies have an epicardial origin.5,6 Epicardial VTs have been 
observed in 10% of post-infarction VTs.7 These numbers may be underestimated, 
considering the moderate outcomes of endocardial VT ablations.8,9 In experienced 
centers, epicardial VT ablation has an acceptable risk-to-benefit ratio.6,10 Current 
recommendations for scar-related VT suggest that patients with ischemic heart 
disease can benefit from an epicardial approach if an endocardial ablation fails.11 The 
aim of this randomized trial is to determine whether combined endo-epicardial scar 
homogenization as a firstline approach will improve the outcome of VT ablation in 
comparison with endocardial scar homogenization only.
Methods/design
Study design
The EPILOGUE study is a multicenter, two-armed, nonblinded, randomized controlled 
trial. Patients will be randomized to endocardial scar homogenization or endoepi-
cardial scar homogenization (Figure 1). The study period is 2 years after the index 
procedure. All participating centers are tertiary referral centers for VT ablation with 
experience in epicardial ablation.
Study population
All patients with a history of ischemic heart disease who are referred for VT abla-
tion will be considered for inclusion. Patients can be included if they meet all of the 
following inclusion criteria: 
• Age ≥18 years; 
• History of ischemic heart disease; 
•  Presence of or planned for implantable cardioverter defibrillator soon  
after VT ablation.
Patients will be excluded if they meet any of the following criteria:
• Presence of unstable angina;
• Acute myocardial infarction <30 days (or in case of incessant VT, <14 days);
•  Absence of visualization of coronary anatomy (coronary angiogram or  
computed tomography);
• Presence of significant coronary stenosis clinically relevant for intervention;
• Presence of mobile left ventricular thrombus;
• Presence of aortic or mitral mechanical valve prosthesis;
• Previous pericarditis;
• Previous coronary artery bypass graft;
•  Other factors that could potentially lead to pericardial adhesion  
(e.g., thoracic radiation therapy);
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Ethics
The study protocol was approved in February 2015 by the Medical Ethical Com-
mittee (2014–248) Erasmus Medical Center, Rotterdam, The Netherlands. In-
formed consent will be obtained from each participant.
Primary and secondary outcomes
The primary outcome of this study is recurrence of sustained VT (defined as 
appropriate implantable cardioverter defibrillator therapy or VT >30 s duration) 
within 2 years. We will use a blanking period of 1 week after the ablation proce-
dure. The secondary outcome parameters will be acute procedure success and 
procedure-related major complications. Procedural success will be defined as 
complete success if there is noninducibility of any sustained monomorphic VT. 
Partial success will be defined as noninducible clinical VT but inducible polymor-
phic VT, or VT with a cycle length <200 ms. Procedural failure will be defined as a 
spontaneous occurrence of VT or inducible clinical monomorphic VT.
Furthermore, the following data will also be determined: procedure time, fluo-
roscopy time, radiofrequency ablation time, time to recurrence of the ventricular 
arrhythmia, number of appropriate implantable cardioverter defibrillator therapies 
on follow-up, number of VT-related hospitalizations, freedom of antiarrhythmic 
drugs on follow-up, repeated (epicardial) ablation procedures, evidence of an 
incessant VT or VT storm during follow-up, and mortality. 
Study groups
This study has two study arms, the endocardial approach only and the combined 
endocardial and epicardial approach (combined approach). Crossover is not 
allowed during the first procedure. When a patient is randomized to the combined 
approach and the epicardial access is unsuccessful, this is considered a screen-
ing failure.
Randomization
Patients are randomized to either the endocardial approach or the combined 
endocardial and epicardial approach. Randomization is performed using a comput-
er-generated program (ALEA). The person carrying out randomization will not be 
the treating physician or involved in the selection procedure. The patient and the 
electrophysiologist who will be performing the procedure will not be blinded for the 
method of approach.
Electrophysiology procedure and catheter ablation
Pre-procedural preparation
In general, anticoagulation therapy will be discontinued before the proce-
dure (unless the operator decides otherwise). When performing the pericar-
dial puncture, the international normalized ratio should be <2.0. Transthoracic 
echocardiography will be used to exclude a thrombus in the left ventricle. If the 
transthoracic echocardiography is inconclusive, contrast transthoracic or trans-
esophageal echocardiography will be used. Antiarrhythmic medications will be 
stopped 5 days before the procedure. In case of an emergency VT ablation, the 
operator can choose to do the ablation while continuing antiarrhythmic drugs. 
Patients who undergo an epicardial ablation will receive general anesthesia; 
otherwise conscious sedation and local anesthesia will be used. The epicardial 
ablation is performed with a surgical team as backup.
Figure 1 EPILOGUE study flow chart 
*Normal recordings are defined as not more than three sharp and discrete deflections from baseline,
amplitude >1.5 mV, duration >70 ms or amplitude-to-duration ratio >0.046. 
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sharp and discrete deflections from baseline, amplitude >1.5 mV, duration <70 ms 
or amplitude-to-duration ratio >0.046.9 Before epicardial ablation, a coronary an-
giogram will be performed to avoid coronary artery damage. In addition to target-
ing abnormal potentials, epicardial homogenization will be performed. Ablation is 
continued until all abnormal potentials are gone.
Clinical outcome and follow-up
Patients will be seen periodically up to 2 years (at 1, 3, 9, 12, and 24 months) after 
the index procedure. All implantable cardioverter defibrillator therapies and clinical 
events are reported. The implantable cardioverter defibrillator will be programmed 
to detect VTs slower than the clinical VTs. Recommended implantable cardioverter 
defibrillator programming consists of a ventricular fibrillation zone with a cut-off 
rate of 220 beats per minute and a therapeutic VT zone with a cut-off cycle length 
of 60 ms below the slowest documented VT. To register VTs with rates below the 
detection limit, a monitor zone will be programmed with a cut-off rate of 120 beats 
per min. Detection duration will be 24/32 beats or 5 s in the ventricular fibrillation 
zone and 26 beats or 10 s in the therapeutic VT zone.
The analysis of recurrence of VT depends on the clear differentiation of VT from 
supraventricular tachycardia events. For reliable adjudication of arrhythmic events, 
implantable cardioverter defibrillator episodes with available electrograms are 
mandatory. In the case of singlechamber devices, the recommended setting is 
storage of both near-field and far-field (shock) electrogram sources. In addition, 
electrogram storage must be available before arrhythmia onset.
Adverse events
In compliance with medical ethics committee regulations, it is compulsory to regis-
ter all serious adverse events. Death, acute myocardial infarction, coronary artery 
damage, type III and V major bleeding, abdominal bleeding, tamponade of more 
than 80 cm3, late tamponade, and an ischemic cerebral event are considered major 
adverse events. Dry right ventricle puncture, drainable hemopericardium, postpro-
cedural precordial pain, phrenic nerve injury and type II minor bleeding12 are con-
sidered minor adverse events.
Safety monitoring
Two committees and one monitor will be appointed to monitor patient safety. A 
data safety monitoring board will review study progress and has the authority 
to end the study if significant benefits or adverse effects in either study arm are 
suspected. The board members are three experienced electrophysiologists and a 
statistician. The clinical events committee will study all serious adverse events for a 
causal relationship between events and the EPILOGUE study. A monitor will evalu-
ate protocol compliance by taking random samples in all participating centers.
Statistical analysis
Continuous variables between groups will be compared using Student’s t test or 
the Mann–Whitney test for continuous variables, where appropriate. Categorical 
variables between groups will be compared with the chi-square test or Fisher’s ex-
act test, where appropriate. The primary outcome parameter will be analyzed using 
Kaplan–Meier survival curves and tested with a log-rank test. A two-sided P value 
of 0.05 will be considered statistically significant for all analyses. Statistical analy-
sis will be performed using SPSS version 20.
Pericardial access
In patients undergoing epicardial ablation, before ablation and systemic heparin-
ization, subxiphoid pericardial access will be obtained by fluoroscopic guidance 
(lateral plane). Using a Tuohy needle, small amounts of contrast are injected while 
carrying out the puncture. Guided by fluoroscopy, a guide wire is inserted into 
the pericardial space and an Arrow sheath is placed. An appropriate sized guiding 
catheter is inserted to keep the sheath open. During ablation, we will use an irri-
gated tip catheter. The baseline flow should be reduced to 1 ml/min. Fluid will be 
drawn from the pericardial space frequently during the ablation. At the discretion of 
the operator, epicardial phrenic nerve capture will be performed if the origin of the 
VT is located in the area of the phrenic nerve. When capture is performed, a bal-
loon is inserted and inflated to avoid phrenic nerve damage during ablation. At the 
end of the procedure, a pericardial drain is inserted for 24–48h. The operator will 
administer an intrapericardial steroid injection. Colchicine should be prescribed for 
up to 1 month, commencing on the first day after the procedure. The first day post 
procedure Colchicine is dosed 1 mg twice daily followed by a maintenance dose of 
Colchicine 0.5 mg twice daily.
Mapping
Endocardial mapping will be performed in all patients. A multipolar diagnostic 
catheter will be placed in the coronary sinus. A quadripolar diagnostic catheter 
will be introduced via the femoral vein to the right ventricular apex. Left ventricle 
mapping will be performed via the retrograde aortic or transseptal approach. The 
procedure will be performed under intravenous anticoagulation with heparin, with a 
target activated clotting time >250 s. Electroanatomical maps will be obtained us-
ing CARTO 3 (Biosense Webster, Diamond Bar, CA, USA) or EnSite NavX (St. Jude 
Medical, St. Paul, MN, USA). This includes activation (if applicable) and voltage 
maps. The bipolar voltage thresholds used to consider dense scar and border zone 
will be 0.5 and 1.5 mV, respectively. We will aim to acquire a very dense map, espe-
cially around scar areas. Areas of fractionated or late potentials will be annotated. 
Programmed ventricular stimulation will be performed, and will involve three extra 
stimuli from two different right ventricular sites, high-rate pacing, and intravenous 
isoproterenol (at the discretion of the operator). In hemodynamically unstable VTs 
mechanical circulation support (Impella, intra-aortic balloon pump) can be consid-
ered. 
Ablation protocol (both groups)
If a hemodynamically tolerated VT is induced during the electrophysiological study, 
a standard activation or entrainment mapping is carried out. The ablation will con-
tinue until the VT is no longer inducible. Additionally, endocardial scar homogeni-
zation will be performed. Based on the substrate map, ablation will be empirically 
extended throughout the entire scar endocardially. Also delayed and fractionated 
electrograms will be targeted for ablation. If clinical VT is still inducible in the endo-
cardial ablation-only group, an epicardial VT ablation will be performed in a ‘redo’ 
procedure. Epicardial mapping and ablation will be performed as described in the 
combined approach. 
Combined endocardial and epicardial group ablation
After obtaining pericardial access, a substrate map is constructed to identify ab-
normal electrograms. Activation mapping during VT – if possible – is done to prove 
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to 4.1%.5,6 Procedure-related death in most studies was 0%.5,6,16 However, a study 
from Hamburg reported two procedure-related deaths in 59 patients undergoing 
epicardial VT ablations.14 Thus, life-threatening complications might occur. Other 
reported major complications were:5,6,9,16
• Hepatic bleeding;
• Pericardial bleeding requiring a drain;
• Phrenic nerve palsy;
• Pleuro-pericardial fistula;
• Coronary artery damage;
• Cardiac tamponade;
• Pericardial inflammatory reaction.
To prevent pericardial inflammation and subsequently adhesions, the use of colchi-
cine after epicardial ablation is mandatory in our study.19 
Study design
The study of Di Biase et al.9 was a retrospective comparison of two techniques. 
Although there was a well-written prospective protocol, the two well-known 
techniques are difficult to compare. In the absence of a large scar or in the pres-
ence of dense scars, patients did not undergo epicardial ablation. Only 14 out of 
43 patients (33%) in the endocardial and epicardial scar homogenization group 
underwent epicardial VT ablation. In the current study both groups will undergo 
scar homogenization. Patients randomized to the combined approach will undergo 
epicardial ablation unless there is a complete absence of abnormal recordings. The 
EPILOGUE study is the first randomized controlled study to compare a combined 
approach with a stepwise approach for VT ablation in patients with ischemic car-
diomyopathy.
Limitations
This study is an open study that may subsequently lead to bias. However, the pri-
mary endpoint is recurrence of VT, an objective endpoint. Patients who have had 
a coronary artery bypass graft will be excluded from this study, thereby excluding 
a relevant part of the scar-related VT population. Open heart surgery is a known 
risk factor for adhesions and has shown to limit epicardial VT ablation.16 When 
considering that VT ablation is not yet general practice, the inclusion rate may be 
low. This approach may change in following years as a consequence of improved 
understanding of the underlying pathophysiology or mechanism of VT.
Trial status
Inclusion of eligible candidates in the EPILOGUE study has not yet started; enrol-
ment is expected to start in May 2015.
Sample size calculation
Sample size was calculated based on the following assumptions: a 29% difference 
in primary outcome event rate (recurrence of VT) between the endocardial and epi-
cardial group (15%) and the control group (44%) after a follow-up time of 2 years9. 
We calculate that a sample size of 86 patients is required to achieve an 80% power 
to detect a significant difference with a (two-tailed) alpha error of 5%. Allowing for 
a dropout rate of 10%, we calculated that we would require 100 subjects.
Discussion
Mechanism of scar-related ventricular tachycardia
Sustained VT in the presence of coronary artery disease is most often the result of 
prior myocardial infarction13. Scar areas form the substrate for macro-reentry which 
is the most frequent mechanism underlying VT. Targets for ablation are the area of 
low bipolar voltage that corresponds to the subendocardial projection of the scar, 
and potential targets within the scar that represent critical diastolic isthmuses 
during VT.
Role of epicardial ablation
In 73% of unsuccessful endocardial ablations, evidence of an epicardial substrate 
of VT was found.14 To reach procedural success in VT ablation, Cesario et al.15 
found that 40% of the patients were in need of an epicardial ablation. A recent 
retrospective observational study from Tung et al.16 compared the outcomes of 
patients who underwent epicardial ablation with the outcomes of patients who 
did not. The pericardial space could not be accessed in 7% by the percutaneous 
technique. The study demonstrated that at 12 months those with an ischemic sub-
strate for VT who underwent a combined endocardial and epicardial ablation had 
improved freedom from VT compared with those who underwent endocardial-only 
ablation (85% versus 56%; P = 0.03). In a multicenter study by Della Bella et al.5, 
67% of a subgroup of patients with ischemic VT etiology were in need of a stepwise 
approach. It could be speculated that an endocardial and epicardial approach as 
a first-choice ablation strategy in this subgroup might have avoided a substantial 
number of repeat procedures and improved outcome. 
Epicardial ablation in ischemic cardiomyopathy
Multiple studies on epicardial VT ablation in scar-related VT have been published5, 
9, 15, 17, 18; however, few have compared endocardial ablation with a combined endo-
cardial and epicardial ablation. In 33 post-infarct patients17, epicardial mapping was 
performed when endocardial ablation failed. These 33 patients were retrospec-
tively compared with patients who had had an endocardial ablation only. There was 
found to be no difference in outcome. However, only 6% of the patients had had 
an epicardial ablation. A recent study from Di Biase et al.9 compared limited endo-
cardial substrate ablation with combined endocardial and epicardial scar homog-
enization in patients with an electrical storm and ischemic cardiomyopathy. There 
was a lower VT recurrence rate in those who underwent endocardial and epicardial 
scar homogenization during a mean follow-up of 25 months (19% versus 47%; P = 
0.006). A limitation of this study is that because these researchers used a histori-
cal control group, the technique of ablation (limited substrate ablation versus scar 
homogenization) differed between groups.
Safety of epicardial ablation
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Introduction
Epicardial ventricular tachycardia (VT) ablation is increasingly performed in 
patients with recurrent VT, in whom epicardial arrhythmogenic substrate is 
suspected. It is a preferred approach if the substrate for VT is located epicardially, 
such as in patients with arrhythmogenic right ventricular cardiomyopathy and 
nonischemic dilated cardiomyopathy. Moreover, endo -epicardial substrate 
homogenisation may also be useful as a first-line therapy in patients with VTs 
after myocardial infarction1,2, especially in the presence of a transmural scar.3 
Complications in epicardial VT ablation can occur during pericardial puncture or 
can be caused by the ablation catheter. The most common cardiac complications 
are right ventricular perforation leading to pericardial bleed (4.5%)4, and coronary 
vessel damage. Furthermore, because of the proximity of surrounding extracardiac 
structures and anatomic variance one should be cautious for intra-abdominal, 
pleural and vessel complications. We report two cases who had pericardial access 




We present a case of a 48 year old male who was seen for second opinion after 
multiple appropriate ICD shocks for VT, that mostly occurred during exercise. 
Four years before he had received an internal cardioverter defibrillator (ICD) for 
secondary prophylaxis. His ejection fraction was moderately reduced. Coronary 
angiogram revealed no epicardial stenosis, cardiac magnetic resonance imaging 
showed a scar with the characteristics of a previous myocardial infarct in the 
inferoposterior region. He consented for a VT ablation and was planned for 
endo - epicardial scar homogenisation in the context of the Epilogue trial5. After 
endocardial access, pericardial access via an anterior xiphoid puncture8 was 
obtained without difficulty. Both the endo -and epicardial voltage did not show 
areas of low voltage. VT induction led to haemodynamic instability for which rescue 
electrical cardioversions were needed. The best depicted location by pacemap 
was the inferior epicardium, however during activation map this area was late. 
Therefore we did not proceed with radiofrequency ablation. 
After replacing the arrow sheath for a pericardial drain (Perivac, Boston Scientific), 
blood was noticed. Contrast injection through a drain with proximal side holes, 
demonstrated extravasation in the thorax and not the pericardium (Figure 1A). He 
remained clinically stable. A CT scan confirmed a pericardial drain positioned at 
an anterior position of the heart, that brushed a side branch of the LIMA (Figure 1B 
/C). Within a few hours after the procedure the drain production stopped and was 
removed without complications. With amiodarone therapy he remained free of VT. 
In the absence of scar on 3D voltage map a new diagnostic effort was made and a 
genetical form (RMB20 mutation) of dilated cardiomyopathy was recognised. 
Patient 2
The second case is a 62-year old male known with a myocardial infarction and a 
moderate impaired LV had recurrent VTs for which he received an ICD. He was 
scheduled for an endo-epicardial VT ablation5 because of recurrent sustained 
VT. Angiography did not reveal novel coronary artery stenosis. Amiodarone and 
oral anticoagulation were withheld. VT ablation was performed under general 











Figure 1 damage to the LIMA patient 1
undertaken, using a Tuohy needle. During the first puncture the guidewire aligned 
the cardiac silhouette, however it took off higher than the normal pericardial folds 
(Figure 2A). Advancing the guidewire further confirmed a localisation in the pleural 
space (Figure 2B). In a second attempt, the needle unintendedly moved up over 
the epicard, resulting in a pleural puncture. A third attempt resulted in successful 
pericardial access. Heparin was given and activated clotting time > 250 seconds 
was targeted. Sequential endo -and epicardial electroanatomical maps (CARTO 3 
RMT, Biosense Webster) revealed a large area of low voltage signals and identified 
various late potentials (Figure 3A /B). During mapping increasing inotropic support 
was necessary to treat hypotension. At a critical isthmus a few RF applications 
were given. Because of therapy resistant hypotension the procedure was impeded. 
A. Fluoroscopy reveals contrast extravasation extra pericardial 
B. The CT (sagittal view) demonstrates the anterior course of the pericardial drain
C. The CT (axial view) shows that the pericardial drain is directly adjacent to the LIMA and courses 
through its side branch (arrow).
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Figure 2 fluoroscopy during and after pericardial puncture patient 2
During the first puncture (patient 2) the guidewire aligned the cardiac silhouette. However it took off 
higher than the normal pericardial folds (Figure A). Advancing the guidewire further confirmed its 
localisation in the pleura space (Figure B). On fluoroscopy extensive pleural fluid on the left thorax is 
seen (Figure C).
Repeated fluoroscopy revealed extensive pleural fluid on the left thorax (Figure 
2C). Immediate drainage of the pleural space resulted in 2 litres of blood. On the 
operation room emergency lateral thoracotomy was performed. A laceration of 
the LIMA near the 6th intercostal space, was identified and repaired with a single 
suture. At follow-up he developed recurrent exudative pleural fluid. 
Figure 3 endo -and epicardial voltage map patient 2
A. Endocardial map showing an area of low voltage, posterior view and on the right intracardiac 
electrogram revealing an abnormal potential 
B. Epicardial map showing an area of low voltage, posterior view, and on the right an intracardiac 














1. One of the complications of a pericardial puncture is laceration of the LIMA.
2. An anterior approach is preferred to avoid right ventricular puncture.
3. An anterior approach may be related to a higher incidence of LIMA damage. 
 
4.  When approaching the pericardium caution is needed during needle 
advancement to avoid a higher than usual puncture or needle take off.
 
5.  A very anterior puncture can can be avoided when the puncture needle is aimed 
at a minimum angle of 20° towards the anterior RV silhouette. A pre-procedural 
CT scan can aid to avoid LIMA puncture in case of difficult anatomy.
 
6.  A pericardial drain with proximal side holes outside the pericardium is 
commended to detect extra pericardial bleed that otherwise is left unnoticed.
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A LIMA laceration, a complication of a pericardial puncture can stay temporarily 
concealed and may lead to a potential life threatening condition. 
We would like to emphasize the importance of understanding the anatomy and 
recognising the person to person variability when performing epicardial VT 
ablation. The angle of a successful pericardial puncture is dependent on the 
rotation of the heart and the type and quantity of tissue that is crossed. Body mass 
index, pulmonary disease and history of abdominal operations are risk elevating 
factors. 
As an alternative, an anterior approach directly accesses the fibrous pericardium 
without going through the diaphragm, can be used. A conventional inferior 
pericardial puncture has been safely used, however still contains a limited risk of 
right ventricle and liver trauma.6,7 Few complications so far have been described.8 
Since the runoff of the LIMA is more anteriorly, an anterior puncture in general may 
contain a higher risk of LIMA perforation. 
CT is very helpful in delineating the structural relationship of pericardium with other 
chest and abdominal organs. CT preceding epicardial VT ablation may prevent 
injury to unexpected structures during pericardial puncture. 
Conclusion
Pericardial puncture may be complicated by a laceration of the LIMA. An anterior 
approach preferred to avoid right ventricular puncture, can potentially increase the 
incidence of LIMA damage. Caution is needed during needle advancement when 













Scar related atrial 
arrhythmias
The scar reminds me of what I can be 
Lawson
What deep wounds ever closed without a scar? The 
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Atrial Fibrillation (AF) is associated with remodeling of the atrial tissue, which leads 
to fibrosis that can contribute to the initiation and maintenance of AF. Delayed- 
Enhanced Cardiac Magnetic Resonance (DE-CMR) imaging for atrial wall fibrosis 
detection was used in several studies to guide AF ablation. The aim of present 
study was to systematically review the literature on the role of atrial fibrosis 
detected by DE-CMR imaging on AF ablation outcome. 
Methods 
Eight bibliographic electronic databases were searched to identify all published 
relevant studies until 21st of March, 2016. Search of the scientific literature was 
performed for studies describing DE-CMR imaging on atrial fibrosis in AF patients 
underwent Pulmonary Vein Isolation (PVI).  
Results 
Of the 763 citations reviewed for eligibility, 5 articles (enrolling a total of 1040 
patients) were included into the final analysis. The overall recurrence of AF ranged 
from 24.4 - 40.9% with median follow-up of 324 to 540 days after PVI. With less 
than 5-10% fibrosis in the atrial wall there was a maximum of 10% recurrence of 
AF after ablation. With more than 35% fibrosis in the atrial wall there was 86% 
recurrence of AF after ablation.  
Conclusion
Our analysis suggests that more extensive left atrial wall fibrosis prior ablation 
predicts the higher arrhythmia recurrence rate after PVI. The DE-CMR imaging 
modality seems to be a useful method for identifying the ideal candidate for 
catheter ablation. Our findings encourage wider usage of DE-CMR in distinct AF 
patients in a pre-ablation setting.
1. Introduction 
Atrial Fibrillation (AF) is the most common supraventricular tachy-arrhythmia, 
which reduces quality of life and overall survival.1,2 Although Pulmonary Vein 
Isolation (PVI) is established as a standard rhythm control strategy for AF ablation, 
its long-term efficacy despite significant improvements in catheter ablation 
technology remains controversial.3-9 Several studies identified that AF is associated 
with electrical, structural and contractile remodeling of the atrial tissue.10-13 It has 
been proven that the electrical remodeling process finally results in loss of atrial 
myocytes and increased level of collagen component, which leads to the fibrosis 
of the atrial wall.12 Fibrotic atrial regions are thought to contribute not only to the 
initiation but also to the maintenance of AF.10-13 The mechanism responsible for 
post-fibrillatory contractile dysfunction (loss of contractility) is still not completely 
understood. However, the atrial contractile dysfunction after prolonged fibrillation 
seems to be mainly associated with the depressed L-type Ca2+ current.13 As for 
structural remodeling, the AF-related structural changes involve: 1) Increase 
in cell size, 2) Perinuclear glycogen accumulation, 3) Myolisis (central loss of 
sarcomeres), 4) Connexin expression alteration, 5) mitochondrial shape changes, 
6) fragmention of sarcoplasmatic reticulum, 7) changes in quantity and localization 
of structural cellular proteins, 8) Homogenous nuclear chromatic distribution.13 
The structural changes in AF might be a result from adaptation to chronic Ca2+ 
overload and metabolic stress. Positive feedback- loops of atrial remodeling 
during AF is suspected. Down- regulation of L-type Ca2+ channels is considered 
responsible for electrical and contractile remodeling. The loss of contractility 
and increase in compliance result in the stretch of the atrial myocardium, which 
is a stimu lus for structural remodeling of the atria.13 The Delayed- Enhanced 
Cardiac Magnetic Resonance (DE-CMR) imaging is a non-invasive, quantitative 
technique for localizing and evaluating the extent of atrial fibrosis and/or 
ablationinduced atrial tissue changes.14 The DE-CMR imaging modality can identify 
tissue remodeling or fibrosis in the atria as these areas have a slower washout 
kinetic of contrast compared to normal atrial tissue, which results in increased 
signal intensity on T1-weighting imaging.14 Several studies investigated the 
extent of atrial fibrosis by using DECMR imaging for guidance of AF ablation and 
exploring its impact on clinical outcome.14-20 However, to date no report exists 
that systematically reviewed the role of DECMR imaging modality in AF ablation 
procedures. The aim of the study was to systematically review the available 
evidence on the role of atrial fibrosis detected by DE-CMR imaging in prediction of 
arrhythmia recurrence after Catheter Ablation (CA) of AF. 
2. Methods 
2.1. Data Sources and Search Strategy 
This review was conducted in accordance with the PRISMA and MOOSE guidelines 
(Appendix 1, 2). We aimed to identify all published articles discussing the role of 
atrial fibrosis detected by DE-CMR imaging in CA of AF. We searched Embase.com, 
Medline via Ovid, Web-ofscience, Scopus, Cinahl (EBSCOhost) and the Cochrane 
Central from inception until the 21st of March, 2016. Additional references were 
obtained from PubMed, the subset as supplied by publisher, containing recent 
references, and the first relevant results from Google scholar. The search strategy 
was created with the assistance of a medical librarian (WB). The search results 
were limited to English language articles. The detailed search methodology for all 
databases is provided in Appendix 3. 
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2.2. Study Selection and Eligibility Criteria 
We included studies that reported the outcome data of patients underwent 
percutaneous PVI for AF after detection of atrial fibrosis by DE-CMR imaging. Only 
those articles on patients who underwent CA for AF, who had had preablation DE-
CMR imaging focusing on atrial fibrosis, and which also reported the follow-up of 
AF recurrence were included. The articles that focus on DE-CMR imaging results of 
patients with structural heart disease were excluded e.g. dilated cardiomyopathy, 
hypertrophic cardiomyopathy, congenital heart disease. Individual case reports, 
editorials, review articles and conference meeting abstracts were not included. 
2.3. Data Extraction Process 
Firstly, two authors (ZK, AAH) independently reviewed the included articles and 
analyzed the following data: degree of atrial fibrosis, type of AF, CA type, catheter 
type, procedural and fluoroscopy time, follow-up time, ablation success rate. 
Secondly, the authors cross-checked their findings to ensure accuracy. Finally, if 
there was no complete agreement, a third author was called to break the tie (TST). 
Only patients with good MRI quality by consensus of at least 2 observers defined 
by the core laboratories of the original study groups were included into the final 
analysis. Detailed description of “poor MRI quality” was not provided in the original 
articles. 
2.4. Risk of Bias Assessments for the Included Studies 
Study quality was assessed by two independent reviewers (ZK, AAH) based on 
the nine-star Newcastle–Ottawa Scale (NOS) using three pre-defined domains: 
selection of participants (population representativeness), comparability 
(adjustment for confounders), and ascertainment of outcomes of interest. The 
NOS assigns a maximum of four points for selection, two points for comparability, 
and three points for outcome. Studies that received a score of nine stars were 
considered to be at low risk of bias; studies that scored seven or eight stars were 
considered at medium risk; those that scored six or less were considered at high 
risk of bias. 
2.5. Outcome Assessment and Statistical Methods 
For each study, we identified whether an association was reported, and when 
applicable, effect sizes were reported. Continuous variables are presented as mean 
± SD. Categorical variables are presented as frequencies and percentages. A Cox 
proportional hazard ratio was used to evaluate the arrhythmia recurrence. 
3. Results 
3.1. Identification of Relevant Studies 
The search strategy identified 763 citations, out of which, following initial 
screening based on titles and abstracts, fulltexts of 40 articles were evaluated 
further. A total of 5 studies without overlapping patient population discussing the 
degree of atrial fibrosis using DE-CMR imaging performed prior PVI for AF were 
included.16-20 (Figure 1)
Figure 1 Flowchart of studies
3.2. General Characteristics of the Included Studies 
Table 1 shows the key characteristics of the included studies. In aggregate, in 
all included studies, 1040 patients who had DE-MRI and underwent ablation 
for AF were included in this review. All 5 included studies were prospective 
with observational design. Out of 5 studies 4 single-center, and 1 multi-center 
were analyzed. The intensity of the follow-up within 1 year after the index 
procedure was comparable among the included studies (Table 1). Four studies 
reporting the outcome data of PVI ablation conducted a clinical visit with at 
least 7-days Holter-monitoring 3 times per year, furthermore symptom driven 
event monitoring was also performed. In the study Khurram et al. a clinical and 
phone visit were scheduled at 6, 12-months of follow-up.20 If a patient was 
suggestive of an arrhythmia recurrence 24-h Holter-monitoring or 30-day event 
monitoring were performed.20 The recurrence of AF was defined as documented 
symptomatic or asymptomatic atrial fibrillation, atrial tachycardia or atrial flutter 
more than 30 seconds duration after 3-month blanking period. Patients with 
poor MRI quality were excluded in the reviewed studies, which ranged from 
3.520, 9.616, to 17.317 percentage of patient population. The value of MRI was 
Flowchart for outcome of atrial fibrosis detection using delayed-enhancement magnetic resonance 












Table 1 Comparison of the extent of pre-ablation atrial fibrosis and the ablation 








































RF Cryo, redo with 
RF
RF, cryo RF RF
Patient number 333 41 272  172 165
Paroxysmal AF 
(n) 
Nd  41 168  92 71
Persistent AF 
(n) 
Nd 0 92 80 94
Follow-up 
(days) 




Nd Nd Nd 14,6 ± 8,4 35,9 ± 14,8
Recurrence 
rate (%) 
40,9 21,9 33 34,9 38,2
Follow-up 
methodology
Clinical visit 3, 6, 12 months 3, 6, 12 months 3, 6, 12 months 3, 6, 12 months 3, 6 months
Holter 
monitoring
8d Holter 3, 
6, 12
months




3, 6, 12 months











Nd: No Data 
Table 2 Correlation between the extent of left atrial fibrosis and arrhythmia recur-
rence after successful pulmonary vein isolation for atrial fibrillation.
Extent of the Left Atrial Wall Fibrosis
Publication < 5% < 10% < 20% < 30-
35%
> 5-10% > 20% > 30% > 35%
Mahnkopf 
2010
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(13%)












N: Number; pts: Patients; Afib: Atrial Fibrillation
limited for patients with a high body mass index and uncontrolled fast heart 
rate. All studies were at medium risk of bias. The quality assessment of the 
involved studies is reported in Supplement 1 and 2. 
3.3. Assessment of left Atrial Wall Fibrosis 
Quantification of Left Atrial (LA) remodeling was obtained using the 
methodology described by Oakes et al.15 Fibrosis was reported as a percentage 
of the atrial surface area with delayed-enhancement using CMR imaging. 
Contrast enhancement is a result of altered washout kinetics of gadolinium 
relative to normal myocardial tissue, indicative of increased fibrosis of 
the myocardium.21 Two studies16,18 used the UTAH scoring system for 
determining fibrosis of the atrial wall. Utah stage I was defined as < 5% LA wall 
enhancement. Utah stage II as > 5% and < 20%, Utah stage III as > 30% and < 
35%, and Utah stage IV as > 35%. In further three reviewed studies different 
cut-off values were used for analysis of left atrial fibrosis.17,19,20 The percentage 
of LA wall fibrosis in these studies ranged from 5%16,18, 10%17,19, 20%16-19, 30%17 
and 35%16,18,20 based on MRI imaging (Table 2). 
3.4. Correlation Between Atrial Wall Fibrosis and Arrhythmia-Free Survival 
After Ablation for AF 
Overall recurrence of AF ranged from 24.4 - 40.9% with median follow-up of 
324 to 540 days after PVI. With less than 5 - 10% fibrosis in the atrial wall there 
was a maximum of 10% recurrence of AF after ablation. With more than 35% 
fibrosis in the atrial wall there was 84% recurrence of AF after ablation. Using a 
cut-off value of 20% there was respectively 25 versus 45% recurrence during 














The noninvasive DE-CMR imaging modality to detect fibrotic left atrial tissue 
in AF patients may allow a better patient selection for CA in certain cases. The 
present systematic review reveals that all included studies uniformly report 
a correlation between higher rate of AF recurrence after successful ablation 
among patients with more extensive atrial fibrosis identified by pre-ablation DE-
CMR imaging. Patients with more extensive pre-ablation left atrial enhancement 
were more likely to suffer AF recurrence after successful PVI compared to those 
with minimal or moderate degrees of contrast enhancement.16-20 Despite three 
out of five included studies derived from the same group of investigators, the 
quantitative evaluation of fibrosis extent in percentage showed a wide range of 
variety, which also might have a positive aspect providing the opportunity to 
study the recurrence in different settings and in relation with different fibrosis 
degree.
4.1. Correlation Between the Extent of LA Wall Fibrosis and  
the Type of Atrial Fibrillation
Atrial fibrillation is a progressive disease and the causality between fibrillation 
and fibrosis is thought to be bidirectional.15 Although one can reason as AF 
begets AF, that the longer a patient is in AF the more LA fibrosis is expected, 
this was not confirmed by all imaging studies.22 The study by Mahnkopf et al. 
pointed out that the amount of LA enhancement was independent from the 
AF duration, comorbidities, and the baseline type of AF.16 The DECAAF study 
also demonstrated a weak correlation between AF phenotype (paroxysmal, 
persistent, longstanding persistent) and the degree of fibrosis.17 Khurram 
et al. hypothesized that the association of AF recurrence with baseline Left 
Gadolinium Enhancement (LGE) extent would be dependent on AF type. 
However, they found no evidence of statistical interaction or effect modification 
between LGE extent and type of AF prior ablation.20
4.2. Predictors of AF Recurrence After Successful PVI
The result of Oakes et al. demonstrated that not only the extent but also the 
location of the Left Atrial (LA) enhancement appeared to be an independent 
predictor of AF recurrence. Patients with contrast enhancement in all LA regions 
had higher recurrence rate, while those responded successfully to ablation 
had limited enhancement focused to posterior wall and the septum.15 Akoum 
et al. reported in 2011 that the overall ablation scar in the LA predicted the AF 
recurrence independently in patients with mild or moderate fibrosis.14 The same 
group concluded in 2015 that the residual fibrosis remaining after ablation was 
a significant predictor of arrhythmia recurrence after ablation irrespective of 
AF type and PV encirclement.18 Patients with baseline anterior wall fibrosis, 
usually not targeted by ablation were more likely to have higher residual fibrosis 
and higher AF recurrence rate compared to those with baseline fibrosis in 
the posterior left atrium and PV antral region.20 In the study by Canpolat et al. 
the extent of LA fibrosis and the early recurrence were found an independent 
predictor of AF recurrence after ablation. One percent increase in LA fibrosis 
increased the risk of AF recurrence with 1,127 fold, while early recurrence 
increased the recurrence risk with 1,442 fold.19
4.3. Pulmonary Vein Encirclement Detection After Ablation by DE-CMR
While CA of AF aims to achieve complete isolation of PVs as a procedural 
endpoint, the intra-procedural achievement of conduction block does not 
always result in longterm block.23 It has been reported that gaps identified 
with DE-CMR in PV regions after ablation correlated with PV electrical 
reconnections.24 In the analysis from the DECAAF study the overall chronic 
complete encirclement of all PVs with PVI was achieved in 7, 3% (12/163) of pa 
tients. Circumferential PV scarring was not an important factor of arrhythmia 
recurrence in paroxysmal AF patients. The proportion of patients where 
complete 4PVs encirclement failed (92,7%) was significantly higher compared 
to those who represented with AF recurrence (36%). It suggests that complete 
encirclement of all PVs is not a critical factor in determining procedural success. 
Taken together the results on PV encirclement with the role of residual fibrosis 
as a significant predictor of AF recurrence, advocates the larger role of atrial 
substrate elimination in rhythm control of AF.22 This is in accordance with 
observation by Narayan et al. who reported that ablation of PV antral regions 
may coincidentally lead to elimination of focal sources and rotor centers that 
maintain the arrhythmia.25
4.4. Strengths and Limitations
To the best of our knowledge, this is the first systematic review attempted to 
evaluate the role of DE-CMR detected LA wall fibrosis on AF ablation outcome. 
One of the reasons for this is that the available literature fulfilling our inclusion 
criteria is novel, with more than half of included studies were published in 
the past two years. Our searching methodology ensured that we included the 
most relevant articles in our review enrolling more than one thousand patients. 
However, this study has a number of limitation. Firstly, despite all efforts made 
to undertake a comprehensive search of the published English literature, the 
possibility of publication bias due to under-reporting of negative findings 
cannot be excluded. Secondly, it is important that the assessment of the 
effect of different ablation methodologies such as (segmental, circumferential 
etc.) “PVI-only” and/or additional linear line ablations due to the considerable 
heterogeneity from the original studies made it impossible to establish a 
relation between the method of ablation and the clinical outcome. Thirdly, the 
included studies were also heterogeneous concerning the type (cryoballon, 
radiofrequency) of ablation. Probably, these facts can also influence the rate of 
arrhythmia recurrence after ablation. Finally, high-quality randomized controlled 
trials with adequate sample sizes and standardized long-term follow-up are 
needed to assess the role of atrial wall fibrosis detected by DE-CMR imaging on 
clinical outcome of CA for AF.
4.5. Clinical Implication
The DE-MRI may become an additive tool in guiding physicians in 
recommending CA for patients with AF. This method could give a helping hand 
in defining the most promising candidates not only for the primary but also for 
redo ablation procedures. However, saying MRI can predict responders to AF 
ablation can we ethically withhold the therapy to those with a high LA fibrosis 
density if a little less than halve are recurrence free after ablation? Alternatively, 
one can argue additional lines, targeting rotors or complex fractionated atrial 
electrograms in addition to PVI in the presence of extensive fibrosis. On the 
other end of the spectrum, in patients with longstanding persistent AF and very 
limited fibrosis AF ablation could become a more feasible therapy. Knowledge 
on limited fibrosis lowers the probability of ablation failure.













In conclusion, the identification of LA wall fibrosis using DE-CMR modality may 
aid to an appropriate patient selection for atrial fibrillation ablation. Our findings 
encourage wider usage of DE-MRI in distinct AF patients in a preablation 
setting.
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Abstract 1 Identify the report as a systematic review and a meta-analysis 1
Structured 
summary
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligi- bility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number. 
3
Introduction
Rationale 3 Describe the rationale for the review in the context of what is 
already known. 
4
Objectives 4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 





5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 




6 Specify study characteristics (e.g., PICOS, length of follow-up) 





7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.
5
Search 8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.
5
Appendix 1
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, 




10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.
5
Data items 11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and simplifications 
made. 
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Risk of bias 
in individual 
studies
12 Describe methods used for assessing risk of bias of individual 
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13 State the principal summary measures 9
Synthesis of 
results
14 Describe the methods of handling data and combining results of 
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each study: (a) simple summary data for each intervention group 






21 Present results of each meta-analysis done, including confidence 
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Limitations 25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias). 
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Conclusions 26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research. 
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Funding
Funding 27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
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Appendix 2 MOOSE checklist.
Criteria Brief description of how the criteria were handled in the 
meta-analysis
Reporting of background 
should include
Problem definition Delayed-enhanced cardiac magnetic resonance (DE-CMR) 
imaging for atrial wall fibrosis detection was used in several 
studies to guide AF ablation. The aim of present study was to 
systematically review the literature on the role of atrial fibrosis 
detected by DE-CMR imaging on AF ablation outcome.
Hypothesis statement The usage of DE-CMR imaging modality may help in identifying 
proper candidates for pulmonary vein isolation (PVI)
Description of study outcomes We included studies that described DE-CMR imaging on atrial 
fibrosis in AF patients who (PVI).
Type of exposure or intervention 
used
DE-CMR imaging was used in all patients before PVI for atrial 
fibrillation
Type of study designs used Eligible study designs included randomized controlled trials 
(RCTs), cohort, case-control studies.
Study population Only studies carried out in adults (>18 years old) were included.
Reporting of search strategy 
should include
Qualifications of searchers The credentials of the investigators are indicated in the authors 
list.
Search strategy, including time 
period included in the synthesis 
and keywords
Search strategy and time periods are detailed in page 5 of the 
manuscript and in Figure 1 and the full search strategy is available 
in Appendix 3.
Databases and registries 
searched
Google Scholar, PubMed, Embase.com, Medline via Ovid, Web-of-
science, Scopus, Cinahl (EBSCOhost) and the Cochrane Central
Search software used, name and 
version, including special features
We did not employ a search software. Endnote was used. to merge 
retrieved citations and eliminate duplications.
Use of hand searching We hand-searched bibliographies.
List of citations located and those 
excluded, including justifications
Details of the literature search process are outlined in the flow 
chart. Citations for the included studies are included in the text 
and Table 1. The citation list for excluded studies is available upon 
request.
Method of addressing articles 
published in languages other than 
English
We placed restrictions to English language. Systematic reviews 
were used to identify further references.
Method of handling abstracts and 
unpublished studies
Systematic reviews were used to identify further references.
Description of any contact with 
authors
Authors of included studies were contacted to retrieve missing full 
texts and to identify any missing studies.
Reporting of methods should 
include
Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested
Detailed inclusion and exclusion criteria were described in the 
methods section.
Rationale for the selection and 
coding of data
A predesigned data collection form was prepared to extract the 
relevant information from the included full texts, including study 














Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible predictors 
of study results
We used the Newcastle- Ottawa Scale (NOS) to evaluate the 
quality of cross-sectional, case- control and cohort studies 
included in this reviews
Assessment of heterogeneity We were not able to pool due to large levels of heterogeneity 
evaluated visually and statistically
Description of statistical methods 
in sufficient detail to be replicated
For each study, we defined whether an association was reported, 
and when applicable, effect sizes were reported.
Provision of appropriate tables 
and graphics
We included 1 main figure, 2 main tables, and 3 appendices, 2 
supplements
Reporting of results should 
include
Graph summarizing individual 
study estimates and overall 
estimate
Figure 2, 3
Table giving descriptive 
information for each study 
included
Table 1
Results of sensitivity testing The heterogeneity of the outcomes across the different studies 
thwarted our ability to provide pooled estimations
Indication of statistical 
uncertainty of findings
95% confidence intervals or SD’s were presented if available
Reporting of discussion 
should include
Quantitative assessment of bias Not applicable
Justification for exclusion We excluded studies that had no or unclear definition of outcome, 
or data extraction was not feasible.
Assessment of quality of included 
studies
We used the Newcastle- Ottawa Scale (NOS) to evaluate the 
quality of cross-sectional, case- control and cohort studies 
included in this review.
Reporting of conclusions 
should include
Consideration of alternative 
explanations for observed results
Due to the lack of standardisation of follow-up, it is difficult to 
provide unifying statements within a larger number of manuscripts 
hampered by large levels of heterogeneity.
Generalization of the conclusions The generalizability of our findings has been enhanced by the 
involvement of data, including region of the Americas, Europe. 
However, there is a clear lack of evidence from West Pacific 
Region, and the African and Asian, Australian Region.
Guidelines for future research Further randomized controlled studies with long-term follow-
up are necessary to investigate the role of DE-CMR imaging on 
detecting atrial fibrosis in AF patients
Disclosure of funding source Nothing to disclose. 
Disclosure of funding source Nothing to disclose.
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Appendix 3 Data search strategy
Embase.com 575 (Fibrosis/de OR 'heart muscle fibrosis'/de OR (fibrosis)) AND ('atrial fibrillation'/exp 
OR (((atrial OR atrium) NEAR/3 fibrillat*) OR AF )) AND ('nuclear magnetic resonance imaging'/de OR 
'nuclear magnetic resonance'/exp OR 'cardiovascular magnetic resonance'/de OR ('magnetic resonance' 
OR mri OR CMR OR (mr NEAR/3 imag*) OR (multimodalit* NEAR/3 imag*))) NOT ([animals]/lim NOT 
[humans]/lim) 
Medline Ovid 130 (Fibrosis/ OR (fibrosis)) AND ("Atrial Fibrillation"/ OR (((atrial OR atrium) ADJ3 
fibrillat*) OR AF )) AND (exp "Magnetic Resonance Imaging"/ OR "Magnetic Resonance Spectroscopy"/ 
OR ("magnetic resonance" OR mri OR CMR OR (mr ADJ3 imag*) OR (multimodalit* ADJ3 imag*))) NOT 
(exp animals/ NOT humans/) 
Cochrane 5 ((fibrosis)) AND ((((atrial OR atrium) NEAR/3 fibrillat*) OR AF )) AND (('magnetic 
resonance' OR mri OR CMR OR (mr NEAR/3 imag*) OR (multimodalit* NEAR/3 imag*))) 
Web of science 184 TS=(((fibrosis)) AND ((((atrial OR atrium) NEAR/2 fibrillat*) OR AF )) AND 
(("magnetic resonance" OR mri OR CMR OR (mr NEAR/2 imag*) OR (multimodalit* NEAR/2 imag*))) NOT 
((animal* OR rat OR rats OR mouse OR mice OR murine) NOT (human* OR patient*))) 
Scopus 285 TITLE-ABS-KEY(((fibrosis)) AND ((((atrial OR atrium) W/2 fibrillat*) OR AF )) AND 
(("magnetic resonance" OR mri OR CMR OR (mr W/2 imag*) OR (multimodalit* W/2 imag*))) AND NOT 
((animal* OR rat OR rats OR mouse OR mice OR murine) AND NOT (human* OR patient*))) 
Cinahl EBSCO 31 (MH Fibrosis OR (fibrosis)) AND (MH "Atrial Fibrillation" OR (((atrial OR atrium) 
N2 fibrillat*) OR AF )) AND (MH "Magnetic Resonance Imaging+" OR MH "Magnetic Resonance 
Spectroscopy" OR ("magnetic resonance" OR mri OR CMR OR (mr N2 imag*) OR (multimodalit* N2 
imag*))) NOT (MH animals+ NOT MH humans) 
PubMed publisher 14 (Fibrosis[mh] OR (fibrosis[tiab])) AND ("Atrial Fibrillation"[mh] OR (atrial 
fibrillat*[tiab] OR atrium fibrillat*[tiab] OR AF[tiab])) AND ("Magnetic Resonance Imaging"[mh] OR 
"Magnetic Resonance Spectroscopy"[mh] OR ("magnetic resonance"[ tiab] OR mri[tiab] OR CMR[tiab] 
OR mr imag*[tiab] OR (multimodalit*[tiab] AND imag*[tiab]))) NOT (animals[mh] NOT humans[mh]) 
AND publisher[sb]
Google scholar Fibrosis "atrial|atrium fibrillation" "magnetic resonance"|mri|CMR|"mr|multimodality 
imaging|images|image".
Embase.com 575 570
Medline Ovid 130 18
Web of science 184 67
Scopus 285 17
Cochrane 5 2
PubMed publisher 14 10
Cinahl EBSCO 31 3
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Abstract
Background 
Catheter ablation (CA) is an important therapeutic option for atrial tachycardias in 
patients with congenital heart disease (CHD). As a result of extensive scarring and 
surgical repair, multiple intra-atrial re-entrant tachycardia (IART) circuits develop 
and serve as a substrate for arrhythmias. The best ablation approach for patients 
with multiple IARTs has not been investigated. Here, we compared substrate-based 
ablation using extensive scar modification (ESM) to conventional ablation.
 
Methods 
The present study included patients with surgically corrected CHD that underwent 
IART ablation. ESM was defined as substrate ablation based on a dense voltage 
map, aimed to eliminate all potentials in the scar region. The control group 
had activation mapping based ablation (AMBA). A clinical composite endpoint 
(CCE) was assessed. Points were given for type, number and treatment of IART 
recurrence.
Results 
In 40 patients 63 (ESM 13) procedures were performed. Acute procedural success 
was achieved in 78%. Procedural duration was similar in both groups. Forty-nine 
percent had a recurrence within 1 year. During a 5-year follow-up [2.5 - 7.5 years] 
46% required repeat CA. Compared to baseline CCE significantly decreased 
by 46% after 12 months (P = 0.001). Acute procedural success, procedural 
parameters, recurrence and repeat ablation were similar between ESM and AMBA.
Conclusion 
CA using ESM for IARTs occurring after surgically corrected CHD illustrated similar 
short and long-term outcomes and procedural efficiency compared to CA using 
AMBA. The choice of ablation approach for multiple IART should remain at the 
discretion of the operator.
Introduction
Atrial arrhythmias have a major impact on the quality of life in patients with congen-
ital heart disease (CHD). Surgical incisions in the atrium and atrial fibrosis form the 
substrate of intra-atrial reentrant tachycardia (IART). The presence of extensive 
scar may cause multiple IART circuits.1,2,3 During catheter ablation (CA) the map-
ping of all the critical isthmuses of these circuits can be time consuming. Moreover, 
even after a successful ablation of all identified critical isthmuses the long-term re-
sults are hampered by a high recurrence rate.4,5 A scar-related approach has been 
used with success in patients with scar-related ventricular tachycardia6 and even in 
atrial fibrillation.7
One of the most important limitations of longterm success in this population is 
complex scar with multiple re-entrant circuits. To the best of our knowledge there 
have not been studies performed addressing this small but very significant patient 
group. Extensive scar modification (ESM) is a treatment option for multiple IART 
circuits using the same scar. We hypothesized that ESM compared to activation 
map based ablation (AMBA) for the treatment of IART in patients with CHD reduces 
procedure times and improves efficiency of procedural outcomes.
Methods
Study population and data collection
Forty-eight consecutive patients with a surgically corrected congenital defect and 
atrial arrhythmias were screened. Forty of these patients had entrainable tachy-
cardias and were included into the study. These 40 patients underwent 63 ablation 
procedures for scar related IART between May 2006 and May 2016 in our center. 
IART was defined as an arrhythmia from which the central obstacle was a surgical 
scar or any anatomical barrier other than the tricuspid annulus.8 If more than 3 dif-
ferent IARTs were present we defined it as multiple. 
All CA procedures were performed in accordance with institutionally approved local 
medical treatment protocols. The local ethical committee approved data collection 
(MEC-2016-705). Procedural informed consent was obtained from all the patients 
prior to the electrophysiological study. All patient information was de-identified. 
Procedural protocol
Anti-arrhythmic drugs were discontinued for at least 4 half lives prior to the pro-
cedure with the exception of amiodarone. The procedures were performed under 
local or general anaesthesia. The procedures were guided using EnSite NavX 3D 
(St. Jude Medical Inc., St. Paul, MN) mapping or CARTO system (Biosense Web-
ster, Inc., Diamond Bar, California). Only detailed extensive maps were included in 
the study. Intracardiac bipolar electrograms filtered at 30 to 500 Hz were recorded 
by a computerized electrophysiological recording system. In all CAs for IART the 
chamber of origin was determined. When a left sided IART was suspected a de-
flectable decapolar catheter was inserted into the coronary sinus and functioned 
as a reference mapping catheter.
Per definition re-entry is the mechanism in patients with IART, and mapping is 
aimed to map the whole cycle length. IARTs were separated from another based on 
both morphology and cycle length.
The target of ablation was identified by activation and/or voltage mapping. Irrigated 
catheters were used for the majority of the procedures. The electrode-tip tem-
perature limit was set at 43°C, with a power ranging from 30 to 45 W, and needed 
irrigation flow of 20-30 mL/min. The catheter selection was dependent on clinical 
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Louis, MO, USA) was used in 58% of the cases. 
If the patient was not in atrial tachycardia (AT) at the beginning of the procedure, 
AT was induced, most commonly with rapid atrial pacing or atrial extra-stimuli. An 
electroanatomic map was created during atrial tachycardia. The only exception 
for creating a biatrial map was if AMBA was performed and the whole atrial cy-
cle length could be mapped in the chamber of origin and tachycardias remained 
non-inducible after ablation. Double potentials depicted the target location. En-
trainment pacing was used to identify and/or confirm atrial tachycardia circuits. 
Sites with a post pacing interval minus atrial tachycardia cycle length within 30 
ms were considered to lie within the circuit. Hereafter in the presence of multiple 
re-entry circuits and at the preference of the operator a conventional AMBA or ESM 
approach was chosen. 
Activation mapping based approach
A line was created across the critical isthmus, usually between areas of scar of 
between a scar and an anatomical structure (e.g. the inferior vena cava, superior 
vena cava or tricuspid annulus). Pacing was performed to prove bidirectional block. 
Localized re-entry was treated with discrete ablation lesions. After termination 
of an IART, we attempted to re-induce the IART using the stimulation protocol as 
described previously.
Extensive scar modification
Using a detailed 3D bipolar voltage map an effort was made to identify the sites 
of surgical incisions and sutures. Substrate mapping was performed during sinus 
rhythm with standard settings defined as normal tissue greater than 0.5 mV and very 
low-voltage area as 0.1 mV.9 Dense scar was defined as areas with amplitudes less 
than the baseline noise level of the recording system (amplitude of < 0.05 mV). Maps 
were considered complete when both atria were extensively mapped and all scar 
borders were clearly defined. After mapping the ablation was extended throughout 
the entire scar.9 Ablation was continued until the scar was unexcitable which was 
proven with pacing manoeuvers. A final result of ESM is illustrated in Figure 1.
Post-procedural protocol
All patients underwent continuous rhythm monitoring for 48 hours, a resting 12-
lead electrocardiogram, laboratory tests and chest radiograph after the procedure. 
Regular follow up was performed at 3 months after the ablation and thereafter 
depending on the underlying symptoms and pathology for every 3 to 12 months. A 
24-hour Holter recording was performed when a patient experienced recurrence 
symptoms.
Outcome definitions
We analyzed the following outcome date per strategy (substrate - ESM versus non 
substrate - AMBA): acute procedural success, early AT recurrences, median time 
to AT recurrence and redo and His bundle ablations during follow-up. Acute proce-
dural success was defined as termination and non-inducibility of all IART. Any AT 
during follow-up was considered a recurrence. Early recurrences were defined as 
recurrences within 1 year after ablation. If during an electrophysiology study the 
arrhythmia was an isthmus dependent atrial flutter without the involvement of scar, 
it was not considered a repeat ablation.
A clinical composite endpoint (CCE) was calculated at baseline, at 6 months and 
12 months follow-up. The CCE was a score per subject and therefore only focused 
on the index procedure (first procedure in our center, or first procedure after May 
2006). Points (1-4) were given for 3 categories: electrocardiographically docu-
mented occurrence of IART, acute and longterm treatment (Table 4). Review of 
medical records and procedure notes was performed to ascertain the dates of 
occurrence of cardioversion and emergency room visit or hospital admission for 
management of arrhythmia or symptoms of the arrhythmia.
Statistical analysis
Data was analyzed using SPSS 15.0 (SPSS INC., Chicago, IL, USA). Descriptive sta-
tistics for categorical data were expressed in absolute numbers and percentages. 
Student t test, chi-square test, and Fisher exact test were used to compare differ-
ences across groups. After checking for normality, mean values and standard de-
viations were calculated for normally distributed continuous variables. Median and 
interquartile ranges (IQR) were computed for continuous variables with non-nor-
mal distribution, and the Mann-Whitney U test to compute statistical significance. 
Wilcoxen signed rank test was used to calculate differences in significance for the 




Sixty-three procedures for IART in a total of 40 patients with surgically repaired 
CHD were included in this analysis (1 procedure n = 21, 2 procedures n = 15, 3 
procedures n = 4). Thirteen procedures were a substrate approach. Two patients 
with an AMBA index procedure (Supplement 2A) underwent ESM during a repeat 
procedure. Two patients with an ESM index procedure (supplement 2B) underwent 
an AMBA approach during the repeat procedure. 
 A median number of 2 sustained IART episodes were recorded in the 6 months be-
fore ablation. Four patients had incessant IART at the index procedure. Thirty-one 
percent used Amiodarone at baseline. Six procedures were performed in paediatric 
patients. 
In 13 IART ablation procedures the approach was ESM, in 50 procedures it was 
AMBA. In 43 out of 63 procedures multiple IARTs could be induced. There were no 
differences in baseline characteristics between the 2 groups (Table 1). The con-
genital cardiac anomalies in this cohort are described in Table 2 according to the 
presence of multiple IART and ESM. Transposition of the great arteries was present 
in 12 cases, Ebstein or tricuspid atresia in 8 cases and tetralogy of Fallot in 5 cases. 
Six out of 40 patients had a Fontan operation and 10 patients were following a Mus-
tard operation.
Procedural data
Number of applications (26 - IQR 18 - 69), time (1124 seconds - IQR 627 - 2385) 
and procedural duration (240 minutes - IQR 163 - 298) were similar in both groups 
(Table 3). 
Complications
There were 6 complications, 1 in the ESM group and 5 in the AMBA group (8 and 
9% respectively in ESM and AMBA) (P = NS). Four were vascular peripheral compli-
cations: there were 2 haematomas, 1 arterio-venous fistula and 1 thrombus in the 
common femoral artery in relation to a percutaneous left ventricular support de-
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One ablation led to altered impedance of the pacemaker lead.
Outcome of the procedures
Acute procedural success was reached in 78% (Table 5) of the IART population. 
Forty-nine percent of the total patients had a recurrence within 1 year. One patient 
was lost to follow-up. The median time to recurrence was 120 days [IQR 30 - 525]. 
In case of a successful procedure (50): the 1-year recurrence rate was 45%. In 
case of an unsuccessful procedure (13): there was a 1-year recurrence rate of 57% 
(P = 0.55). The CCE in the overall group was reduced by more than one-third after 
6 and 12 months (Figure 2). After 6 and 12 months 66% and 68% of the patients 
improved. This was a significant change compared to baseline (Table 6). Three 
patients required reinstitution and 2 patients needed an increase of antiarrhythmic 
drugs at 12 months after the index procedure, while 7 patients were able to discon-
tinue their antiarrhythmic drugs altogether. Of the 16 patients with an early recur-
rence of IART, 4 had non-sustained AT episodes.
Substrate modification versus a conventional approach
There was no significant difference in procedural success between both approach-
es. ESM compared to AMBA was similar with regard to early and late recurrence 
and repeat procedures. The CCE after 6 and 12 months was not significantly differ-
ent between the two groups (Table 7).
Repeat procedure
During a median follow-up of 5 years [IQR 2.5 - 7.5] a repeat procedure was con-
sidered necessary in 29 patients, 46% of the patients in both groups. One of the 
patients had multiple IARTs and one had a single IART which foci could not be 
reached during the index ablation. Both patients had AMBA as an ablation strategy.
In 4 patients a His bundle ablation with pacemaker implantation was needed, and in 
6 patients cavo-tricuspid isthmus ablation (CTI) after IART ablation was necessary 
to control recurrence (Figure 2). The underlying congenital heart disease in the 
patients who required CTI was pulmonary stenosis, double outlet ventricle, atrial 




N = 63 procedures
ESM
N = 13 procedures
AMBA
N = 50 procedures
p-value 
male 40 (64) 9/13 (69) 31/50 (62) 0.75
median age [ IQR ] 34 [ 25-47 ] 33 [ 26 - 43 ] 35 [ 25 - 47 ] 0.66
median age at 
correction (years) [ 
IQR ]
5 [ 2 -11 ] 5 [ 1 - 10 ] 5 [ 3 - 12 ] 0.44
pediatric 7/63 (11) 1/13 (6) 6/50 (12) 1.00
number of sustained 
episodes 6 months 
before the the 
procedure [ IQR ]
2 [ 1 - 3 ] 1.5 [ 0 - 2.75 ] 2 [ 1 - 3 ] 0.65
Pacemaker for 
SN dysfunction at 
baseline
17 (27) 1 (8) 16 (32) 0.16
index procedure is a 
repeat procedure*
31 (49) 9 (69) 22 (44) 0.129
Medication
betablocker 16 (25) 1 (8) 15 (30) 0.16
verapamil 1 (2) 0 (0) 1 (2) 1.00
class 1C AAD 1 (2) 0 (0) 1 (2) 1.00
sotalol 24 (38) 7 (54) 17 (34) 0.21




40 (63) 13 (100) 27 (68) 0.006
HD support device 3 (5) 2 (15) 1 (2) 0.51
RMN 40 (64) 8 (62) 32 (64) 1.00
Follow-up
median duration of 
follow-up (years) 
[ IQR ]
5 [ 2.5 - 7.5 ] 5 [ 3 - 7 ] 5 [ 1.5 - 8 ] 0.98
* In 13 of the repeat procedures the index procedure was performed before 2006 or in another center
AMBA: activation map based ablation; AAD: anti-arrhythmic drugs; ESM: extensive scar modification; 
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Table 2 Patient characteristics congenital heart defects Table 4 Clinical composite endpoint count
Table 5 Procedural outcome
Table 3 procedural parameters






tricuspid atresia 6 5 1
ebstein 2 2 1
transposition of the great arteries 12 7 1
double outlet left ventricle 5 4 1
Tetralogy of Fallot 5 3 2
atrial septal defect / venous sinus defect 5 3 1
- concomitant atrial septal defect 5 3 1
atrioventricular septal defect 2 1 0
hypoplastic left ventricle 1 1 1
cor triatriatum 1 1 0
pulmonary stenosis, valvular or sub or 
supravalvular
5 3 0
congenital aortic stenosis, valvular and 
subvalvular
1 1 0
SURGERY CORRECTION CONGENITAL HEART DEFECT
Fontan 6 6 3
Mustard 10 5 1
Points documented IART acute treatment long term treatment
0 none none none, betablocker, 
verapamil, digoxin
1 non sustained only 1 ECV class I, sotalol
2 1 sustained > 2 ECV class III
3 incessant hospitalisation for symtpoms 
of heart fialure, syncope of 
cardiac arrest
His, redo ablation
all ESM AMBA p-value 
acute success  50/63 (79) 11/13 (85) 39/50 (78) 0.719
early recurrence 29/63 (46) 4/13 (31) 25/50 (50) 0.349
repeat procedure 29/62* (46) 6/13 (46) 23/49* (46) 1.00
The distribution of anomalies among all procedures, procedures with multiple intra-atrial re-entry 
tachycardias (multiple) and extensive scar modification (ESM) procedures
AMBA: activation map based ablation; ESM: extensive scar modification
all
median [ IQR ]
ESM
median [ IQR ]
AMBA
median [ IQR ]
p-value  
applications number 26 [ 18 - 69 ] 31 [ 23 - 68 ] 24 [ 15 - 71 ] 0.43
application time (sec) 1124 [ 627 - 2385 ] 1100 [ 851 - 2494 ] 1148 [ 459 - 2400 ] 0.39
procedural duration 
(min)
240 [ 163 - 298 ] 240 [ 165 - 329 ] 225 [ 158 - 293 ] 0.73
ECV: electrical cardioversion
* 1 patient was lost to follow-up
AMBA: activation map based ablation; ESM: extensive scar modification
Table 6 Composite endpoint - changes over time
AMBA: activation map based ablation; ESM: extensive scar modification; p/s: per subject
all ESM AMBA
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This is an illustrations of a CARTO map of a patient who underwent extensive scar modification. Bipolar 
voltage scale was in the range of 0.1 - 0.5 mV. The dots represent a location of ablation. In case of 
dragging every 15 seconds a subsequent dot is placed.
Chapter 12 Chapter 12
Figure 1 An illustration of a patient with atrial extensive scar modification
Figure 2  Clinical composite endpoint 
Clinical composite endpoint in p/subject in the ESM and AMBA group at 
baseline, 6 months and 12 months
 Supplement 1  Clinical composite endpoint countbaseline,  
6 months and 12 months
AMBA: activation map based ablation; ESM: extensive scar modification 
ECV: electrical cardioversion; IART: intra-atrial re-entrant tachycardia
Points documented IART acute treatment long term treatment
0 none none none, betablocker, 
verapamil, digoxin
1 non sustained only 1 ECV class I, sotalol
2 1 sustained > 2 ECV class III
3 incessant hospitalisation for 
symptoms of heart 




Baseline ( p/s ) 6 months ( p/s ) 12 months ( p/s )
ESM 4.25 2.38 2.13
AMBA 4.07 2.33 2.30
p-value 0.785 0.570 0.687
* in 2 subjects no data on composite endpoint, one in the ESM and one in the AMBA group












11 recurrences 3 recurrences
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AMBA: activation map based ablation; CTI: cavo-tricuspid isthmus; ESM: extensive scar modification; 
His: his bundle ablation; IART: intra-atrial reentrant tachycardia; LTFU: lost-to follow-up; Maze: maze 
surgical ablation
AMBA: activation map based ablation; CTI: cavo-tricuspid isthmus; ESM: extensive scar modification; 
His: his bundle ablation; IART: intra-atrial reentrant tachycardia; LTFU: lost-to follow-up; Maze: maze 
surgical ablation
Supplement 2 contains a flow chart describing the recurrences and repeat procedures throughout 
the complete follow-up of patients with activation map based ablation (AMBA) and extensive scar 
modification (ESM) respectively, thereafter in case of recurrence it shows again the chosen strategy. 
If this ablation strategy was IART it is specified whether it was AMBA or ESM and if there were 
recurrences.
31 AMBA patients 
[ index procedure ] 
9 ESM patients 
[ index procedure ]
1 LTFU 1 LTFU
1 His





15 repeat IART 
ablation - 2 ESM
4 repeat IART ablation 
- 2 ESM
8 repeat procedures 0 repeat procedures
4 repeat IART 
procedures
3 recurrences 1 recurrence free
4 recurrence free 1 recurrence free
24 recurrences 8 recurrences
19 repeat procedures 7 repeat procedures
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To the best of our knowledge this is the first study that analyzed different abla-
tion approaches in a difficult patient population. The major finding of this study is 
that ESM compared to AMBA in patients with intra-atrial re-entry tachycardia as a 
result of congenital heart surgery is not different with regards to short and long-
term outcome and procedural efficiency.
Outcome IART ablation
IART ablation in the present study has an acute success of 78% and leads to a 
significant reduction in arrhythmia burden after 6 and 12 months. A high recur-
rence rate after ablation and even after repeat ablation in patients with IART is a 
standard in today’s practice.4,5 
Complex atrial anatomy, markedly enlarged, scarred right atria with wall thick-
ening and high right atrial pressure are factors associated with pour ablation 
outcome.4 In the contrary, IART that are CTI dependent are associated with a 
better long-term outcome after ablation. These type of IART were excluded in the 
present study
Even if IART episodes are not eliminated entirely by ablation, the procedure can 
often provide substantial improvement by reducing the frequency of episodes 
and eliminating the need for ongoing drug therapy11 illustrated by a significant 
drop in composite endpoint score after ablation. Triedman et al.12 reported similar 
results to the current study regarding the frequency of clinical events pre-abla-
tion and post-ablation periods and found a subsequent significant decrease in 
clinical events.
In our study, alike other studies13, multiple atrial tachycardias are present in more 
than half of the patients referred for IART ablation. The clinical value of multiple 
arrhythmias during an ablation procedure is not completely known, also consider-
ing that one arrhythmia frequently dominates. Recurrences during the follow-up 
however, frequently means the development of novel onset atrial tachyarrhyth-
mias1,2,3 even in the absence of multiple atrial arrhythmias at baseline.
Challenges in the ablation of IART
The circuit of the IART predominantly uses a central obstacle formed by the 
right lateral patch or right lateral atriotomy scar14, and is less frequently formed 
between the scar and IVC, SVC or TV.15 Multiple IART circuits may develop due 
to incisional scar and obstacles in the atria.1,2,3 Rather than mapping all the IART 
individually, ESM can be applied as an alternative. In the present study ESM was 
equally effective compared to AMBA in treating IART. The equal number of RF 
applications and duration of RF between the two groups may be a representation 
of multiple unsuccessful ablation points in conventional ablation. A combination 
of ESM and AMBA is not performed in the present study, yet it is likely to assume 
it can become a successful future ablation approach, especially in case of a fre-
quently re-occurring clinical IART with identical morphology.
Scar modification in VT ablation
Shorter procedural and fluoroscopy times are needed for a direct substrate 
VT ablation strategy compared to ablation guided by entrainment maneuvers.6 
Higher scar heterogeneity is related to a higher arrhythmogenic potential of the 
ventricular scar16, which rationalizes scar modification in VT ablation. In a recent 
multicenter randomized study that compared scar modification with clinical VT 
ablation in ischemic cardiomyopathy, a significantly larger freedom from VT re-
currence is seen at one year.6 Moreover a larger percentage of patients were able 
to discontinue anti-arrhythmic drugs after substrate ablation. 
Scar modification in the atria
Possible drawbacks of scar modification approach are the lack of an established 
endpoint to verify individual or multiple point lesion efficacy, need for remap-
ping to assess for complete elimination of abnormal electrograms, and ablation 
of bystander regions.17 In the atria the latter might be of less importance. In VT 
ablation abundant ablation leading to a reduced ventricular function is of critical 
importance. On the contrary a large ablation area in a scarred atrium will not de-
prive cardiac output substantially. A theoretical disadvantage of ESM is a higher 
chance of complications with more extensive ablation. The current study does 
not support this potential hazard.
In ESM there is no need for arrhythmia induction. This can be an advantage not 
only in case of non-inducibility, but also for hemodynamic instability. Especial-
ly patients with an univentricular heart can become hemodynamically unstable 
during mapping and ablation.18 Substrate mapping would abolish the need for a 
hemodynamic support device.
Candidates for ESM
The recurrence risk is particularly high among Fontan patients who tend to have 
the largest number of IART circuits, the largest atrial dimensions and most atrial 
hypertrophy.4,19 Therefore potential candidates for ESM are patients with RA-
PA Fontan connections. On the contrary in Mustard patients the cavotricuspid 
isthmus usually is the target.20 Our ESM cohort is represented by a heteroge-
neous group of congenital heart disease. Also surgically corrected ASD and TOF 
patients, who usually have limited areas of low-voltage are represented. In the 
current study invasiveness of congenital heart surgery did not correlate with the 
arrhythmia burden and the presence of multiple IARTs. Disease progression is a 
possible explanation for the presence of multiple IART. If multiple re-entrant cir-
cuits are present in ASD and TOF more extensive areas of low voltage should be 
suspected and ESM can be a feasible approach.
Limitations of the study
The main limitation of the study is that it is a single-center retrospective analysis 
with a low number of patients who have ESM. Not all patients with a recurrence 
had an electrophysiology study, therefore we cannot be sure about the mech-
anism of the recurrent atrial tachycardia. In some analysis patients were used 
repeatedly as unique events which adds potential bias. One should be cautious to 
draw conclusions on the specific congenital population referred for IART ablation 
there the analysis included a heterogeneity of anomalies. The follow-up duration 
in this study is representative of standard clinical practice. A single recurrence 
or the time to a first recurrence in this population does not represent the most 
important clinical outcome marker. In this article we have made an effort to give 
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Conclusions
In the ablation treatment of intra-atrial re-entry tachycardias in patients after 
congenital heart surgery, extensive scar modification illustrated similar outcome 
compared to a conventional mapping approach, even in the presence of multiple 
intra-atrial re-entry tachycardias. Based on the outcome of this study we don’t 
recommend operators to change their current approach. Longterm recurrence 
rates remain high so further studies are needed to develop the best treatment 
strategy.
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Percutaneous ventricular assist device for circulatory support during ablation 
of atrial tachycardias in patients with a Fontan circulation
Case series
Sr. Editor:
In the current paper we describe two patients with Fontan circulation in whom a 
haemodynamically unstable atrial arrhythmia was successfully ablated with the aid 
of a continuous flow percutaneous ventricular assist device (pVAD).
A 34 year old male patient was referred to our clinic for an ablation for symptomatic 
frequently recurring intra atrial re-entrant tachycardias (IART). He was diagnosed 
with tricuspid atresia, atrial and a ventricular septal defect. At the age of 8 a Fontan 
circulation had been created and resulted in a pulmonic homograft between the 
right atrium (RA) and a hypoplastic right ventricle (Bjork modification). Pre-proce-
dure examination revealed moderately reduced left ventricular (LV) function and a 
mildly stenosed homograft. The first ablation procedure was discontinued due to 
haemodynamic instability. During the repeat procedure we decided to use haemo-
dynamic support with the use of a pVAD (Impella 3.5 CP catheter - Abiomed Inc., 
Danvers, MA, USA), that was placed via the right femoral artery in a retrograde 
approach across the aortic valve in the LV (figure 1A). A dense bipolar voltage map 
(figure 1B) of the RA identified multiple locations of scarring. An IART was induced 
and ablation was performed during tachycardia. During ablation on the lateral wall 
the tachycardia terminated. However, multiple different IART’s could be re-in-
duced. After ablation of all channels in the scar no IART could be induced at the 
end of the procedure . 
Initially, during atrial tachycardias the patient was haemodynamically unstable. 
With a continuous blood flow of 2.7L per minute the tachycardias were tolerated, 
but only after correction of the preload.
There has not been a recurrence during a follow-up of 30 months.
A 21 year old male born with a tricuspid valve atresia underwent a bidirectional 
Glenn anastomosis at nine months. Completion of the Fontan circulation followed 
at the age of 2 when the RA was connected to the pulmonary artery.
He was referred for catheter ablation because of multiple episodes of drug re-
sistant IART. The patient had deteriorated LV function and subsequently overt 
congested heart failure. Considering he was haemodynamically unstable during 
his tachycardias we used haemodynamic support with an Impella 3.5 CP catheter 
(Abiomed Inc., Danvers, MA, USA) that was placed via the left femoral artery. 
Bipolar voltage map illustrated an area of low-voltage on the lateral wall of the RA, 
most probably the result of the atriotomy. Entrainment mapping suggested that 
the area of low-voltage on the lateral RA wall was part of the induced IART circuit. 
Consequently an ablation line in the target area led to termination of the IART. With 
the use of the pVAD and preload correction by administrating 1.5L lactated ringer’s 
solution to obtain a left ventricular end diastolic pressure of more than 12 mmHg, 
he maintained stable haemodynamics (Figure 2) and a urine production of > 200ml 
per hour. 
He continued on Sotalol twice daily, and experienced a single episode of atrial 






symptoms of heart failure have ceased and his functional class remained stable.
To the best of our knowledge this is the first report illustrating percutaneous circu-
latory LV support as a human implant during complex atrial arrhythmia ablation in 
univentricular physiology.
Despite extended periods of haemodynamic instability during ablation end-organ 
perfusion can be safely maintained by using circulatory support devices such as 
continuous flow pVAD. Haemodynamic support in VT ablation is widely accepted1, 
but uncommon during the ablation of atrial arrhythmias. Instability during ablation 
may vary according to the type of arrhythmia and underlying structural morphology. 
In both single ventricle patients, with the use of pVAD, resulting in a blood flow of 
2.7L /min and 3.5L/min respectively, stable blood pressure and cardiac output was 
maintained. This allowed for extensive mapping and ablation2 during prolonged 
periods of atrial arrhythmia without developing haemodynamic compromise as 
suffered by one of our patients in a previous ablation attempt.
Arrhythmias are a well-known long-term complication of surgically repaired con-
genital heart defects such as after Fontan operation.3 The pathophysiology is a 
complex interplay between cardiac anatomy, chamber enlargement from abnormal 
pressure and volume loads, cellular injury from cardiopulmonary bypass and fibro-
sis at sites of suture lines and patches.4 Cardiac failure due to loss of sinus rhythm 
was already recognised by Fontan in his first report.5
In conclusion, in single ventricle patients with a Fontan type repair the use of pVAD 
combined with adequate preload results in a stable cardiac output, facilitating 
mapping and ablation of atrial arrhythmias.
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Figure 1  Radiographic image during the procedure (A), bipolar voltage map (B), 
case 1 
A. Percutaneous ventricular assist device is placed via the right femoral artery in a retrograde approach 
across the aortic valve in the left ventricle.












Figure 2 Mean arterial pressure during ablation, case 2
X-axis time in hours, Y-axis blood pressure in mmHg
During ablation the tachycardias were well tolerated under impella support, but only after correction of 
the preload.
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Beauty lies in the eye of the beholder  
Plato
A lot of us grow up and we grow out of the literal 
interpretation that we get when we're children, but 
we bear the scars all our life. Whether they're scars of 
beauty or scars of ugliness, it's pretty much in the eye 
of the beholder. 
Stephen King





Scar related arrhythmias, whether they arise from myocardial infarction or cardi-
ac surgery, represent a major health burden. The substrates of these arrhythmias 
are subject to the complexity of a scar. Scar related ventricular tachycardia (VT) 
can be life threatening and treating VT may be life saving. Freedom of VT recur-
rence after ablation ranges between 40 and 88% during a mean follow-up period 
of 12-28 months.1-4 VT ablation has advanced from a targeted ablation only, limit-
ed to inducible and stable tachycardias, to a combination of targeted and sub-
strate ablation applicable for almost all VT patients. Targeted ablation abolishes 
circuits relevant to the arrhythmia burden at the time of the procedure, but more 
extensive ablation may target potential future VTs.5 Refinement of techniques for 
induction, mapping and ablation all aid to improve VT ablation outcome.
The aim of this thesis was to investigate the outcome of catheter ablation on scar 
related arrhythmias. We studied the role of remote magnetic navigation, contact 
force, a substrate approach and image-integration.
Outcome of VT ablation, and the role of magnetic navigation and contact force
In Chapter 2 we discussed the role of catheter ablation for VT in the treatment 
of patients with electrical storm. An increasing number of studies support the 
finding that catheter ablation is effective in suppressing electrical storm and it 
may be a direct life-saving therapy for the affected patient population. In Chap-
ter 3 we provided an educational review on electrical storm. Electrical storm 
often presents as part of an advanced cardiac disease and may predict a serious 
deterioration in the underlying processes. Both the trigger and the substrate of 
electrical storm may change over time. This may be influenced by progression of 
scarring, heart chamber remodelling and progression of heart failure. Electrical 
storm directly affects the patients’ prognosis. However, by preventing the next 
episode of electrical storm mortality does not necessarily decrease.6
Catheter ablation for electrical storm has led to a 6-fold ICD - therapy reduction 
as compared to an increase in ICD - therapy of 1.5 in time when treating electrical 
storm with medication alone. In Chapter 4 we conclude that ablation for electrical 
storm in the absence of reversible triggers may reduce the burden of ICD- 
therapy, only if performed within 90 days after the first episode of electrical storm.
Procedural and long-term clinical outcome of idiopathic outflow tract ventricular 
arrhythmias ablation in Chapter 5 were equal for manual ablation, remote magnetic 
navigation and contact force guided ablations. Remote magnetic navigation was 
shown to have a favourable procedural safety profile due to the shorter fluoroscopy 
time compared with manual and contact force guided ablations. In Chapter 6 we 
have described the first study that investigated the long-term clinical outcome in 
VT ablation using contact force catheters. The use of contact force sensing cath-
eters did not improve procedural outcome or safety profile in comparison to non- 
contact force sensing ventricular arrhythmia ablation. However, remote magnetic 
navigation was superior with regard to acute success, reduction of major complica-
tions, and lower recurrence rate. The excursion of the ventricle during a VT ablation 
especially during tachycardia itself might lead to a less stable catheter position. 
An unstable catheter position results in intermittent impaired energy delivery and 
subsequent inappropriate lesion formation. Moreover there is no way for the oper-
ator to produce a real-time response to contact force data requiring precise control 
over the catheter tip. This may explain why contact force in VT ablation is not well 
established. More complete substrate ablation may be obtained by ways of en-
hanced maneuverability7,8, improved accessibility to difficult anatomical structures8, 
greater catheter stability9,10 and preventing operator fatigue.
Adding contact measurement to remote magnetic navigation would possibly 
overcome the disadvantage of not being in contact with the myocardial wall 
throughout the whole ventricular contraction period. The awareness of inade-
quate contact may lead to more detailed mapping and limits errors on the pre-
sumption of false channels. Improved contact allows for a better demarcation of 
the low voltage areas11 and increases the sensitivity of late potential detection.12 
Implementation of contact feedback in Chapter 7, using e-contact in remote 
magnetic navigation for an ischemic VT ablation population resulted in a higher 
1-year VT free survival. The e-contact module significantly reduced fluoroscopy 
exposure. These observations were most likely the result of improved accuracy of 
mapping and advanced ablation lesion formation due to the contact feedback.
Catheter ablation of ventricular tachycardia, imaging and epicardial substrate
Bipolar voltage map may show absence of low voltage in the presence of a small, 
patchy and non-transmural scar13 and consequently a VT substrate may be 
missed. The VT substrate is potentially unmasked with right ventricular extra-
stimulation14, and may be better visualized with CT or DE-CMR. Visualizing myo-
cardial scar pre-procedurally may facilitate substrate guided ablation procedures. 
In the presence of an intramural scar, VT recurrences occur more frequently.15 
By recognizing the presence of intramural scar, and by methods such as high 
output endocardial ablation, bipolar ablation or radiofrequency needle ablation, 
the mid-myocardium may be reached and the VT circuit may still be successful-
ly ablated.16 A meta-analysis on imaging guided versus non imaging guided VT 
ablation is presented in Chapter 8. We concluded that image-guided VT ablation 
in ischemic VT was associated with a significant benefit in VT free and overall 
survival as compared to conventional VT ablation.
Endo- epicardial substrate homogenization may be useful as a first-line therapy 
in patients with VTs after myocardial infarction17,18, especially in the presence of 
a transmural scar.19 In Chapter 9 we proposed a study protocol for a randomized 
controlled trial: VT in ischemic cardiomyopathy; a combined endo- epicardial 
ablation as the first procedure versus a stepwise approach (EPILOGUE). It is the 
first randomized trial that evaluates the role of a combined endo- epicardial scar 
homogenization versus endocardial scar homogenization for the treatment of 
ischemic scar-related VT. We investigate whether risks20 outweigh the benefit of 
an epicardial ablation. Even with the preferred anterior approach, that lowers the 
risk of RV puncture and liver damage21,22, other life threatening complications are 
seen, such as laceration of the left internal mammary artery. In Chapter 10 we 
described a case series on a pericardial puncture complicated by damage to the 
left internal mammary artery. We concluded that the anterior approach was pre-
ferred to avoid right ventricular puncture and to obviate the potential increased 
incidence of damage to the left internal mammary artery.
Scar related atrial arrhythmias
Substrate based ablation has been primarily used for ventricular arrhythmia, 
however can be applied to atrial arrhythmias such as atrial fibrillation and atrial 
tachycardias in the presence of scar or fibrosis.23 The role of atrial fibrosis detect-
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analysed in Chapter 11. Our analysis suggests that more extensive left atrial wall 
fibrosis prior ablation predicts higher arrhythmia recurrence rate after pulmonary 
vein isolation. DE-CMR imaging modality seems to be a useful method for identify-
ing the ideal candidate for catheter ablation. Our findings encourage wider usage 
of DE-CMR in distinct atrial fibrillation patients in a pre-ablation setting. 
Surgery in the atrium leaves scar tissue that can give rise to arrhythmia by ways of 
a re-entry mechanism. As a result of abundant scaring, often multiple atrial tachy-
cardia morphologies are seen.24,25,26 Chapter 12 revealed a study on atrial substrate 
modification for the treatment of intra-atrial re-entrant tachycardia in patients after 
congenital heart surgery. In catheter ablation for intra-atrial re-entry tachycardias 
after congenital heart surgery, substrate homogenisation compared to activation 
map based linear ablation was non-inferior in short -and longterm outcome. Es-
pecially if multiple intra-atrial re-entry tachycardias are present, substrate homo-
genisation is a reasonable alternative. In addition, in substrate homogenisation 
there is no need for arrhythmia induction. This can be an advantage not only in 
case of non-inducibility, but also for hemodynamic instability during tachycardia. 
Induction of tachycardias that result in circulatory deterioration prevents adequate 
mapping and ablation. A report illustrating percutaneous circulatory left ventricle 
support during complex atrial arrhythmia ablation in single-ventricle is described in 
Chapter 13. Only with the use of circulatory support devices, end-organ perfusion 
can be safely maintained during ablation with extended periods of hemodynamic 
instability. However, in single-ventricle patients with a Fontan-type repair, the use 
of percutaneous ventricular assist devices only when combined with adequate pre-
load resulted in stable cardiac output.
Discussion + future perspectives
The optimal timing of VT ablation remains to be determined. After the first 
sustained ventricular arrhythmia? Or after multiple episodes of VT storm? Any 
sustained VT without a reversible cause could mean a potential deterioration 
in arrhythmic stability. But when is late, too late? When VT is merely a result of 
general poor condition, VT ablation may be disadvantageous.
In the era of targeting scar instead of a single arrhythmia circuit27, there are 
different endpoints for VT ablation. Firstly, termination by ablation of the on-
going VT translates to a high rate of VT isthmus identification. Secondly, when 
the clinical VT remains non-inducible after ablation and when no VT at all is 
inducible at the end of the procedure we speak of partly and complete proce-
dural success respectively. Theoretically an entire substrate may be abolished. 
If we consider elimination of all abnormal potentials a marker for abolishing the 
substrate, we know that when complete elimination of all mappable abnormal 
potentials is reached, it is associated with a good clinical outcome.28 Whereas 
today’s clinical practise is an anatomical scar modification, the future may indi-
cate a more physiological scar modification approach.30 Undoubtedly, what we 
cannot obtain after VT ablation of scar related arrhythmia, is a healthy heart. 
In this period of time we are dealing with revascularized myocardial infarctions, 
and consequently with smaller and more inhomogeous scar as compared to an 
era in which we treated patients with VT from non-revascularized infarctions. 
These types of scars are associated with fast and poorly tolerated VT29 and 
absence of low voltage on electro-anatomical maps.13 Knowledge of the sub-
strate can come from pre - and periprocedural imaging which can function as a 
plan of approach and potentially as a roadmap. Ten percent of the patients with 
ischemic VT have inducible VT from the epicardium and at least 30% have low 
voltage in the epicardium on bipolar electro-anatomical maps.31 
If good long term effect can be reached in a single procedure, performing 
multiple procedures should be avoided. Yet, is a single time of abolishing 
endocardial and epicardial VT circuits in the substrate enough to take away 
the threat of future VT’s? In other words, does scar after ablation stay in a 
steady-state, or is it an everlasting changeable entity? Ventricular remodelling 
in heart failure leads to electrophysiologic changes, which in the early stages 
may be a modifiable process.32 These electrophysiologic changes include 
abnormal calcium homeostasis, repolarization, and gap junction remodelling, all 
mechanisms that trigger ventricular arrhythmia.33 
The Epilogue trial will teach us whether all patients with ischemic substrate 
benefit from complete substrate ablation. The issue with pericardial access 
at a first approach is the risk of adhesions, complicating a future epicardial 
VT ablation. If there is no second chance, and the substrate is changing, wild 
cards shouldn’t be used early. Yet, patients with poor left ventricular function, 
ventricular arrhythmia and heart failure, generally have poor life expectancy and 
we believe optimal timing for complete scar homogenisation should be seen in 
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I Nederlandse Samenvatting
Litteken gerelateerde aritmieën (ritmestoornissen), zowel afkomstig van een doorge-
maakt myocardinfarct (hartinfact) als na hart chirurgie, zijn een belangrijk onderwerp in 
de hedendaagse gezondheidsproblematiek. Het substraat van deze aritmieën is onder-
hevig aan de complexiteit van het litteken. Litteken gerelateerde ventrikel tachycardieën 
(kamerritmestoornissen) (VT) kunnen levensbedreigend zijn en het behandelen van een 
VT kan levensreddend zijn. Gedurende een gemiddelde follow-up periode van 12-28 
maanden na een VT ablatie (behandeling van een kamerritmestoornis) is er uitblijven van 
VT recidief in 40-88% van de patiënten.1-4 Katheter ablatie wordt van oudsher beperkt 
tot het behandelen van de klinische VT, alleen toepasbaar op induceerbare en stabiele 
tachycardieën. Hedendaags heeft VT ablatie zich ontwikkeld tot  een combinatie van een 
beperkte en een substraat (litteken) ablatie die toepasbaar is op bijna alle VT patiënten. 
De beperkte ablatie heft circuits op die relevant zijn voor de ritmestoornis die op het mo-
ment van de procedure voorkomt, maar een uitgebreidere ablatie kan in potentie ook VTs 
die ontstaan uit toekomstige circuits, voorkomen.5 De uitkomst van VT ablatie is verbe-
terd door verfijning van opwekken van de ritmestoornis, van het mappen (origine van de 
ritmestoornis bepalen) en van de ablatie techniek. 
Het doel van het huidige proefschrift was om de uitkomsten van katheter ablatie voor 
litteken gerelateerde aritmieën te onderzoeken. Wij onderzochten de rol van magneet ge-
stuurde ablatie, ablatie met behulp van katheters die contact met het myocard (hartspier) 
meten (contact force katheters), een substraat aanpak en ablatie met integratie van 
beeldvorming.
Resultaten van VT ablatie, en de rol van magneet gestuurde navigatie en contact force
In Hoofdstuk 2 bediscussiëren we de rol van katheter ablatie voor VT in de behandeling 
van patiënten met een VT storm (3 of meer kamerritmestoornissen < 24u). Een toe-
nemend aantal studies laten zien dat katheter ablatie effectief is in het bedwingen van 
elektrische instabiliteit, en het een levensreddende therapie kan zijn voor een zeer zieke 
patiënt populatie. In Hoofdstuk 3 verstrekken we een educatieve review over VT storm. 
VT storm kan een uiting zijn van het natuurlijk beloop van vergevorderde hartziekte en 
kan een waarschuwingssignaal zijn voor verslechtering van de aandoening zelf. De trigger 
en het substraat van een VT storm kunnen veranderen, zij zijn onderhevig aan progres-
sie van verlittekening, remodelering van de ventrikel en van het hartfalen an sich. Een VT 
storm beïnvloedt direct de prognose van de patiënt. Daarentegen wordt door middel van 
het voorkomen van de volgende episode, niet direct de mortaliteit verlaagd.6 Katheter 
ablatie voor VT storm leidde tot 6x minder ICD therapie (shocks en anti-tachy pacing), dit 
in vergelijking met 1.5x meer ICD therapie gedurende follow-up als een VT storm conser-
vatief behandeld werd. In Hoofdstuk 4 concluderen we dat ablatie voor VT storm in de 
afwezigheid van omkeerbare triggers, multipele ICD shocks zou kunnen voorkomen, mits 
de ablatie procedure wordt verricht binnen 90 dagen van het eerste voorkomen van de 
VT storm.
De procedurele en lange termijn klinische uitkomsten van ablatie voor idiopatische 
uitstroombaan ventriculaire aritmie (kamerritmestoornissen uit de uitstroombaan van de 
hartkamers zonder andere oorzaak) in Hoofdstuk 5 waren gelijk voor manuele ablatie, 
magneet gestuurde ablatie en contact force ablatie. Magneet gestuurde ablatie heeft een 
beter procedureel veiligheidsprofiel doordat er een kortere doorlichtingstijd is in verge-
lijking met manuele en contact force geleide ablaties. In Hoofdstuk 6 wordt de eerste 
studie beschreven die de lange termijn klinische uitkomsten van VT ablatie laat zien ge-
bruik makend van contact force katheters. Het gebruik van contact force katheters heeft 
niet geleid tot verbetering van procedurele uitkomsten of verbetering van de veiligheid, in 
vergelijking met niet contact force gestuurde ablatie voor ventriculaire aritmie. Daarente-
gen was magneet gestuurde ablatie superieur in acuut succes, het optreden van majeure 
complicaties en recidieven. De beweging van de ventrikel tijdens een VT ablatie, vooral 
ten tijde van de tachycardie zelf kan leiden tot een minder stabiele katheter positie. Een 
instabiele katheter positie resulteert in intermitterend onvoldoende afgeven van energie 
aan het weefsel en zodoende suboptimale laesies. Bovendien is het niet mogelijk om 
onvertraagd te reageren op de contact force data en daarmee de precise controle te 
hebben over de catheter tip. Dit zou de verklaring kunnen zijn waarom contact force geen 
grote rol heeft in VT ablatie. Magneet gestuurde VT ablatie kan leiden tot completere sub-
straat ablatie door een tal van factoren: betere manoeuvreerbaarheid7,8, het beter kunnen 
bereiken van anatomische structuren9, stabielere katheter positie10, en het voorkomen van 
vermoeidheid bij de operateur. 
Het toevoegen van contact meting aan magneet gestuurde ablaties geeft de mogelijkheid 
te corrigeren wanneer er foutief verondersteld wordt dat er contact is met het myocard 
ten tijde van ablatie. Bovendien kan het weten of er wel of niet adequaat contact is, tot 
meer gedetailleerd mappen leiden en kan het fouten voorkomen met betrekking tot het 
veronderstellen van niet bestaande ‘channels’ (resterend elektrisch geleidend weefsel 
in een litteken). Verbetering van contact geeft de mogelijkheid om gebieden van lage 
voltage te definiëren11 en het verbetert de sensitiviteit van het detecteren van late poten-
tialen.12 Implementatie van contact feedback, gebruik makend van de e-contact module 
in magneet gestuurde ablatie in VTs uitgaande van een oud myocardinfarct, resulteerde 
in een hogere 1 jaars VT vrije overleving wat beschreven is in Hoofdstuk 7. De e-contact 
module reduceerde blootstelling aan röntgenstraling significant. Accuratere mapping en 
geavanceerde ablatie laesie formatie (het maken van een nieuw litteken) door contact 
feedback zijn mechanismes die ten grondslag zouden kunnen liggen aan de betere lange 
termijn resultaten met e-contact.
Katheter ablatie van ventriculaire tachycardie, beeldvorming en het epicardiale  
substraat
Wanneer er sprake is van een klein, en niet-transmuraal (niet de hele hartwand omvat-
tend) litteken kan het er toe leiden dat er geen laag gevolteerd gebied zichtbaar is op 
de bipolaire voltage map13 en als gevolg daarvan kan een VT substraat gemist worden. 
Substraat ablatie procedures kunnen worden vergemakkelijkt door het visualiseren van 
het myocardiale litteken, preprocedureel maar ook door beeldvorming te integreren in 
de procedure. Dit kan uiteindelijk de lange termijn uitkomsten van de ablatie procedure 
verbeteren. In de aanwezigheid van een intramuraal (midden in de hartwand) litteken, is 
er vaker sprake van een recidief VT na endocardiale ablatie (ablatie vanaf de binnenkant 
van het hart).15 Door de aanwezigheid van een intramuraal litteken te erkennen, kunnen 
methodes worden toegepast zoals ‘high output’ endocardiale ablatie, bipolaire ablatie 
en ablatie middels een radiofrequente naald.16 In Hoofdstuk 8 wordt een meta-analyse 
gepresenteerd gericht op VT ablatie die geleid is door beeldvormende technieken versus 
VT ablatie niet geleid door beeldvormende technieken. De conclusie is dat ablatie geleid 
door beeldvorming in VT na een myocardinfarct is geassocieerd met een significante 
verbetering in VT vrije overleving en überhaupt overleving.
Endo-epicardiale (binnenkant en buitenkant van het hart) substraat ablatie kan bruikbaar 
zijn als een eerste-lijns behandeling in een patiënt met VT na een hartinfarct17-18, vooral 
als er sprake is van een transmuraal infarct.19 In Hoofdstuk 9 presenteren we een protocol 
voor een gerandomiseerd onderzoek: VT in ischemische cardiomyopathie, een gecombi-
neerde endo-epicardiale ablatie in de eerste procedure versus een stapsgewijze aanpak 
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rol van een gecombineerde endo- epicardial litteken ablatie onderzoekt en vergelijkt 
met het ableren van alleen het endocardiale litteken. We onderzoeken of de risico’s20 
opwegen tegen de voordelen van een epicardiale ablatie. Zelfs met een geprefereer-
de anterieure (meer aan de voorzijde) aanpak, die het risico op punctie van de rech-
ter kamer en lever schade verkleint21,22, kunnen zich weer andere levensbedreigende 
complicaties voordoen, zoals beschadiging van de linker arteria mammaria interna 
(LIMA). In Hoofdstuk 10 beschrijven we een tweetal casussen waarbij een pericard 
(hartzakje) punctie gecompliceerd werd door beschadiging van de LIMA. Een anteri-
eure aanpak kan in potentie de incidentie van LIMA schade doen toenemen.
Litteken gerelateerde atriale aritmieën
Ablatie gebaseerd op het substraat werd in eerste instantie toegepast op ventrikel 
tachycardieën, desalniettemin kan deze ook toegepast worden op atriale aritmieën 
zoals atriumfibrilleren (boezemfibrilleren) of atriale tachycardieën (georganiseerde 
boezemritmestoornis), vooral wanneer het voorkomen hiervan geassocieerd is met 
de aanwezigheid van litteken (fibrose).23 Geanalyseerd in Hoofdstuk 11 is de rol van 
atriale fibrose in atriumfibrilleren gedetecteerd door middel van delayed-enhanced 
cardiale MRI (DE-CMR). Onze analyse suggereert dat uitgebreidere fibrose van het 
linker atrium te zien voorafgaande aan een ablatie, een hogere recidief kans voor-
spelt van atriumfibrilleren na pulmonaal vene isolatie (ablatie voor boezemfibrille-
ren). De DE-CMR beeldvormende techniek lijkt een haalbare methode om de ideale 
kandidaat voor katheter ablatie te selecteren. Onze bevindingen moedigen gebruik 
van de DE-CMR aan in een pre-ablatie setting in een geselecteerde groep patiënten 
met atriumfibrilleren. 
Na chirurgie in het atrium blijft litteken weefsel achter, ten gevolge daarvan kun-
nen zich aritmieën voordoen en meestal gaat het om re-entry (vast circuit waar de 
ritmestoornis gebruik van maakt). Uitgebreide verlittekening resulteert vaak in een 
atriale tachycardie met multipele morfologieën (verschijningsvormen).24,25,26 Atriale 
substraat modificatie voor de behandeling van intra-atriale re-entry tachycardieën 
na chirurgie voor aangeboren hartaandoeningen wordt beschreven in Hoofdstuk 12. 
Substraat modificatie in vergelijking met lineaire ablatie gebaseerd op activatie maps 
waren non-inferieur op de uitkomsten op korte en lange termijn, bij patiënten die 
katheter ablatie ondergingen voor een intra-atriale re-entry tachycardie na aangebo-
ren hart chirurgie. Vooral als er sprake is van multipele intra-atriale re-entry tachy-
cardieën, is substraat modificatie een goed alternatief. Daarnaast is er bij substraat 
modificatie geen noodzaak tot opwekken van de aritmie. Dit kan voordelen hebben, 
niet alleen als de ritmestoornis niet opwekbaar is, ook wanneer er hemodynamische 
instabiliteit (lage bloeddruk) tijdens de tachycardie is. Mappen en ook ablatie kan 
onvoldoende bewerkstelligd worden indien er sprake is van een circulatoir gecom-
promitteerde situatie (verminderde doorbloeding van de organen) na het opwek-
ken van de tachycardie. Hoofdstuk 13 betreft een tweetal casussen waar dit wordt 
geïllustreerd, waarin patienten met een univentriculair hart ondersteund worden door 
een percutaan circulatoir steun device van de linker ventrikel, wanneer zij een ablatie 
ondergaan van een complexe atriale aritmie. Gedurende langere periodes van hemo-
dynamische instabiliteit kan eind-orgaan perfusie alleen bewerkstelligd worden met 
het gebruik van een circulatoir steun device. Echter in patiënten met een Fontan-ty-
pe reparatie en een univentriculair hart resulteerde het gebruik van een percutaan 
ventriculair steun device, alleen wanneer gebruikt in combinatie met een adequate 
preload (vulling), in een goede cardiac output.
Discussie en toekomst perspectief
Het blijft een belangrijk vraagstuk wat de meest optimale timing van VT ablatie is. Na 
de eerste episode van een sustained ventriculaire aritmie? Na multipele episodes van 
VT storm. Kan elke sustained VT zonder een reversibele oorzaak een potentieel verval 
betekenen van aritmische stabiliteit? En wanneer is laat te laat? VT ablatie kan zelfs in het 
nadeel werken van de patiënt, wanneer VT slechts een uiting is van een algeheel slechte 
conditie. 
In een tijd waar het aanpakken van het litteken de standaard is geworden in plaats van het 
aanpakken van een enkel VT circuit, zijn andere eindpunten bruikbaar.27 Allereerst leidt 
het door ablatie beëindigen van een ongoing VT vaak tot de identificatie van de kritische 
isthmus. Ten tweede, als de klinische VT niet meer induceerbaar is na de ablatie of wan-
neer er geen enkele VT meer induceerbaar is aan het einde van de procedure spreken we 
van respectievelijk gedeeltelijk of volledig succes. Theoretisch gezien kan een volledig 
substraat uitgeschakeld worden. Als we het elimineren van alle abnormale potentialen als 
een marker zien voor het uitschakelen van het substraat, is het daadwerkelijk geassoci-
eerd met een goede klinische uitkomst.29 Wat we ongetwijfeld niet kunnen bereiken na VT 
ablatie voor litteken gerelateerde aritmieën, is een gezond hart. 
In de laatste decennia hebben we te maken gekregen met gerevasculariseerde myocard 
infarcten, met als gevolg kleinere en inhomogene littekens. Deze type littekens zijn geas-
socieerd met snelle VT’s die hemodynamisch slecht verdragen worden29 en in de afwe-
zigheid zijn van lage voltage op electro-anatomische maps.13 Kennis over het substraat 
kan verkregen worden door middel van pre en periprocedurele beeldvorming, deze kan 
de procedure vergemakkelijken door te fungeren als een plan van aanpak en kan poten-
tieel ook dienen als een roadmap. Tien procent van de patiënten met ischemische VT’s 
hebben ten tijde van elektrofysiologisch onderzoek induceerbare VTs vanuit het epicardi-
um en ten minste 30% heeft lage voltage in het epicardium op de bipolaire maps.31
Als een enkele procedure een goed lange termijn effect kan doen bereiken, zou het on-
dernemen van multipele procedures voorkomen dienen te worden. Hoewel, is een enkele 
keer uitschakelen van endo en epicardiale VT circuits in het substraat wel genoeg om 
toekomstige VT’s te behandelen? In andere woorden blijft een litteken na ablatie in een 
soort steady-state, of is het een steeds veranderende entiteit. Ventriculaire remodeling 
in hartfalen heeft elektrofysiologische veranderingen tot gevolg, welke in de vroege fase 
een mogelijk reversibel proces betreft.32 Abnormale calcium homeostase, remodelering 
van repolarisatie en gap juncties zijn voorbeelden van de verschillende elektrophysiologi-
sche veranderingen die op deze verschillende wijzen ventrikel aritmie kan triggeren.33
Of alle patiënten met een ischemisch substraat baat hebben bij volledige substraat abla-
tie zal duidelijk worden na het bekend worden van de resultaten van de Epilogue studie. 
Wanneer pericardiale toegang is verkregen bij een eerste poging tot VT ablatie is er het 
risico op adhesies, wat een toekomstige epicardiale VT ablatie zou kunnen compliceren. 
Als er geen tweede kans is, en er sprake is van een veranderend substraat, dan zal de 
troef niet te vroeg ingebracht moeten worden. Aan de andere kant, wanneer er sprake 
is van ventriculaire aritmieën en hartfalen bij patiënten met een sterk verminderde linker 
ventrikel functie, is de levensverwachting onafhankelijk van de aritmie sterk verminderd. 
De optimale timing voor complete scar homogenistatie, zo geloven wij, dient dan ook te 
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